













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 






Biophysical, biochemical and 

















Hexokinase is the first enzyme in glycolysis, a major pathway for the generation of 
energy in all eukaryotes. Mammalian cells have four isoforms (I, II, III, IV) that have 
different tissue distribution and kinetic properties. Among all isoforms, human 
hexokinase II (hHKII) has been found to be implicated in many cancers with an 
increased expression which serves a dual role. First, it maintains the high glycolytic 
rate of malignant cells (Warburg effect) and second it prevents apoptosis when is 
bound to mitochondria. Trypanosoma brucei is a parasite that causes Human African 
Trypanosomiasis (HAT) and has two isoforms with extensive sequence similarity 
(98%), TbHKI (active form) and TbHK2 (inactive form). The bloodstream-form 
parasites (BSF) depend exclusively on glycolysis for their survival. The enzyme 
from both organisms is a validated target for drug-discovery against both cancer and 
HAT. The aim of the present study is the discovery of novel and specific inhibitors 
of the enzymes based on their structure. Structure-based drug discovery is commonly 
used in pharmaceutical companies to aid in the discovery of potent lead compounds. 
In silico studies were performed in this project using the known crystal structure of 
human hexokinase I and a model of TbHKI generated by the protein modelling tool 
Phyre2. The docking programs, AutoDock (AD) and AutoDock Vina (Vina), were 
chosen to perform the docking of ~3 million compounds to the target molecules and 
scoring functions calculated the predicted binding affinities of each compound. In 
total, 28 compounds were purchased to test on the target molecules. 
In the experimental part of the project, the two enzymes were cloned, expressed and 
purified. hHKII was successfully purified giving a high yield of active and pure 
protein. The protein was characterised using many biophysical methods to establish 
the oligomeric state, the homogeneity and the secondary structure. Crystallisation 
trials failed and for this reason, N and C domains of the hHKII were purified 
separately. Unfortunately, the domains also failed to crystallise thus SAXS data were 
collected and analysed to gain information of their shape at low resolution. A novel 




TbHKI was difficult to express in a soluble form as most of the protein was 
expressed in inclusion bodies. The purification resulted in a small amount of active 
protein that was used entirely for biochemical assays. Four compounds were 
purchased from the docking of the TbHKI model and one was found to inhibit the 
enzyme over 65% at 100 μΜ. Because the active site of both enzymes (hHKII, 
TbHKI) is well conserved the compounds from hHKII docking were also screened 
against the TbHKI. Four compounds were found to inhibit this enzyme while one of 
them was also an inhibitor for human isoform. The remaining three were specific for 
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1. Chapter 1: Introduction 
Glycolysis and reaction catalysed by hexokinase 
Hexokinase (ATP:D-hexose 6-phosphotransferase, EC 2.7.1.1) is the first enzyme in 
glycolysis, a major pathway that generates ATP by catabolism of hexoses. 
Hexokinase, catalyses the reaction: 
Glucose + ATP-Mg
2+                              
Glucose 6-Phosphate + ADP-Mg
2+
 
The ATP-dependent phosphorylation of glucose (Glc) is the first step in glycolysis. 
Hexokinase converts the nonionic Glc to ionic glucose 6-phosphate (G6P) which 
cannot exit the cells. The glycolytic metabolism of glucose occurs in all eukaryotic 
organisms, while many but not all prokaryotic organisms also use a similar glycolytic 
pathway (Cárdenas et al., 1998), (Pelicano et al., 2006). Glc is the preferred substrate 
of the hexokinases, but as the name implies, they can phosphorylate also other 
hexoses e.g. mannose, 2-deoxyglucose, fructose and galactose (Grossbard and 
Schimke, 1966). Negatively charged G6P fuels both glycolysis and the pentose 
phosphate pathway (PPP) (Fig. 1.1) and can also be used to synthesise 
polysaccharides like glycogen (not shown). Thus, hexokinase plays an important role 





Figure 1.1: Glycolytic pathway consists of 10 reaction steps 
The solid arrows indicate glycolytic reactions, whereas the dashed arrow indicates the 
interconnection with the pentose phosphate pathway (PPP). The blue arrows show the further 
metabolism of pyruvate. The first part of glycolysis (specifically in reactions 1 and 3) is the 
ATP requiring part, where two molecules of ATP are required to split the six-carbon sugar 
molecule into two three-carbon molecules. The red arrows show the ATP consumption steps. 
The second half of glycolysis (specifically in reactions 7 and 10) will produce a net gain of 
two ATP molecules by substrate phosphorylation. The green arrows show the energy release 
steps. HK, hexokinase; PGI, phosphoglucose isomerase; PFK, phosphofructokinase; ALDO, 
aldolase; TPI, triosephosphate isomerase; GAPDH, glyceraldeyde-3-phosphate 
dehydrogenase; PGK, phosphoglycerate kinase; PGM, phosphoglycerate mutase; ENO, 
enolase; PK, pyruvate kinase; PDH, pyruvate dehydrogenase; LDH, lactate dehydrogenase; 








Mammalian hexokinases and cancer 
1.1 Isozymes of mammalian hexokinases 
Four isozymes of hexokinase are found in a variety of mammalian tissues. One of the 
first studies on hexokinase categorised these isoforms in the rat as I, II, III and IV 
based on their electrophoretic pattern in a starch gel (Katzen and Schimke, 1965). 
The presence of four hexokinases appears to be characteristic of all animals, 
including the human, with each type being different from the other with regard to its 
kinetic properties and tissue distribution. HKI-III (100 kDa) are known as the “low-
Km hexokinases” with HKI mainly found in brain, hexokinase II in skeletal muscle 
and adipose tissue, whereas HKIII is found in small amounts in all tissues. HKIV (50 
kDa) is also called Glucokinase, with the name being unfortunate as this is known as 
the “high-Km hexokinase”, so the glucose affinity is lower. Product inhibition (G6P) 
is a characteristic of 100 kDa hexokinases, while glucokinase does not seem to share 
this regulation. It is believed that hexokinases have evolved by a gene duplication 
and fusion of an ancestral hexokinase with a similar size of yeast hexokinase and 
HKIV (Katzen and Schimke, 1965, Cárdenas et al., 1998, Grossbard and Schimke, 
1966). The 100 kDa HKI, HKII and HKIII contain two domains (N and C domains 
containing the residues 1-475 and 476-917, respectively). Studies on each domain of 
these isoforms have shown that only HKII has two active sites (Tsai and Wilson, 
1996). The N regulatory domain has been found inactive in HKI and HKIII (Tsai, 
1999). Two different evolutionary hypotheses exist about the origin of the 
mammalian glucokinase. Whereas the most popular one suggests that glucokinase 
diverged from a lineage leading to HKI-III before their ancestral gene underwent the 
duplication, Irwin and Tan 2008, propose that glucokinase evolved from a 
hexokinase already containing two active domains, but secondarily lost its N domain 
(Irwin and Tan, 2008). The evolutionary analysis of the hexokinase gene family in 
verterbrates, performed by the same group, led also to the discovery of a fifth 
hexokinase-like gene (HKDC1). HKDC1 genes were found in all genomes examined 
implying that it could be functional (Irwin and Tan, 2008). To date all published 
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papers and reviews refer to just four hexokinases (HKI-IV) which suggests that 
HKDC1 does not have sugar-phosphorylation activity.  
The isoforms (HKI-IV) show an extensive sequence similarity and particularly HKI-
HKII show 73% identity while the percentage drops to ~52-55% for HKIII with the 
other three isoforms. Figure 1.2 shows the sequence alignment performed with the 
Clustal Omega (ClustalW) online tool (Larkin et al., 2007). The sequences were 
obtained from UniprotKB (http://www.uniprot.org/) (2017).  
 
 
Human_glucokinase         ------------------------------------------------------------ 
Human_hexokinase_III      MDSIGSSGLRQGEETLSCSEEGLPGPSDSSELVQECLQQFKVTRAQLQQIQASLLGSMEQ 
Human_hexokinase_II       --MIASH-------LLAYFFTE--LNHDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEK 
Human_hexokinase_I        --MIAAQ-------LLAYYFTE--LKDDQVKKIDKYLYAMRLSDETLIDIMTRFRKEMKN 
                                                                                       
Human_glucokinase         ------------------------------------------------------------ 
Human_hexokinase_III      ALRGQASPAPAVRMLPTYVGSTPHGTEQGDFVVLELGATGASLRVLWVTLTGIEGHRVEP 
Human_hexokinase_II       GLGATTHPTAAVKMLPTFVRSTPDGTEHGEFLALDLG--GTNFRVLWVKVTDNGLQKVEM 
Human_hexokinase_I        GLSRDFNPTATVKMLPTFVRSIPDGSEKGDFIALDLG--GSSFRILRVQVNHEKNQNVHM 
                                                                                       
Human_glucokinase         ------------------------------------------------------------ 
Human_hexokinase_III      RSQEFVIPQEVMLGAGQQLFDFAAHCLSEFLDAQPVNKQGLQLGFSFSFPCHQTGLDRST 
Human_hexokinase_II       ENQIYAIPEDIMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESF 
Human_hexokinase_I        ESEVYDTPENIVHGSGSQLFDHVAECLGDFMEKRKIKDKKLPVGFTFSFPCQQSKIDEAI 
                                                                                       
Human_glucokinase         ------------------------------------------------------------ 
Human_hexokinase_III      LISWTKGFRCSGVEGQDVVQLLRDAIRRQGAYNIDVVAVVNDTVGTMMGCEPGVRPCEVG 
Human_hexokinase_II       LVSWTKGFKSSGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIG 
Human_hexokinase_I        LITWTKRFKASGVEGADVVKLLNKAIKKRGDYDANIVAVVNDTVGTMMTCGYDDQHCEVG 
                                                                                       
Human_glucokinase         ------------------------------------------------------------ 
Human_hexokinase_III      LVVDTGTNACYMEEARHVAVLDEDRGRVCVSVEWGSFSDDGALGPVLTTFDHTLDHESLN 
Human_hexokinase_II       LIVGTGSNACYMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLN 
Human_hexokinase_I        LIIGTGTNACYMEELRHIDLVEGDEGRMCINTEWGAFGDDGSLEDIRTEFDREIDRGSLN 
                                                                                       
Human_glucokinase         ------------------------------------------------------------ 
Human_hexokinase_III      PGAQRFEKMIGGLYLGELVRLVLAHLARCGVLFGGCTSPALLSQGSILLEHVAEMEDPST 
Human_hexokinase_II       PGKQLFEKMISGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKD 
Human_hexokinase_I        PGKQLFEKMVSGMYLGELVRLILVKMAKEGLLFEGRITPELLTRGKFNTSDVSAIEKNKE 
                                                                                       
Human_glucokinase         ------------------------------------------------------------ 
Human_hexokinase_III      GAARVHAILQDLGLSPGASDVELVQHVCAAVCTRAAQLCAAALAAVLSCLQHSREQQTLQ 
Human_hexokinase_II       GIRKAREVLMRLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLR 




Figure 1.2: Sequence alignment of all four mammalian hexokinase isoforms (HKI-HKIV) 
Sequence alignment of all mammalian hexokinases shows an extensive identity between 
isoforms I and II reaching 73%. HKIII does not hold the same identity with HKI or II as the 
percentage of identity ranges between 52-55%.Glucokinase (HKIV) shows approximately 
52-55% identity with the other three isoforms. 
  
1.2 Cancer metabolism and hexokinase II  
In 1931 Otto Warburg was attributed the Nobel Prize in Physiology and Medicine 
mainly for his research on the metabolism of tumours and the respiration of cells. 
Warburg observed that the metabolism of cancer cells is different from that of 
normal adult cells. In order for normal cells to replicate, energy is required which is 
acquired as follows. Glucose upon entering inside the cells through glucose 
transporters (GLUTs) is metabolised to pyruvate after sequential reactions of the 
Human_glucokinase         -----------------------------------------------MLDDRARMEAAKK 
Human_hexokinase_III      VAVATGGRVCERHPRFCSVLQGTVMLLAPECDVSLIPSVDGGGRGVAMVTAVAARLAAHR 
Human_hexokinase_II       STIGVDGSVYKKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQH 
Human_hexokinase_I        TTVGVDGSLYKTHPQYSRRFHKTLRRLVPDSDVRFLLSESGSGKGAAMVTAVAYRLAEQH 
                                                                          
Human_glucokinase         EKVEQILAEFQLQEEDLKKVMRRMQKEMDRGLRLETHEEASVKMLPTYVRSTPEGSEVGD 
Human_hexokinase_III      RLLEETLAPFRLNHDQLAAVQAQMRKAMAKGLRGEA---SSLRMLPTFVRATPDGSERGD 
Human_hexokinase_II       RARQKTLEHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGD 
Human_hexokinase_I        RQIEETLAHFHLTKDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGD 
                           
Human_glucokinase         FLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKHQMYSIPEDAMTGTAEMLFDYISECISDF 
Human_hexokinase_III      FLALDLGGTNFRVLLVRVTTG------VQITSEIYSIPETVAQGSGQQLFDHIVDCIVDF 
Human_hexokinase_II       FLALDLGGTNFRVLLVRVRNGKWGG--VEMHNKIYAIPQEVMHGTGDELFDHIVQCIADF 
Human_hexokinase_I        FLALDLGGTNFRVLLVKIRSGKKRT--VEMHNKIYAIPIEIMQGTGEELFDHIVSCISDF 
                           
Human_glucokinase         LDKHQMKHKKLPLGFTFSFPVRHEDIDKGILLNWTKGFKASGAEGNNVVGLLRDAIKRRG 
Human_hexokinase_III      QQKQGLSGQSLPLGFTFSFPCRQLGLDQGILLNWTKGFKASDCEGQDVVSLLREAITRRQ 
Human_hexokinase_II       LEYMGMKGVSLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRRE 
Human_hexokinase_I        LDYMGIKGPRMPLGFTFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRRE 
                             
Human_glucokinase         DFEMDVVAMVNDTVATMISCYYEDHQCEVGMIVGTGCNACYMEEMQNVELVEGDEGRMCV 
Human_hexokinase_III      AVELNVVAIVNDTVGTMMSCGYEDPRCEIGLIVGTGTNACYMEELRNVAGVPGDSGRMCI 
Human_hexokinase_II       EFDLDVVAVVNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCV 
Human_hexokinase_I        EFDLDVVAVVNDTVGTMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMVEGDQGQMCI 
                           
Human_glucokinase         NTEWGAFGDSGELDEFLLEYDRLVDESSANPGQQLYEKLIGGKYMGELVRLVLLRLVDEN 
Human_hexokinase_III      NMEWGAFGDDGSLAMLSTRFDASVDQASINPGKQRFEKMISGMYLGEIVRHILLHLTSLG 
Human_hexokinase_II       NMEWGAFGDNGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRG 
Human_hexokinase_I        NMEWGAFGDNGCLDDIRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKG 
                           
Human_glucokinase         LLFHGEASEQLRTRGAFETRFVSQVESDTGDRKQIYNILSTLGLRPSTTDCDIVRRACES 
Human_hexokinase_III      VLFRGQQIQRLQTRDIFKTKFLSEIESDSLALRQVRAILEDLGLPLTSDDALMVLEVCQA 
Human_hexokinase_II       LLFRGRISERLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTV 
Human_hexokinase_I        FLFRGQISETLKTRGIFETKFLSQIESDRLALLQVRAILQQLGLNSTCDDSILVKTVCGV 
                           
Human_glucokinase         VSTRAAHMCSAGLAGVINRMRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVRRLTPS 
Human_hexokinase_III      VSQRAAQLCGAGVAAVVEKIRENRGLEELAVSVGVDGTLYKLHPRFSSLVAATVRELAPR 
Human_hexokinase_II       VARRAAQLCGAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPK 
Human_hexokinase_I        VSRRAAQLCGAGMAAVVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTVKELSPK 
                            
Human_glucokinase         CEITFIESEEGSGRGAALVSAVACKKACMLGQ 
Human_hexokinase_III      CVVTFLQSEDGSGKGAALVTAVACRLAQLTRV 
Human_hexokinase_II       CDVSFLQSEDGSGKGAALITAVACRIREAGQR 
Human_hexokinase_I        CNVSFLLSEDGSGKGAALITAVGVRLRTEASS 
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glycolytic pathway. The glycolytic process results in the production of just two ATP 
molecules per glucose. In normal tissues the tricarboxylic acid (TCA) cycle and 
oxidative phosphorylation (OXPHOS) follow, resulting in an additional 36 
molecules of ATP. Cancer cells have increased energy requirements to maintain their 
increased proliferative rate thus the glucose use is increased. Cancer cells show the 
characteristic increase of glycolysis even in the presence of oxygen, a phenomenon 
called aerobic glycolysis, the Warburg effect (Marie and Shinjo, 2011). The 
molecular basis of this shift in phenotype remains elusive. 
Pedersen and his colleagues published a minireview about HKII which plays a 
pivotal role in fast growing cancer cells maintaining their growth and survival, thus 
HK isoform II may be considered as a target for cancer therapy (Pedersen et al., 
2002). It is known that the genes for each of the four hexokinase isozymes are 
localised on different chromosomes; more specifically the HKI, HKII, HKIII and 
HKIV genes are localised on 10q22, 2p13, 5q35, and 7p15, respectively. None of the 
hexokinases derive from alternate exon splicing events from a single chromosomal 
locus or due to chromosomal rearrangements or deletions. This could indicate that 
epigenetic events and/or gene amplification play a significant role in the up-
regulation of HKII gene expression during tumorigenesis (Mathupala et al., 2009). 
Among the four hexokinase isoforms (HKI-IV) HKII has been reported since early 
years to be overexpressed in fast growing tumours. More specifically it has been 
demonstrated that AS-30D rat hepatoma cells contain 5-fold more HKII gene copies 
than normal hepatocytes with no observed structural differences in the HKII gene 
locus (Rempel et al., 1996).  
Hexokinase isoforms from highly glycolytic tumours have been sequenced and found 
to contain overexpressed HKII, even 100-fold higher, than found in normal cells. 
This is possibly not the case for brain cancer where HKI expression may be higher 
(Pedersen et al., 2002). Nevertheless, HKII was recently found to be implicated in 
human glioblastoma multiforme (GBM), the most common brain cancer. More 
specifically an increased expression of HKII transcript and protein, instead of HKI 
which is mostly predominant in brain, was found in this type of cancer which 
correlated with the worse overall survival of GBM patients. Knockdown of HKII in 
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GBM cells led to decreased proliferation; all these findings suggest that HKII could 
be a target for GBM therapy (Wolf et al., 2011). 
Apart from the elevated expression of this isoform, HKII in rapidly growing cancers 
is bound to the mitochondrial voltage dependent anion channel (VDAC) (Nakashima 
et al., 1986) resulting in relief from its product inhibition (G6P) while helping cancer 
cells to immortalise, likely by inhibiting the proapoptotic factor Bax to bind to the 
mitochondria (Mathupala et al., 2009), (Pastorino et al., 2002), (Robey, 2005). HKII 
when bound to mitochondria also benefits from preferential access to ATP produced 
during OXPHOS (Arora and Pedersen, 1988). The combination of the above results 
in G6P accumulation which has a dual role: it serves as a carbon source both for 
entrance in the pentose phosphate pathway (PPP), and as the initial substrate for 
glycolysis (Pedersen et al., 2002). The binding/ detachment of HKII in normal cells 
might be controlled by growth-related signalling pathways that are unable to 
“unlock” the enzyme in cancer cells. This can result in inhibition of apoptosis, thus 
the cells show increased survival (Pedersen et al., 2002). 
All the above-mentioned characteristics and findings regarding hexokinase isoform II 
suggest that the latter is a major contributor of the immortalised profile that cancer 
cells exhibit (Figure 1.3). An excellent review by Lis, 2016, has demonstrated why 
HKII stands out from other targets of cancer treatment. Specifically the ability of 
HKII to bind to mitochondria is referred as the “Achilles heel” of cancer cells thus 




Figure 1.3: HKII, a key intermediate in cancer cell immortalisation 
Glucose is brought inside the cell across the plasma-membrane by GLUTs. HKII is mainly 
bound to the outer mitochondrial membrane (OMM) via VDAC. G6P produced from HKII 
reaction can either enter the PPP for nucleic acid biosynthesis or can either be converted to 
pyruvate following the glycolytic pathway. Most of the pyruvate is converted to lactate 
instead of proceeding to the TCA cycle/ OXPHOS which takes place in normal cells in the 
presence of O2. This results in the production of two ATPs in cancer cells instead of 38 ATP 
molecules per molecule of glucose consumed. The aerobic glycolysis is characteristic of 
most cancer cells and is known as the “Warburg effect”. Moreover, HKII is strategically 
located on the OMM thus it gains a preferential access to ATP generated in the mitochondria 
and it becomes less sensitive to G6P inhibition. Also, HKII when bound to mitochondria can 
inhibit Bax induced cytochrome c release, thus it prevents apoptosis leading to cancer cell 




1.3 Therapeutic studies targeting HKII 
Considering the multiple roles that HKII plays in tumours, it can be considered as an 
attractive target for therapeutic intervention. Agents showing glycolytic inhibition (2-
deoxyglucose (2-DG), and citrate) have already been tested as potential anticancer 
targets but have never shown to eradicate real cancers in animals. 2-DG is a glucose 
analogue, which enters the cancer cells to be phosphorylated by hexokinase. The 
product, 2-DG-6P cannot be further metabolised and it accumulates in a greater yield 
in cancer cells than in normal cells. The technology positron emission tomography 
(PET) uses the 
18
fluorine labelled radioisotope 2-DG to image the solid tumours and 
is the most effective method for cancer detection (Lis et al., 2016). 
Lonidamine (C15H10Cl2N2O2) is a known specific inhibitor of mitochondrial HKII 
since the early eighties when it was shown that 5 μM of lonidamine can decrease HK 
activity by 66% (Floridi et al., 1981). However, when lonidamine went to Phase II 
trials for GBM treatment combined with diazepam no therapeutic benefit was 
observed. The same drug reached Phase II/III trials for the treatment of benign 
prostatic hyperplasia but it was suspended after severe hepatic adverse effects 
(Porporato et al., 2011). 
Methyl jasmonate (C13H20O3), a plant stress hormone, can detach HKII when is 
bound to mitochondria although a high dose is required to have a significant effect 
(Goldin et al., 2008). 
3-Bromopyruvate (C3H3BrO3, 3BrPa) is a structural analogue of pyruvic acid, highly 
reactive with alkylating properties which covalently modifies cysteines with 
consequences for the conformation/ activity of the proteins (Lis et al., 2016). Studies 
have demonstrated that 3BrPa inhibits HKII in an ex vivo model of rabbit liver 
cancer (VX2 tumour model) (Ko et al., 2001). In a follow-up study on rats, 3BrPa 
was shown to selectively deplete ATP when animals were treated with this 
compound. All animals with advanced hepatoma were completely cancer free after 
3BrPa treatment without reoccurrence of cancer (Ko et al., 2004). However, the 
mechanism of 3BrPa is not completely understood and it is possible, because it is a 




The need for a more effective anticancer drug that would selectively inhibit HKII is 
still required and under research, since all previous drug candidates have not been 
successful at the clinical trials.  
 
1.4 Structural studies on HKII 
The crystal structure of hHKII has been determined by the Structural Genomic 
Consortium (SGC) in 2006, with Glc (substrate) and G6P (product, allosteric 
inhibitor) present (PDB code: 2NZT) in both domains. In contrast to HKI and HKIII, 
where many studies have been performed on the catalytic C domain and the inactive 
N domain (Arora et al., 1993), (Tsai and Wilson, 1997), (White and Wilson, 1989), 
HKII contains two functional domains with comparable catalytic activities (Tsai and 
Wilson, 1996), (Ardehali et al., 1996).  
The interaction of ATP with the active site of hexokinase II is still unknown since 
there is a lack of available crystal structures with the Hexokinase-ATP complex. 
However the putative ATP binding site has been studied  by molecular modelling 
and site-directed mutagenesis in brain hexokinase (Zeng et al., 1996). Based on the 
latter studies ATP is predicted to interact with D532, R539, K621, D657, T680, 
E783, T863. Figure 1.4 shows the active site of hHKII with the exact positions of the 
Glc and G6P as identified by the crystal structure and the putative site for ATP 
binding.  
 
Figure 1.4: Active site of hHKII 
The left panel shows the binding site of Glc and G6P shown as orange sticks. The 
white residues are the residues in hydrogen bond distance. The right panel shows the 
residues (pink sticks) which are predicted to interact with the ATP. As can be seen 
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the ATP putative binding site is in the same pocket as for Glc/G6P and in close 
proximity to both ligands 
Figure 1.5 shows hexokinase II (Chain A) consisting of two domains along with a 
closer representation of residues of N and C domains which interact with Glc and 
G6P, respectively. 
 
Figure 1.5: Monomer of hHKII and active site occupied by Glc and G6P 
Cartoon representation of monomer hHKII (2NZT) consisting of two domains, the N 
(purple-blue) and C (cyan) domain. Both domains bind the ligands, Glc and G6P, which are 
shown as pale green and salmon sticks, respectively.  
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It is observed that Glc forms one contact less in the C-terminal domain and T863 
substitutes for the N-terminal domain residue S415, maintaining, however, two 
hydrogen bonds to the G6P atom O7. The active site between the two domains are 
highly conserved but not identical. 
HKII is considered as a potential target for cancer treatment; however, the extremely 
polar active site, the sequence similarity with HKI (73% identical and 84% similar) 
and the conserved glucose binding sites among all hexokinases have made it less 
attractive for drug discovery projects. Nevertheless, a group from the USA recently 
published a very interesting article regarding the discovery of a novel 2,6-
disubstituted glucosamine series which selectively inhibited HKII in the nanomolar 
range (Lin et al., 2016). The following table contains the compounds discovered 
which were successfully co-crystallised with HKII, revealing for the first time an 
inhibitor-bound conformation of HKII. Unfortunately, there are no crystal structures 
for the compounds which showed an improved HKII selectivity. However, a 
Structure Activity Relationship (SAR) analysis revealed the following: a) 2,3-
disubstituted sulphonamides at the 6-position, b) less-bulky amides at the 2-position 
and c) sulphonamide at the 2-position could improve the IC50 for HKII by 500-fold 




Table 1.1: Compounds which were co-crystallised with HKII. The first reported 
inhibitor-bound HKII 
Compound_1 was one of the glucosamine derivatives discovered in a High-Throughput 
Screen (HTS). The co-crystal of compound_1 with HKII was rationalised to develop 











of ligand bound 
HKII (PDB code) 
Compound_1 
 
6.3 2.0 5HG1 
Compound_27 
 
0.13 0.0079 5HFU 
Compound_30 
 




The very first crystallographic data for HKII bound with inhibitory ligands were 
obtained with compound_1 and G6P. Compound_1 is a weak inhibitor of HKII with 
no specificity over HKI. All donor-acceptor interactions of the hydroxyl groups 
observed when Glc binds to HKII are present upon compound_1 binding to HKII. 
The comparison with crystal structure 2NZT shows that the enzyme is flexible and 
an “induced-fit” mode is seen for HKII in order to accommodate the bulky 
compound (Fig. 1.6.A). In more detail compound_1 places its glucosamine ring in 
the glucose-binding pocket, which is consistent with the glucose competitive mode 
of these compounds. The cocrystal structure of compound_1 with HKII reveals a 
flexible loop in the active site (residues 616-633) which does not close over the 
pyranose ring, thus a wider pocket is formed which can accommodate bigger 
compounds. 
Compounds 27 and 30 were subsequently co-crystallised with HKII without any 
other ligand present on the crystal (Fig. 1.6 B,C). The potency of compound_1 was 
improved by introduction of polar substitutions in the 6-position to mimic hydrogen 
bond interactions between the protein and G6P, since these new analogues were 
designed to extend into the G6P pocket. These modifications resulted in 
compound_27. Finally, a meta-carboxylic acid modification of the analogue resulted 
in compound_30 that was found to be more potent against HKII. However, the 









Figure 1.6: 2,6-disubstituted glucosamine analogues which were co-crystallised with 







A. 2NZT is shown as a grey cartoon and 5HG1 as a pink cartoon. The superposition of the 
two structures is shown. The flexible loop in the active site (residues 616-633, shown as blue 
loop for 5HG1 structure) does not close over the pyranose ring. The pink loop is shifted 3Å 
in the free HKII (without ligand). 
B. 5HFU is shown as a light orange cartoon. Compound_27 is shown as light orange stick. 
The interactions are shown along with the distances from each residue. 
C. 5HEX is shown as salmon cartoon. Compound_30 binding orientation is shown as salmon 
stick along with the interacting residues. 
 
The present study from (Lin et al., 2016) shows that a specific inhibitor for isoform II 
can be found with activity in the nanomolar range. These results suggest that the 
HKII target might be a difficult target but should not be considered as unattractive 
and more effort should be done to discover more inhibitors. Finally, it is very 
interesting and important that some of the compounds from the same study were 
tested against a tumour cell line (UM-UC-3) which mostly expresses HKII (over 
HKI) and the results revealed a) inhibition of G6P production, b) reduction of 




Trypanosome hexokinases and Human African Trypanosomiasis 
1.5 Trypanosoma brucei and HAT 
The African trypanosome Trypanosoma brucei is known to be the causative agent of 
human sleeping sickness or Human African Trypanosomiasis (HAT), a fatal disease 
if left untreated. T. brucei has traditionally been grouped into three subspecies: T. b. 
brucei, T. b. gambiense and T. b. rhodesiense. Parasites of the latter two subspecies 
affect humans, while T. b. brucei, together with other species (T. congolense and T. 
vivax) cause a similar disease in cattle called ‘nagana’ causing major economic 
losses (up to 4 billion US dollar annually in sub-Saharan countries). Unfortunately, 
HAT is a neglected disease, since the affected people belong to deprived populations 
which do not provide an economic market for the pharmaceutical industry. 
In the last century several major epidemics of sleeping sickness occurred each with 
thousands of victims. By better surveillance and vector control in the last two 
decades the number of annually infected people has now come down to less than 
3000 (Drugs for Neglected Diseases initiative, DNDi, 2017, 
http://www.dndi.org/diseases-projects/hat/). However, there is a serious risk of 
increased number of infected people yet again when health control breaks down in 
the politically unstable African countries. 
HAT consists of two stages: during the first stage the parasite spreads in the blood 
and the lymphatic system of the human host before the parasite crosses the blood-
brain barrier (stage II). Treatment of HAT is difficult especially in the CNS stage 
(stage II) and it is fatal if left without medical treatment (Russell et al., 2016). 
Figure 1.7 shows the life cycle of Trypanosoma brucei parasites. When a tsetse fly 
takes a blood meal it injects metacyclic trypomastigotes which are transformed to 
bloodstream-form (BSF) trypomastigotes in the human host while they are spreading 
into its blood and lymphatic system. Asexual multiplication of trypomastigotes takes 
place and a tsetse fly during a blood meal is infected from the host. In the infected 
tsetse fly the BSF trypomastigotes transform into procyclic-form (PF) 






Figure 1.7: Life cycle of Trypanosoma brucei parasites 
Picture taken from https://www.cdc.gov/parasites/sleepingsickness/biology.html 
 
The parasites, when in bloodstream form (BSF), rely exclusively on glycolysis for 
ATP production and it is that form that is pathogenic to the human host. Otherwise, 
when they are found in the midgut of the insect vector they belong to the procyclic 
form (PF), most of the time catabolising amino acids to produce ATP (Chambers et 
al., 2008b). Only after a blood meal, they preferentially consume glucose from the 
blood that is however exhausted within 15-30 minutes. Trypanosome glycolysis has 
a unique difference compared to human as the majority of the enzymes of the 
glycolytic pathway are compartmentalised in peroxisomes called glycosomes 




Figure 1.8: Glycolysis in the BSF of the African Trypanosome 
The first seven enzymes of the glycolytic pathway are organised inside glycosomes. Under 
aerobic conditions glucose is converted to 3-phosphoglycerate which then is further 
converted to pyruvate in the cytosol. 
 
Since BSF parasites depend entirely on the glucose metabolism for energy 
production, the glycolytic pathway could be exploited as a therapeutic target. 
Moreover, the unique organisation of glycolysis within glycosomes has led the 
trypanosomatid enzymes to adopt distinct kinetic, regulatory and structural 
properties. Thus, there is a good potential that a drug designed against the 
trypanosomatid enzymes will be selective, not affecting the human host enzymes 
(Albert et al., 2005). 
T. brucei expresses two hexokinases (TbHKI, TbHKII) which show 98% sequence 
identity. Most of the difference is located at the end of the amino acid sequence as 
shown in Figure 1.9. Recombinant TbHKI is active with activity levels similar to that 
of other hexokinases, while recombinant TbHKII lacks any detectable activity 
(Morris et al., 2006). Later, it was shown that parasites express active TbHKI which 
forms homohexameric complexes, not covalently linked (Chambers et al., 2008b). It 
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is not clear why T. brucei expresses two almost identical proteins with one of them 
being in an inactive form when forming a homomeric complex, in contrast to the 
active hexameric TbHKI. However, TbHKII can be activated when mixed with 
TbHKI and for this reason it might play a regulatory role (Chambers et al., 2008b).  
 
Figure 1.9: Sequence alignment between the two isoforms of T. brucei hexokinase 
Comparison of amino acid sequences between TbHKI and TbHKII. The different residues 
are underlined. The enzyme contains 471 amino acids with apparent mass at 50 kDa. 
Adapted from (Morris et al., 2006). 
 
TbHKI shares a low sequence identity with mammalian hexokinases (36-37%) and 
due to the unique organisation of glycosomes, TbHKI has distinct kinetic and 
regulatory properties like most of the other trypanosomatid glycosomal enzymes 
when compared with their counterparts in non-trypanosomatid organisms. For 
example, TbHKI is not regulated by its product G6P and it has a low specificity for 
ATP while it can also use ITP, UTP and GTP. Thus, the discovery of a selective 
inhibitor of trypanosomatid hexokinase could be considered. Moreover, TbHKI has 
been chemically and genetically validated as a target for therapeutic development. 
Morris and coworkers have shown the efficacy to kill BSF T. brucei with various HK 
inhibitors (see next section, 1.6) and Albert et al (2005) have proved that depletion of 





1.6 Inhibition studies on TbHKI, a therapeutic approach for 
sleeping sickness 
The currently available treatments need optimisation since they have toxic side 
effects, are not fully available, or are difficult to administer. For most drugs the exact 
mode of action is not clear. Figure 1.10 shows the structure of the established 
therapeutics and the drug candidates in clinical trials. Suramin and pentamidine fail 
to treat the disease when it is in the neurological stage and melarsoprol can cause 
death to 5-10% of patients receiving this drug. Finally, eflornithine has three 
drawbacks as it is expensive, is only effective against T. brucei gambiense 
subspecies and requires a long period (14 days) of many doses (4 times per day) of 
intravenous administration. However, it is successful in both stages of the disease 
(Sharlow et al., 2011). Recently, a combination of nifurtimox with eflornithine 
(NECT = nifurtimox, eflornithine combination therapy) has been introduced to lower 
and shorten the dose of eflornithine; nifurtimox is a drug frequently used in treatment 
American trypanosomiasis or Chagas disease. Like eflornithine, NECT is effective 
for stage II of the disease but only the form caused by T. brucei gambiense (Russell 
et al., 2016). Pafuramidine was suspended from clinical trials as it causes renal 
toxicity. Clinical phase I trials of the oxaborole compound SCYX-7158 have been 
successfully completed in 2016 and fexinidazole is undergoing phase II/III clinical 
trials (Russell et al., 2016). Because none of the above mentioned drugs have been 
effective it becomes clear that there is a need for development of novel compounds 




Figure 1.10: Currently available drugs and drug candidates for treatment of HAT 
Suramin and pentamidine are effective for the stage I of the disease. Melarsoprol, 
eflornithine, and its combination therapy with nifurtimox (NECT) are designated for stage II. 
Pafuramidine was recently taken to clinical trial but failed because of renal toxicity. 
Oxaborole is scheduled to enter clinical trials phase II/III in the near future, after completion 
of phase I in 2016 and a phase II/III clinical trial on fexinidazole is underway. Adapted from 
(Russell et al., 2016). 
 
A number of known inhibitors against TbHKI have been developed as potential 
drugs for HAT treatment (Table 1.2). However, they have not yet been tested in 
preclinical trials. Querquetin (QCN) is a natural flavanol found in plants such as 
apples, onions and capers. QCN was found to be a mixed inhibitor with respect to 
ATP against recombinant TbHKI. The compound potency did not result from 
dissociating the hexamer formation (Dodson et al., 2011). 
Lonidamine, a known inhibitor of mitochondria-bound mammalian HK, has been 
also investigated as a potential anti-parasitic compound. The compound was found to 
inhibit recombinant TbHKI and TbHKI purified from parasites, with the inhibition 
being non-competitive with respect to ATP. Moreover, lonidamine was shown to be 
toxic against both BSF and PF parasites cultured in vitro. However, when PF 
23 
 
parasites were grown in low-glucose medium, and rely heavily on amino acid 
oxidation for their ATP supply, the toxicity was overcome suggesting that the 
compound indeed inhibits glycolysis of the parasites. TbHKII 
-/- 
homozygous 
trypanosomes did not show sensitivity to lonidamine and finally TbHKI 
overexpression limited the toxic effects of the compound; all findings suggesting that 
TbHKI is the target (Chambers et al., 2008a). 
A HTS campaign to identify potential inhibitors of TbHKI led to the discovery of ten 
inhibitors (Sharlow et al., 2010). The most potent among these inhibitors were 
Ebselen (EbSe) and EbS (the latter differs from EbSe by replacement of the selenium 
atom with sulphur). These structurally related inhibitors were found to be mixed 
inhibitors with respect to ATP (Sharlow et al., 2010). Ebse was further studied to 
reveal that it inhibits TbHKI by oxidising a single critical Cys residue (Cys327) 
(Joice et al., 2012). It is suggested that the BSF parasite toxicity is because of 




Table 1.2: Selective known inhibitors of TbHKI 
Listed are some known inhibitors of TbHKI with IC50 values determined in the low-high 
micromolar range. (R) indicates the IC50 of recombinant TbHKI while (L) is the IC50 for 
lysates of BSF T. brucei parasites. 























































1.7 Structural studies on TbHKs 
The crystal structure of T. brucei hexokinase is not yet known. The only published 
structural study involves a model of T. brucei hexokinase by Willson et al., 2002. 
During this study a series of analogues of glucosamine were tested on TbHKI 
purified from BSF parasites and potent specific inhibitors (with selectivity over yeast 
hexokinase) were identified. 
The most potent compound (Compound 8, Fig. 1.11 A) is an m-bromophenyl 
glucosamide whose binding mode was predicted by molecular dynamics simulation 
performed with the structure TbHKI model (Willson et al., 2002). The compound 
was predicted to bind close to the glucose binding site (Fig.1.11 B) and in close 
proximity to ortho-toluyl-glucosamide (OTG) that has been modelled in yeast 
hexokinase (Steitz et al., 1977). The trans conformer of the bromine atom yielded 
lower interaction energy and both the aromatic and amidic bonds were coplanar 
compared to perpendicular for yeast hexokinase bound to ortho-toluyl-glucosamide 
(OTG). The bromine atom interacts with R176, T178 and Q300, whereas the close 
distance of both the terminal and internal NH of R176 could induce a positive π 
interaction which is stronger than common hydrogen bonds which could account for 






Figure 1.11: Inhibition value IC50 (mM) for most potent glucosamine derivative on HK of 
yeast and T. brucei. The ligand is modelled to propose the binding mechanism 
A series of glucosamine analogues were studied on both the yeast and T. brucei hexokinase 
A: The R substitution of the glucosamine analogue is shown along with the IC50 value for 
yeast and T. brucei respectively. The dash indicates no effect at 20mM. 
B: The modelling studies with compound 8, the most potent and selective inhibitor, show 
that the selectivity is provided by the coplanar orientation of the aromatic ring attached at the 
glucose moiety which makes a π
+
-NH3R interaction with the Arg176 which is unique to 
parasites. Adapted from (Willson et al., 2002). 
 
No crystallographic studies have been reported for TbHKI and the binding mode of 
all of the above mentioned compounds is still unknown. Moreover, the glucosamine 
compounds need further optimisation since the IC50 is in millimolar range. However, 
the fact that the glucosamine analogues are specific for TbHKI gives hope for the 
discovery of potent and selective inhibitors for future therapeutic development of 
HAT. 
 
1.8 Aims of the project 
From a review of the literature, it is clear that mammalian and parasite hexokinases 
are involved in two major diseases, cancer and HAT, respectively. The enzymes are 
validated targets against both diseases although the current compounds/ drugs tested 
 
R Compounds Yeast T. brucei
C6H5 1 7 8
o-CH3-C6H4 2 8 6
o-NH2-C6H4 3 1 4.5
m-NH2-C6H4 4 6 1.8
o-NO2-C6H4 5 3 0.4
m-NO2-C6H4 6 6 2
o-Br-C6H4 7 – 3
m-Br-C6H4 8 – 0.5
o-I-C6H4 9 – 4
CH2Br 10 9 3
CH2CH2Br 11 7 3




have not succeeded to reach the market. Both diseases are in need of a therapeutic 
method which will be effective, without toxic effects on the human host and, 
particularly for the neglected parasitic disease, without significant high cost of 
administration. Therefore, the aim of this project is the discovery of novel 
compounds that will effectively inhibit the recombinant hexokinases from both 
organisms. There is also a lack of biophysical characterisation of the aforementioned 







2. Chapter 2: Protein expression and purification of hHKII 
and TbHKI 
 
The expression and purification strategies of hHKII and TbHKI will be discussed in 
this chapter. The plasmid containing the ORF of human hexokinase II was purchased 
from Addgene (Cambridge, USA, plasmid no 25529). This construct, Thr hHKII, is 
lacking the first 16 amino acids of the human hexokinase isoform II and has a 6His 
tag with a Thrombin cleavage site at the N terminal site. During the project 4 
different constructs of hHKII were made. Cloning by restriction enzyme digests was 
performed to create these using the NdeI as the 5’ cloning site and and EcoRI as the 
3’ site respectively. The Addgene plasmid DNA was used as the template DNA for 
all cloning methods. The different constructs created are numbered here: 
1) hHKII (17-917) with a TEV recognition site (ENLYFQ/S) on the N-terminal site 
(TEV hHKII) 
2) hHKII (17-917) without an affinity tag (untagged hHKII) 
3) N domain of hHKII with a TEV recognition site on the N-terminal (17-475) (N 
hHKII) 
4) C domain of hHKII with a TEV recognition site at the beginning of C domain 
(476-917) (C hHKII) 




FLhHKII_Uniprot      ---MIASHLLAYFFTELNHDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHP 
TEV_hHKII            ----HHHHHHGAENLYFQSDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHP 
Thr_hHKII            MGSSHHHHHHSSGLVPRGSDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHP 
Untagged_hHKII       -------------------DQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHP 
N_hHKII              ----HHHHHHGAENLYFQGDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHP 
C_hHKII              ------------------------------------------------------------ 
                                                                                  
 
FLhHKII_Uniprot      TAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPED 
TEV_hHKII            TAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPED 
Thr_hHKII            TAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPED 
Untagged_hHKII       TAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPED 
N_hHKII              TAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPED 
C_hHKII              ------------------------------------------------------------ 
                                                                                  
 
FLhHKII_Uniprot      IMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKS 
TEV_hHKII            IMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKS 
Thr_hHKII            IMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKS 
Untagged_hHKII       IMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKS 
N_hHKII              IMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKS 
C_hHKII              ------------------------------------------------------------ 
                                                                                  
 
FLhHKII_Uniprot      SGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNAC 
TEV_hHKII            SGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNAC 
Thr_hHKII            SGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNAC 
Untagged_hHKII       SGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNAC 
N_hHKII              SGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNAC 
C_hHKII              ------------------------------------------------------------ 
                                                                                  
 
FLhHKII_Uniprot      YMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMI 
TEV_hHKII            YMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMI 
Thr_hHKII            YMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMI 
Untagged_hHKII       YMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMI 
N_hHKII              YMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMI 
C_hHKII              ------------------------------------------------------------ 
                                                                                  
 
FLhHKII_Uniprot      SGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLM 
TEV_hHKII            SGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLM 
Thr_hHKII            SGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLM 
Untagged_hHKII       SGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLM 
N_hHKII              SGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLM 
C_hHKII              ------------------------------------------------------------ 
                                                                                  
 
FLhHKII_Uniprot      RLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVY 
TEV_hHKII            RLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVY 
Thr_hHKII            RLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVY 
Untagged_hHKII       RLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVY 
N_hHKII              RLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVY 




Figure 2.1: Sequence alignment of all hHKII constructs created for the project 
FL_hHKII_Uniprot is the protein sequence taken from Uniprot database 
(http://www.uniprot.org/uniprot/P52789). The coloured sequence in FL-hHKII shows the 
FLhHKII_Uniprot      KKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHL 
TEV_hHKII            KKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHL 
Thr_hHKII            KKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHL 
Untagged_hHKII       KKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHL 
N_hHKII              KKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLE-- 
C_hHKII              -------------------------------------------HHHHHHGAENLYFQGHL        
 
FLhHKII_Uniprot      QLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTN 
TEV_hHKII            QLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTN 
Thr_hHKII            QLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTN 
Untagged_hHKII       QLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTN 
N_hHKII              ------------------------------------------------------------ 
C_hHKII              QLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTN 
                                                                                  
 
FLhHKII_Uniprot      FRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLP 
TEV_hHKII            FRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLP 
Thr_hHKII            FRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLP 
Untagged_hHKII       FRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLP 
N_hHKII              ------------------------------------------------------------ 
C_hHKII              FRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLP 
                                                                                  
 
FLhHKII_Uniprot      LGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVND 
TEV_hHKII            LGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVND 
Thr_hHKII            LGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVND 
Untagged_hHKII       LGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVND 
N_hHKII              ------------------------------------------------------------ 
C_hHKII              LGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVND 
                                                                                  
 
FLhHKII_Uniprot      TVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGC 
TEV_hHKII            TVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGC 
Thr_hHKII            TVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGC 
Untagged_hHKII       TVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGC 
N_hHKII              ------------------------------------------------------------ 
C_hHKII              TVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGC 
                                                                                  
 
FLhHKII_Uniprot      LDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLK 
TEV_hHKII            LDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLK 
Thr_hHKII            LDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLK 
Untagged_hHKII       LDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLK 
N_hHKII              ------------------------------------------------------------ 
C_hHKII              LDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLK 
                                                                                  
 
FLhHKII_Uniprot      TRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAG 
TEV_hHKII            TRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAG 
Thr_hHKII            TRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAG 
Untagged_hHKII       TRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAG 
N_hHKII              ------------------------------------------------------------ 
C_hHKII              TRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAG 
                                                                                  
 
FLhHKII_Uniprot      MAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGS 
TEV_hHKII            MAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGS 
Thr_hHKII            MAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGS 
Untagged_hHKII       MAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGS 
N_hHKII              ------------------------------------------------------------ 
C_hHKII              MAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGS 
                                                                                  
 
FLhHKII_Uniprot      GKGAALITAVACRIREAGQR 
TEV_hHKII            GKGAALITAVACRIREAGQR 
Thr_hHKII            GKGAALITAVACRIREAGQR 
Untagged_hHKII       GKGAALITAVACRIREAGQR 
N_hHKII              -------------------- 
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residues that are absent from all other constructs. The coloured sequence for the rest 
shows the affinity tags at the beginning of each construct. 
 
T. brucei hexokinase I ORF was purchased from Geneart. According to TriTrypDB 
database (Aslett et al., 2009) the amino acid sequence for the active form of 




The DNA sequence was optimised for E.coli expression system to overcome the 
codon usage bias. The NdeI and EcorI restriction sites were used as the 5’ and 3’ 
cloning sites. The 5’ cloning site was designed in order to attach the 6His tag with a 





2.1.1 Cloning of human HKII constructs 
For cloning we used the DNA coding sequence for Thr hHKII (17-917) that was 
obtained from Addgene. The following set of primers were designed and purchased 
from Integrated DNA Technologies (IDT) to amplify the DNA coding sequence. 
 
Table 2.1: All the primers used for the cloning procedures 
The below set of primers were designed and purchased from Integrated DNA Technologies 
(IDT) to amplify the DNA coding sequence (ORF of hHKII from Addgene). 
Primer name Description 5’-3’ Sequence 
TEV For Replaces Thr site 
for TEV site 
(ENLYFQ/S) 
Attaches NdeI 







hHKII Rev Attaches EcoRI 
restriction site at 




N For Attaches NdeI 
restriction site at 
the beginning and 








Primer name Description 5’-3’ Sequence 
N Rev Attaches EcorI 
restriction site at 




C For Attaches NdeI 
restriction site at 
the beginning and 






C Rev Attaches EcorI 
restriction site at 




Untag For Attaches NdeI 





For all PCR reactions the Elongase enzyme mix kit (Invitrogen) was used. The 





Table 2.2: Reaction set up for PCR Elongase enzyme mix 
Elongase enzyme mix was used for the DNA amplification. The recommended protocol was 
followed. Mix 1 is added to Mix 2 in an amplification tube on ice.  
 
Mix 1 Volume Mix2  Volume 
dNTP mix (10mM) 1 μl 5x Buffer A 5 μl 
Forward primer 
(10μM) 
1 μl 5x Buffer A 5 μl 
Reverse primer 
(10μM) 
1 μl Elongase 1 μl 
DNA template 
(>100nM) 
1-2 μl (depending 
the concentration of 
the template) dH2O  Up to 30 μl 
dH2O Up to 20 μl 
 
The annealing temperature was not the same for all cloning as the primers had 
different annealing temperatures (Ta) based on their length and composition. 
 
The PCR reaction conditions for the untagged and TEV hHKII are shown below: 
1) Pre-amplification denaturation 94oC for 30sec, 1cycle 
2) Thermal cycling Denaturation: 94oC for 30sec 
 Annealing: 55-65
o
C for 30sec       30 cycles 
 Extension: 68
o






For the amplification of the N and C domains of hHKII the following cycling 
conditions were performed: 
1) Pre-amplification denaturation 94oC for 30sec, 1cycle 
2) Thermal cycling Denaturation: 94oC for 30sec 
 Annealing: 50
o
C for 30sec                 10 cycles                                                                                                       
 Extension: 68
o
C for 2min:15sec 
 Denaturation: 94
o
C for 30sec 
 Annealing: 60
o
C for 30sec                 20 cycles 
 Extension: 68
o
C for 2min:15sec 
The PCR cycling conditions are done in two steps for the N and C domains. The 
reason for this is because the Tm of the part of the primer complementary only to the 
gene is lower compared to the Tm of the entire primer (Restriction site + His tag + 
gene). In this case the first 10 cycles performed are specific for the part of the primer 
complementary to the gene (55 degrees Celsius). Then the Tm is increased to 65 
degrees Celsius to factor in the whole length of the primer, thereby making the PCR 
product more likely to be highly specific. 
The PCR products were verified on a 0.7% agarose gel. The band at the expected 
size was cut out from the agarose gel and purified using a PCR purification kit 
(QIAquick).  
After the purification of the DNA, the overnight restriction digests for the donor and 
recipient plasmid were performed separately. All restriction enzymes were purchased 




Table 2.3: Set up reaction for double restriction digest 
The overnight digests of vector and DNA insert were performed at 37
o
C using both 
restriction enzymes (1 μl each is added to the mix). The mix volume is made up to 50 μl 
following the instructions below. 
Component Volume 
Restriction enzyme 1 1 μl 
Restriction enzyme 2 1 μl 
Vector or Insert ~1 μg  
10X NEBuffer 5 μl 
dH2O Up to 50 μl 
 
The overnight incubation took place at 37
o
C. The restriction digest was verified in a 
0.7% agarose gel and the desired bands were excised from the gel and purified. 
Finally, we conducted a DNA ligation to fuse the insert with the recipient plasmid, 
pET3a. T4 DNA ligase from New England Biolabs was used for this step and the 
following reaction was set up in a microcentrifuge tube on ice: 
 
Table 2.4: Set up reaction for DNA ligation 
DNA ligation was performed following the titration below, to ligate pET3a with the insert 
DNA.  
Component Volume 
10X T4 DNA ligase Buffer 2 μl 
Vector DNA (4.64 kb) 70 ng or 30 ng 
Insert DNA (2.7 and 1.35kb) 30 ng or 35 ng 
T4 DNA ligage 1 μl 




The ligation was made with a 4:1 molar ratio of insert to vector taking into account 
the DNA sizes. For whole hHKII (2.7 kb) the ratio was 30 ng:70 ng of insert:vector 
and for the N and C domains (1.35 kb) respectively, the ratio was 35 ng:30 ng. The 
ligation mix was incubated for 20 min at room temperature (RT), then cooled on ice 
for a couple of minutes. DH5α cells were then transformed following the common 
protocol. Plates were left overnight at 37
o
C and next day were examined for single 
colonies. Mini-preps were set up overnight in 5 ml LB containing 100 μg/ml 
carbenicillin and plasmid DNA was purified using QIAprep Spin Miniprep kit from 
QIAGEN. All DNA sequencing was carried out by either the GenePool service of 
University of Edinburgh or the Dundee sequencing facility within the Medical 
Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) in 
Dundee, Scotland. DNA chromatograms were viewed with FinchTV 
(http://www.cambridgesoft.com/services/SupportNews/details/?SupportNews=124) 
and sequences were analysed with Clustal Omega software (Larkin et al., 2007). 
 
2.1.2 TbHKI subcloning to expression vector  
The plasmid containing the gene of interest is shown in Figure 2.2. The cloning 
plasmid has a size of 3754 bp from which 1476 bp belong to the gene of interest. The 
plasmid was transformed to DH5a cells following the common protocol. 
 
 
Figure 2.2: Cloning plasmid containing the ORF of TbHKI 





Following the transformation of DH5a cells the DNA of interest was cloned to the 
expression vector pET3a. Restriction reactions were set up for both cloning and 
expression vectors. EcorI and NdeI were purchased from New England Biolabs and 
the recommended protocol was used. To maximise the capacity of the restriction 
enzyme the reaction was left overnight at 37
o
C.The reactions were run in a 0.7% 
agarose gel, stained with the Safeview dye, for 50 min at 100 mAU. The expression 
vector pET3a with TbHKI ORF was kept at -20
o
C for future transformation of 
different cell lines for protein expression trials. 
 
2.1.3 Transformation and expression of hHKII and TbHKI constructs 
2.1.3.1 hHKII 
Plasmid DNA was transformed to E.coli BL21 Codon Plus (DE3) RIL competent 
cells (Agilent). Protocols from suppliers were followed. All agar plates and mediums 
contained the appropriate antibiotics. 
Construct Antibiotics used in LB plates and 
mediums 
Thr hHKII (pET28-LIC) 50 μg/ml Kanamycin (plasmid), 34 μg/ml 
Chloramphenicol (cells)  
Untagged hHKII, TEV hHKII, N hHKII, 
C hHKII (pET-3a) 
100 μg/ml Carbenicillin (plasmid), 34 
μg/ml Chloramphenicol (cells) 
 
Single colonies of transformants were picked from LB plates and used to inoculate 
50 ml of LB and left shaking overnight at 250 rpm, 37
o
C. 50ml of the overnight 
culture was used to inoculate each of 500 ml of Terrific broth (TB) medium, LB 
medium, 2xTY medium and SOC medium. When OD600= 3.0, protein expression 
was induced with 1 mM IPTG and the cultures transferred to 15
o
C and left shaking 
overnight. For N and C domains only TB and LB medium were used. For cold shock 
treatment, when OD600= 0.8, cultures were transferred to 4
o
C for 1 hour. Finally 
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protein expression was induced with 1mM  IPTG at 20
o
C overnight. Induction 
performed at 250 rpm unless otherwise stated. 
 
2.1.3.2 TbHKI 
The following table contains in summary the cell lines, media and conditions tested 
in order to get soluble expression of TbHKI. For every cell line the suggested 
protocol was followed. BL21 star (DE3) and C43 (DE3) competent cells were 
available within the group. BL21-CodonPlus RIL (DE3) and ArcticExpress 
competent cells were purchased from Agilent. Overnight cultures (obtained as in 
section 2.1.3.1) were inoculated to the appropriate medium for induction. 
 
Table 2.5: Conditions screened for expression of TbHKI 
Cell line Antibiotics used Media Description 
BL21-CodonPlus 






1 mM IPTG induction, 
Overnight at 30
o
C, 250 rpm 
BL21-CodonPlus 





1 mM IPTG induction, 
Overnight at 18
o
C, with and 
without cold shock, 250 
rpm 
BL21-CodonPlus 
(DE3) RIL strain 
Carbenicillin and 
Chloramphenicol 
LB, TB 1 mM IPTG induction, 3h at 
37
o
C, 250 rpm 
BL21-CodonPlus 
(DE3) RIL strain 
Carbenicillin and 
Chloramphenicol 




250 and 100 rpm 
C43 (DE3) Carbenicillin LB, TB 1 mM IPTG induction, 
Overnight at 18
o
C, 3h at 
37
o
C, 250 rpm 
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Cell line Antibiotics used Media Description 
BL21 star (DE3) Carbenicillin LB, SB, 
2xTY 
1 mM IPTG induction, 
Overnight at 18
o
C, 250 rpm, 
with and without cold shock 
BL21 star (DE3) Carbenicillin LB, TB 1 mM IPTG induction, 
Overnight at 18
o
C, 3h at 
37
o
C, 250 rpm 
BL21 star (DE3) Carbenicillin TB Coexpression with GroEL/ 
GroES, 1 mM IPTG 
induction, Overnight at 
18
o
C, 250 rpm 
ArcticExpress 
(DE3) 
Carbenicillin and 20 
μg/ml Gentamycin 






2.1.4 Common steps before any purification strategy  
All purifications were performed using AKTA purifier systems (10 ml/min or 100 
ml/min) at 6
o
C. All buffers were prepared at 4-6
o
C unless otherwise stated. The 
cellular pellet was resuspended in 5 ml of Lysis Buffer (i.e the buffer used to 
equilibrate the first chromatographic column containing a protease inhibitor cocktail 
tablet, unless otherwise stated) per 1 gram of cell pellet. The resuspension was 
passed through a Constant Systems cell disruptor to break open the cells. The lysate 
from this was then centrifuged at 20,000xg for 45 min at 4-8
o
C. The supernatant was 





2.1.5 Three step purification of Thr hHKII 
2.1.5.1 Anion Exchange Chromatography (AEX)  
The supernatant was loaded into the column HiPrep 16/10 DEAE FF, pre-
equilibrated with Buffer A (10 mM Tris pH 7.5, 0.5 M NaCl, 5% glycerol, 5 mM 
imidazole) with a stable flowrate set at 5ml/ min. Molecules that are bound to the 
resin elute with 0.5 M NaCl. The collected fractions were pooled together for the 
next step.  
 
2.1.5.2 Immobilised Metal Ion Affinity Chromatography (IMAC) 
The fractions from previous step were loaded onto a 5 ml affinity column (HiTrap FF 
5 ml, charged with 0.1 M NiCl2, pre-equilibrated with Buffer A) at 5 ml/min 
flowrate. The column was washed with 30 column volumes (CV) of Buffer B (10 
mM Tris pH 7.5, 0.5 M NaCl, 5% glycerol, 30 mM imidazole). The target protein 
was eluted with 10 CV of Buffer C (10 mM Tris, pH 7.5, 0.5 M NaCl, 5% glycerol, 
250 mM imidazole). The purity of the fractions was confirmed in SDS-PAGE gel 
and the fractions containing the desired protein were pooled together. The pooled 
fractions were concentrated to ~10 ml for the next step using a Vivaspin column 
(molecular weight cut-off= 30 kDa). 
 
2.1.5.3 Size exclusion chromatography (SEC) 
HiLoad 26/60 Superdex 200pg was equilibrated with 2 CV of Gel Filtration Buffer 
(10 mM Tris, pH 8.0, 0.5 M NaCl, 5 mM MgCl2 and 10 mM DTT). The sample was 
injected through a 10 ml loop, the flowrate was set to 2.5 ml/ min and fractions were 
collected and resolved in an SDS-PAGE. Pure hHKII was pooled and concentrated to 
1 mg/ ml. 
 
2.1.6 Cleavage of 6His tag using Thrombin protease 
1) hHKII in Gel Filtration Buffer was incubated with Thrombin (GE healthcare) 
at 4
o
C overnight (10 U/mg of protein). SDS-PAGE analysis was performed.  
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2) As Thrombin could be more active in a lower concentration of NaCl and in 
the presence of CaCl2, hHKII in Gel Filtration Buffer was diluted 1:10 in Thr 
Buffer: 50 mM Tris, pH 8.0 (adjusted at RT), 150 mM NaCl, 2.5 mM CaCl2. 
50 μg of protein was incubated overnight at RT with 2 U and 4 U of 
Thrombin. Samples were analysed by SDS-PAGE (200 V, 55 min) and 
Western Blot. 
 
2.1.7 Solubility assay 
10 μl of the protein (initial concentration 10 μM) was diluted to 90 μl of buffer under 
study and left for incubation on the bench for 1 hour. Using a Vivaspin concentrator 
with a molecular weight cut-off= 300 kDa (GE Healthcare), soluble protein was 
separated from the aggregates (after centrifugation at 16,000x g for 15 minutes) and 
collected in the flow through. The aggregated protein was retained in the membrane 
and to retrieve it 30 μl of dH2O was pipetted across the membrane. 30 μl of soluble 
and 30 μl of aggregated protein were mixed separately with 10 μl of 4x Sample 
Buffer (250 mM Tris-HCl, 40% glycerol, 140 mM SDS, 0.6M β-mercaptoethanol, 
pH 6.8) and heated to 90
o
C for 10 minutes prior to SDS-PAGE. 
 
2.1.8 Three step purification of N and C domain of hHKII 
The purification protocol for both domains of hHKII is exactly the same as described 
at section 2.1.5 for Thr hHKII. All columns and buffers used were the same as 
previously mentioned apart from Gel Filtration Buffer: 10 mM Tris, pH 8.0, 0.5 M 
NaCl, 5 mM MgCl2, 2 mM DTT, 2% glycerol. All fractions after each step were 
analysed with SDS-PAGE gel to monitor the presence and the purity of the target 
protein. Both proteins were concentrated to 1 mg/ml using a Vivaspin concentrator 
with molecular weight-cut off= 30 kDa. 
 
2.1.9 Three step purification of TEV hHKII 
The purification process for the 6His tag TEV cleavable protein was the same as 




2.1.10 Cleavage of 6His tag using TEV protease 
TEV cleavage screening conditions were set up as follows:  
Protein was desalted in TEV Buffer (50 mM Tris, pH 8.0 adjusted at RT, 1 mM 
DTT, 150 mM NaCl) using a HiTrap Desalting 5ml column.  
a) In 50 μg of desalted hHKII add 2.5 U of TEV and leave for overnight 
incubation at 4
o
C and RT (21
o
C) 6His tag Cyclophilin A used as a 
positive control).  
b) In 50 μg of desalted hHKII add 5 U of TEV and leave for overnight 
incubation at 4
o
C and RT (21
o
C). (Cyclophilin A as a positive control). 
SDS-PAGE was used to analyse results. 
                        
2.1.11 Three step purification of Untagged hHKII 
The AEX was chosen as the first step for the purification of the hHKII lacking any 
affinity tag. Resource 30Q (2 ml/ min) was used to perform the pH screening from 
7.0-8.0 (0.5 intervals). The Akta automated buffer preparation system was used to 
make the buffers that are differing in their pH value and ionic strength during the 
elution steps. Buffer A: 0.1 M Hepes and Buffer B: 0.1 M Hepes. 2 M NaCl is made 
up by the user and the Akta system mixes them along with 2 M NaOH to create the 
desired pH and anionic strength. Lysis Buffer: 10 mM Tris, 50 mM NaCl, 5% 
glycerol, pH 7.5 (+ protease inhibitor tablets) was used to resuspend the cell pellets. 
After cell disruption and centrifugation the soluble supernatant was loaded to the 
Resource 30Q (2 ml/min) pre-equilibrated with Buffer A. The elution protocol was 
the same for all runs: 
Elution protocol 
(20 ml of lysate loaded to column) 
1) Linear gradient: 0-60% Buffer B in 
60 CV 
2) Linear gradient: 60-100% Buffer B in 
5 CV 




All fractions were analysed with SDS-PAGE to monitor the purity of the target 
protein under different pH conditions. 
Resource 6Q (20 ml/min) was used when purification performed in bigger scale 
(~100 ml of lysate loaded into the column). The elution profile was the same as 
previously mentioned. 
The pooled fractions from this step were loaded into the affinity column HiTrap blue 
HP (1 ml/ min). The unbound material was washed with 15 CV of Buffer A and 
target protein eluted with a gradient of 0-100% B in 10 CV. SDS-PAGE were run to 
determine the presence of the target protein. The fractions containing a band at the 
expected size were pooled together and finally loaded to the SEC Superdex 26/600 
200pg pre-equilibrated with the Gel Filtration Buffer: 10 mM Tris, 0.5 M NaCl, 5 
mM MgCl2, pH 8.0. Fractions were analysed with SDS-PAGE gel and protein was 
stored for further analysis. 
 
2.1.12 TbHKI purification from inclusion bodies 
The protein was captured and eluted as unfolded in an affinity column and the 
refolding process took place during the SEC step. The Buffers used for this protocol 
are as follows: 
Buffer A: 50 mM HEPES, pH 7.8, 6 M GuHCl, 1 mM DTT, 20 mM Imidazole  
Buffer B: 50 mM HEPES, pH 7.8, 6 M GuHCl, 1 mM DTT, 500 mM Imidazole 
Buffer C: 50 mM HEPES, pH 7.8, 500 mM NaCl, 2 mM DTT, 250 mM L-Arginine, 




Figure 2.3: Schematic representation of refolding protocol of TbHKI in SEC column 
The diagram is a representation of the steps performed for the isolation of inclusion bodies 
and refolding of the denaturing protein. A two-step purification protocol was performed with 
an affinity step to capture the unfolded TbHKI followed by in SEC column refolding. The 
unfolded TbHKI enters the Superdex 200 10/300GL which has a 6ml inverse gradient from 6 
M Guanidine Hydrochloride (GuHCl) to 0 M GuHCl. 
 
Cell pellet from 0.5 L cell culture was resuspended in Buffer A (+ protease inhibitor 
cocktail tablet), containing 6 M of the denaturant GuHCl. The cells were disrupted 
by sonication at 25 kPsi and the lysate was left stirring at RT for 1 hour. The lysate 
was then centrifuged at 15,000g for 30 min and the supernatant was filtered using a 
0.22 μm filter. The supernatant was loaded into a 5ml cOmplete His-Tag purification 
column (Roche, 5 ml/min), pre-equilibrated in Buffer A. The unbound proteins were 
eluted with 25 CV of Buffer A and the target protein eluted with 10 CV of Buffer B 
(2 ml fractions collected). The fractions were not analysed with SDS-PAGE as the 
protein and the SDS were precipitating even after 1:1 dilution in dH2O. The fractions 
from the elution step that had a high absorbance at Abs280 were pooled together for 
the next stage.  
Superdex 200 10/300GL was used for the in-column refolding of TbHKI. The 
column was equilibrated with 2 CV of Buffer C and then an inverse linear gradient of 

































that protein gradually inserts into the refolding Buffer C. One ml concentrated, 
pooled fractions from previous step (Vivaspin column molecular weight cut-off= 30 
kDa) was loaded manually from a 1 ml loop to the system. The flow rate was 0.5 
ml/min so the passage of the protein from 6 M to 0 M of guanidine (6 ml inverse 
gradient) lasted for 12 min. The fractions were analysed with SDS-PAGE. 
 
2.1.13 TbHKI purification from soluble fraction 
Buffer A: 20 mM NaHPO4, pH 7.5, 250 mM NaCl, 5 mM imidazole, 2% glycerol, 
150 mM NDSB 201, 0.1% Tween 20 (+ protease inhibitor tablet) 
Buffer B: 20 mM NaHPO4, pH 7.5, 250 mM NaCl, 5 mM imidazole, 2% glycerol, 
150 mM NDSB 201, 0.1% Tween 20, 0.1% Reduced Triton 
Buffer C: 20 mM NaHPO4, pH 7.5, 250 mM NaCl, 20 mM imidazole, 2% glycerol, 
150 mM NDSB 201, 0.1% Tween 20 
Buffer D: 20 mM NaHPO4, pH 7.5, 250 mM NaCl, 250 mM imidazole, 2% glycerol, 
150 mM NDSB 201, 0.1% Tween 20 
Cell pellets from 4 L of cell culture in BL21 star (DE3) were resuspended in Buffer 
A, and centrifuged at 30,000xg for 45 min. The supernatant was sonicated and 
filtered before loading into 1 ml cOmplete His-Tag resin (1 ml/min). The unbound 
material was washed with 10 CV of Buffer B, the lightly bound protein on the 
column was removed by passing 20 CV of Buffer C and finally the target protein was 
eluted with 10 CV of Buffer D (2 ml fractions).  
The fractions containing the target protein, as seen from SDS-PAGE, were 
concentrated and 0.5 ml was loaded into the SEC column, Superdex 200 10/300GL 
(pre-equilibrated with Gel Filtration Buffer: 20 mM NaHPO4, 250 mM NaCl, 2 mM 




2.2 Results and Discussion 
2.2.1 Expression and purification of Thr hHKII 
With the vector pET28a-LIC the biosynthesis of proteins is driven by the T7 lac 
promoter. The T7 expression system is also supported from the BL21-CodonPlus 
(DE3) RIL E. coli. Overexpression of Thr hHKII protein induced by IPTG (final 
concentration 1 mM) was proven by the detection of a thick band at the expected 
mass (~100 kDa) in SDS-PAGE gel. It was concluded that the protein is expressed in 
a better yield when grown in TB medium compared to 2xTY and SOC medium, 
whereas cultures grown in LB medium showed no expression at all.  
 
Figure 2.4: SDS-PAGE after expression of Thr hHKII 
SDS-PAGE gel after expression trials of Thr hHKII shows that the over-expression of 
soluble protein was successful in TB, SOC and 2xTY medium. The red box highlights the 
thick bands that correspond to the ~100 kDa Thr hHKII. The fractions run in the gel are 
separated as pre-induced sample (pre), after induction sample (post), soluble fraction (sol) 
and insoluble fraction (pell). The band in the soluble fraction of TB medium is more intense 
than for SOC and 2xTY. The LB broth did not show any overexpression.  
 
1 L of pellets were purified and passed through the cell disruptor at 25 kPSI. The 
filtered supernatant was loaded into the AEX HiPrep 16/10 DEAE FF at 0.5 ml/min. 
Ion exchange chromatography (IEX) separates proteins that differ in their net surface 
charge. Each protein has its own unique net charge change when pH changes but the 
general rule that applies to the IEX is that a protein at a pH above its pI will bind to a 
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positively charged medium (anion exchanger) and at a pH below its pI a protein will 
interact with a negatively charged medium (cation exchanger). hHKII has a 
theoretical pI of 5.85 (estimated by Expasy Protparam tool, 
http://web.expasy.org/protparam) so it is negatively charged in the Buffer A (pH 
7.5). It ies expected therefore to interact with the positively charged resin HiPrep 
16/10 DEAE FF. SDS-PAGE gel comparing the cell lysate and the flow through 
after the DEAE shows little difference so we could speculate that all proteins elute 
from resin at the same time apart from other negatively charged molecules such as 
DNA and RNA nucleotides. All proteins elute in one broad peak (Fig. 2.5). 
 
Figure 2.5: First step of purification of Thr hHKII (AEX) 
The soluble fraction of the cells was loaded to the HiPrep 16/10 DEAE FF. The elution 
profile of AEX step contains a broad peak. All proteins elute in this peak according to SDS-
PAGE. Two fractions (50 ml each) were pooled together for the next step.  
 
The fractions collected from the AEX are loaded onto a 5 ml affinity column HiTrap 
FF (5 ml/min). Histidine tagged proteins have a high selective affinity for Ni
2+
 and 
other metals (i.e Co, Zn, Fe and Cd) that can be immobilised on chromatographic 
media using chelating ligands and for this reason a protein containing a histidine tag 
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will be the strongest binder among all the rest proteins in a crude sample extract. The 
target protein was eluted with a step of 100% Buffer C (250 mM imidazole, 10 CV) 
resulting in a sharp peak (Fig. 2.6). The 2 ml fractions of sharp peak were analysed in 
an SDS-PAGE gel. The fractions containing the desired protein were pooled together 
and concentrated for the final step.  
 
Figure 2.6: Second step of purification of Thr hHKII (IMAC) 
14 fractions (28 mls) were analysed by SDS-PAGE. As seen from SDS-PAGE gel all 
fractions contain a band at ~100 kDa so Thr hHKII elutes as expected when high imidazole 
(step of 100% of Buffer C) is used. Peaks 1 and 2 contain also Thr hHKII (data not shown) 
but in very low concentration and fractions were discarded. 
 
The final polishing step was performed using the HiLoad 26/60 Superdex 200 pg. 
Size exclusion chromatography can separate molecules based on their molecular 
weight in solution. The concentrated pooled sample from IMAC was injected using a 
10 ml loop. Thr hHKII elutes in a big symmetrical peak (peak 3) with elution volume 
~180 ml (Fig. 2.7). SDS-PAGE also shows the presence of Thr hHKII in peak 2. 
Peaks 1 and 4 when resolved in an SDS-PAGE did not show anything, possibly 
because the concentration is very low (SDS-PAGE data not shown here). Peak 2 




Figure 2.7: Third step of purification of Thr hHKII 
Protein after IMAC was concentrated to ~10ml and loaded to SEC column. Protein elution 
volume is ~180 ml. All fractions of the symmetrical peak 3 were analysed and Thr hHKII 
was present in all with a small number of impurities at very low concentration. Thr hHKII at 
1 mg/ml was found to be >95% pure based on SDS-PAGE where 1 μg and 5 μg of protein 
were analysed. 
 
All fractions from peak 3 were pooled together and the concentration measured using 
a NanoVue spectrophotometer reading the absorbance at 280 nm using the molar 




. Protein was concentrated to 1 
mg/ml. The final yield is estimated to be 34 mg from 1 L of cell culture. Aliquots of 






C for further analysis. 
Thrombin cleavage trials were set up: 
1) hHKII in Gel Filtration Buffer was incubated with Thrombin at 4oC (24 
hours) (10 U/mg of protein). 
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2) Purified protein was diluted 1:10 in Thr Buffer: 50 mM Tris, pH 8.0 (adjusted 
at RT), 150 mM NaCl, 2.5 mM CaCl2. 50 μg of protein was incubated 
overnight at RT with 2 U and 4 U of Thrombin. Samples were analysed by 
SDS-PAGE (200 V, 55min). 
 
Figure 2.8: Tag removal using Thrombin protease 
A. The first cleavage trial did not succeed. 
B. The optimised Buffer conditions showed a sign of cleavage. HK with the addition of 2 
and 4 U of Thrombin seem to have a lower faint band that could correspond to the cleaved 
protein. The lower band is more obvious when 4 U of Thrombin are added. However the 
cleaved: uncleaved ratio is very small.  
(Bondos and Bicknell, 2003) , developed a solubility assay which was performed to 
help determine in which buffers the protein aggregates less. Six different buffers 
were tested which had different NaCl concentrations supplemented with or without 
DTT. 
 Buffer 1: 10 mM Tris, pH 8.0,  5 mM MgCl2, 0.15 M NaCl 
 Buffer 2: 10 mM Tris, pH 8.0,  5 mM MgCl2, 0.25 M NaCl 
 Buffer 3: 10 mM Tris, pH 8.0,  5 mM MgCl2, 0.5 M NaCl 
 Buffer 1 + 5 mM DTT 
 Buffer 2 + 5 mM DTT 





















































As explained in 2.1.7 the aggregated protein (agg) was retained in the membrane and 
to retrieve this 30 μl of dH2O was pipetted across the membrane. 30 μl of soluble 
(sol) and 30 μl of aggregated protein were mixed separately with 4x Sample Buffer 
and heated to 90
o
C for 10 minutes prior to SDS-PAGE. The gel results (Fig. 2.9) 
show that protein in high concentration of  NaCl (0.5 M) is more stable since agg 
band is less intense than band for Buffers 1 and 2 (0.15 M and 0.25 M NaCl 
respectively). On the other hand the addition of 5 mM DTT did not seem to reduce 




Figure 2.9: Solubility assay for Thr hHKII 
 
2.2.2 Expression and purification of TEV hHKII 
The percentage of cleavage of the 6His tag from Thr hHKII was not good enough 
and for this reason we decided to create a new construct with a different cleavable 
site. The new construct is identical to the Thr hHKII with the only difference in the 
N-terminal end of the protein. The Thrombin cleavage site is replaced by a TEV 
cleavable site (Fig. 2.1). TEV protease is considered to be more specific than 
Thrombin. The cloning of TEV hHKII was successful and plasmid DNA was sent for 
sequencing to Genepool and the correct sequence verified. The same cell line and 
medium were screened for the expression of the TEV hHKII construct (2.1.3.1). As 
seen from SDS PAGE (Fig. 2.10) the protein is overexpressed in all medium apart 
from LB. The same results were seen previously for Thr hHKII. However, the 







Figure 2.10: SDS-PAGE after expression of TEV hHKII 
TEV hHKII was overexpressed in SOC, TB and 2xTY medium. LB medium did not lead to 
a significant soluble expression of the protein. 
 
The three step purification of TEV hHKII gave similar peaks as previously for Thr 
hHKII. The protein comes off the Superdex 26/60 200pg at a consistent elution 
volume and protein is expected to be a monomer. The protein was concentrated to 1 
mg/ml and kept in -80
o
C freezer, with addition of 10% of glycerol, for future studies. 
TEV cleavage trials were again unsuccessful (Fig. 2.11). TEV protease did not 
manage to cleave the tag so previous cleavage failures cannot be attributed to lack of 
Thrombin specificity. All of the studies on hHKII were performed using the 6his 



































































Figure 2.11: Tag cleavage trials with TEV protease 
SDS-PAGE gel shows that TEV protease is active since control Cyclophilin A (CypA) is 
cleaved when 2.5 and 5 U of TEV are incubated with the protein at RT. There is not a lower 
band for hHKII even with 5 U of TEV suggesting that the cleavage was not successful.  
 
2.2.3 Expression and purification of N and C domains of hHKII 
The cloning of N and C domains was successful and both DNA sequences were 
verified. Successful overexpression was observed for C domain when plasmid DNA 
was transformed to BL21 plus (RIL) competent cells and single colonies were left 
shaking in TB medium until OD600=0.8 before cold shock for 1 h at 4
o
C. The cell 
expression was induced with 1 mM IPTG and cells were transferred at 20
o
C and left 
shaking overnight. N domain of hHKII was overexpressed following the same 
protocol as for C domain but LB medium was also screened. SDS-PAGE gel shows 


































































































































Figure 2.12: Overexpression of N and C domain hHKII 
The yield of overexpression from both domains was analysed in an SDS-PAGE where the 
uninduced, and induced whole and soluble cell fractions were compared (Panel A: C domain 
samples, Panel B: N domain fractions). For both constructs we could observe that the soluble 
amount is almost 50% less than the amount of protein in the whole cell fraction. The other 
50% of the protein is probably expressed in inclusion bodies.  
 
The purification protocol for both domains was kept the same as for Thr hHKII 
(2.1.5). For both constructs the fractions after IMAC that contained the target protein 
were loaded into a Superdex 26/600 200 pg pre equilibrated with Gel Filtration 
Buffer (2.1.8). The three-step purification protocol gave almost identical peaks 
during the AEX and IMAC steps but the SEC step resulted in two different elution 
profiles as seen at Figure 2.13. The N domain elutes in a main symmetrical peak that 
corresponds to a monomer of ~50 kDa. SDS-PAGE analysis proves the presence of a 
protein close to 50 kDa. The C domain elutes in a double peak with low resolution 
between the two species that could be a ratio of monomer: dimer. 
50kDa 50kDa




















Figure 2.13: N and C domain elution profiles after SEC step 
The elution profile after the SEC step differs between the N and C domain. SDS-PAGE 
across the two peaks showed the presence of a single band at 50 kDa for peak 1. Peak 2 also 
contains a thick band at the right size with a small number of impurities present at ~25 kDa 
(arrow). There are 2 more small peaks for both domains before the elution of the main big 
peaks which correspond to aggregates of the N and C domain respectively as seen from the 
SDS-PAGE. 
 
The main peak of N domain was pooled together and concentrated to 1 mg/ml (Fig. 
2.14). 
 
Figure 2.14: N domain at 1 mg/ml 















The two peaks corresponding to the C domain were pooled separately (Refer to as 
pool 1 and pool 2 for the combined fractions of peak 1 and peak 2 respectively). All 
purified proteins, with the addition of 8% glycerol, were kept at -80
o
C for future use. 
 
2.2.4 Expression and purification of Untagged hHKII 
The cloning process was successful and sequencing confirmed the correct sequence 
for the Untagged HKII. The plasmid DNA was transformed in BL21 plus RIL (DE3) 
cells and expression trials were set up as mentioned in section 2.1.3.2. The protein 
shows soluble expression under all conditions with significant overexpression in TB 
and 2xTY medium. LB medium resulted in a lower yield of soluble protein and even 
lower for SOC medium.  
 
Figure 2.15: Overexpression of Untagged hHKII 
The overexpression trials screening 4 different medium were successful for all, nevertheless 
TB and 2xTY medium were the optimal medium for this construct as the expression yield is 
significantly better on these two compared to LB and SOC. 
 
Resource 30Q (2 ml/min) was used to perform the screening of the optimal pH for 
the purification of the untagged hHKII as the selectivity and capacity of a weak 
anion exchanger column changes depending on the pH during the elution of the 
protein. This could lead to a cleaner target protein, less contaminated with bulk 
impurities, when the right pH is chosen. Based on the elution chromatograms and 
SDS-PAGE gels it was shown that the best separation of target protein from 
impurities occurs when purification process was performed at pH 7.0.  
1: LB soluble fraction
2: SOC soluble fraction
3: TB soluble fraction
4: 2xTY soluble fraction













The process was scaled up after optimal pH had been decided. Resource Q 6 ml was 
equilibrated with 10 CV of Buffer A, the flow rate was kept at 20 ml/min and 1.5 ml 
fractions were collected. Fractions were analysed with SDS-PAGE. Pooled fractions 
containing the target protein were then loaded to an affinity column, the Hi Trap 
Blue HP (1 ml/min).  The column is prepacked with Blue Sepharose High 
Performance and via this matrix, the dye ligand, Cibacron Blue F3G-A is covalently 
attached via the triazine part. The dye has been exploited as a chromatographic 
medium to separate and purify a variety of proteins, such as dehydrogenases, kinases, 
serum albumins, interferons, several plasma proteins etc. There are studies regarding 
the chromophore itself and the immobilised ligand to fully understand the 
interactions that it makes with the proteins (Subramanian and Ross, 1984). Some 
proteins could interact with this dye because of the structural similarity with 
nucleotide cofactors so since hexokinase has a binding site for ATP it has a good 
potential to bind to the column. 
The unbound material was washed with 15 CV of Buffer A and the target protein 
was eluted with a linear gradient to 100% in 10 CV. SDS-PAGE showed that protein 
eluted at 61.6% B and above. The fractions that contained the target protein were 
pooled together. Finally SEC was performed and the protein elution volume is 
consistent with Thr hHKII elution volume. This result was expected since both 
constructs have the same molecular weight. It is expected that Untagged hHKII is a 





); 1 μg and 5 μg were run in SDS-PAGE to check the purity of 





Figure 2.16: Three step purification of Untagged hHKII 
The AEX step resulted in the elution of 3 peaks. All peaks were analysed with SDS-PAGE 
and a band around 100 kDa was present in all. The highest amount was found in peak 1 and 
fractions in the black box were pooled together for next step. The target protein was then 
60 
 
bound to HiTrap Blue HP column and eluted when linear gradient performed (elution started 
when %B was ~62%). Only the fractions in the black box proceeded to SEC (Superdex 
26/60 200pg). When final protein was concentrated and run at 1μg and 5μg did not run as a 
pure band. Instead many bands appear within the range from 25 kDa to 75 kDa). The protein 
is estimated to be ~90% pure.   
 
2.2.5 Expression and Purification of TbHKI 
TbHKI has proven a difficult target since many different conditions were tested 
without any significant increase of the protein’s soluble expression. The DNA 
sequence is codon optimised for E.coli system as the tRNA levels between species 
can be very different and potentially affect the expression levels. However, the codon 
optimisation performed (GeneOptimizer, GeneArt) did not seem to improve the 
expression process even with the use of special host strains such as BL21-CodonPlus 
(RIL) competent cells. These cells contain a ColE1-compatible, pASYC-based 
plasmid containing extra copies of the argU, ileY, and leuW tRNA genes. By 
comparison of the SDS-PAGE in Table 2.6 we could observe that the latter cell line 
gave the best expression yield of protein along with the host strain BL21 star (DE3). 
These are also designed for applications that require high-level expression of 
recombinant proteins from low copy number, T7 promoter-based plasmids. There 
was no overexpression (soluble or in inclusion bodies (IBs)) of TbHKI in C43 (DE3) 
and ArcticExpress (DE3) cell lines. The latter cells have been engineered for 
improved protein processing at low temperatures, since low temperature cultivation 
could lead to an increased recovery of soluble protein (Schein, 1989). Using this cell 
line, the induction with IPTG was performed at 13
o
C for 24 hours. Under these 
conditions no protein expression was observed. However, the cold-shock expression 
at BL21 star (DE3) cells resulted in an increased expression of insoluble TbHKI. We 
could say that the cold-shock for a shorter time could result in a high-yield of protein 
expression while a cold-shock period of 24 hours could minimize it. On the other 
hand, protein is overexpressed at high temperature of 37
o
C after 3 hours, although 
insoluble. The recombinant GroEl/ GroES co-expression chaperone system was used 
which is known to prevent protein aggregation and promote the right folding (Hartl 
et al., 2011). Unfortunately, it did not show an increase in the soluble protein 
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expression of the transformed cells. However, the analysis of the SDS-PAGE does 
not show any big band in the expected size of GroEL/ GroES (60/ 10 kDa) so the 
failure of the soluble expression of TbHKI could be a result of the low inadequate 
expression level of the chaperone system. 
 
Table 2.6: TbHKI expression resulted in no or very small amount of soluble protein 
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no significant 
overexpressio
n can be seen 














































































































































































































































































































































































































































Cell line SDS-PAGE Comments 
C43 (DE3) 
























































































































































































































































































































Cell line SDS-PAGE Comments 
BL21 star 
(DE3) 












































































































































































Cell line SDS-PAGE Comments 
ArcticExpres
s (DE3) 











Despite all efforts the target protein is still expressed in IBs so the final effort was to 
denature and refold the protein in vitro. Refolding of IBs is not a straightforward 
process and IBs need to be solubilised and then refolded into an active conformation. 
The choice of solubilising agents is crucial as well as the rate of refolding (Tsumoto 
et al., 2003). In this case guanidine hydrochloride (GuHCl) was chosen as the 
solubilising agent and The TbHKI purification from the IBs was performed in two 
steps where the affinity step (Fig. 2.17) was initially performed to separate the 6His 
tagged unfolded TbHKI from the other E.coli impurities. The elution profile when 
high imidazole buffer was used leads to a small peak that was pooled together and 


















































Figure 2.17: Elution profile of unfolded TbHKI with high imidazole 
The unfolded TbHKI is captured in a 1 ml cOmplete His-Tag resin (1 ml/min). The small 
peak is not resolved in an SDS-PAGE gel as high concentration of GuHCl precipitated the 
SDS (added in the SDS-PAGE Running Buffer). The fractions under the small peak were 
pooled together and concentrated for the next step. 
 
The denaturant gradient procedure was performed during the size exclusion step in 
Superdex 200 10/300GL. An inverse linear gradient of 6 M to 0 M of GuHCl was 
implemented for 6 ml (1/4 of the total column volume) so that protein gradually 
inserted into the refolding Buffer C in 12 min. Another key parameter in the 
refolding process is the effect of small additives. Two different Refolding Buffers 
were screened here: 
Optimised Buffer: 50 mM HEPES, pH 7.8, 500 mM NaCl, 2 mM DTT, 250 mM L-
Arginine, 45 mM NDSB-211, 2% glycerol, 0.005% Tween 20 
Refolding Buffer 1: 50 mM HEPES, pH 7.8, 500 mM NaCl, 2 mM DTT; 250 mM L-
Arginine, 150 mM NDSB-201, 2% glycerol, 0.01% Tween 20 
The two buffers have a different type of non-detergent sulfobetaine (NDSB) and a 



















refolding buffers are almost identical with same peaks (Fig. 2.18), with an earlier 
elution for Optimised buffer (~0.5 ml faster elution).  
 
Figure 2.18: Overlay of SEC profiles between two different Refolding Buffers 
An overlay of the two chromatograms shows that the elution profile stays unaffected 
between the two runs. SDS-PAGE across all peaks shows the elution of a macromolecule at 
the expected size. 
 
Activity assays across the peaks show that Optimised Buffer increased the yield of 
activity even up to 10 times for specific fractions. However the protein was unstable 





so no further studies were performed. For this reason, since we could not verify if 
protein was properly folded after the denaturation, we did not proceed in screening 
the compounds against this purified protein. 
Instead, we expressed the TbHKI in 4 L of cell culture and purified the soluble 
fraction in 2 step purification process. The protein after the affinity column 
precipitated during concentration so serial injections of 0.5 ml were performed with 
diluted protein. All chromatograms were very consistent to each other and looked 
like the chromatogram on Figure 2.19. 
 
Figure 2.19: Chromatogram of TbHKI after SEC step 
The peak with elution volume ~15 ml corresponds to the monomer TbHKI as seen from 
SDS-PAGE. Protein is also present in previous peaks that could represent TbHKI in dimer-
tetramer formation. The fractions that pooled together are shown in the black box. 
 
The final yield was ~2.5 mg from 4 L of culture and protein concentration was 
estimated at 0.3 mg/ml after SEC (using NanoVue spectrophotometer measuring the 





). The purified protein was assayed and Km values for the substrates (Glc and 
G6P) were determined. This protein was used for screening the compounds as will be 






























2.3 Summary and Conclusions  
The hHKII was successfully expressed and purified in 5 different constructs. Thr 
hHKII resulted in high yield of soluble protein. However the tag removal using the 
Thrombin protease was not successful and another construct was created with a 
difference in the N terminal site. This site had a TEV cleavable site but again, after 
successful purification, the tag was unable to be removed. As a last attempt the 
untagged hHKII was created and purified but the purity is estimated ~90% and the 
activity of the protein was dramatically reduced (Chapter 3, section 3.3.3). The 
biophysical and biochemical analysis performed on both tagged constructs did not 
show any signs of tag interference with the active site of the protein. However the 
crystallisation trials were not successful and for this reason N and C domains were 
also purified separately. The purification process resulted in interesting results as N 
domain elutes as a monomer but C domain elutes as a mixture of monomer and 
dimer. Further studies show that both domains are active and their functional 
parameters were determined (Km for ATP and Glc). A low resolution structure was 
determined through SAXS (Chapter 4) for both domains. 
TbHKI expression trials did not result in a high yield of soluble fraction and two 
different refolding protocols were tested. Both resulted in an active protein but the 
activity was improved with the Optimised Refolding Buffer. This purified protein 
was unstable in solution and it precipitated during concentration and/or buffer 
exchange so we could not continue the studies in order to investigate the 
oligomerisation state of the protein. As it was essential to produce an active and 
properly folded protein to screen against the hits from virtual screening we purified 
the soluble fraction of TbHKI from 4 L of culture. The final yield was 2.5 mg, the 







3. Chapter 3: Biophysical and Biochemical characterisation 
of hHKII and TbHKI 
 
3.1 Introduction 
The biophysical and biochemical analysis of proteins has the ultimate goal of 
obtaining meaningful parameters to enable a characterisation of the biochemical 
function of the molecule. An understanding of the oligomeric state, homogeneity and 
secondary structure of the proteins is fundamental in aspects of drug discovery and 
development. Structural elucidation should follow after proper characterisation of the 
macromolecule. A proper strategy for this should involve a combination of 
techniques that show reliable and consistent information about the protein under 
study (Malik and Shrivastava, 2013). To this end, I performed dynamic light 
scattering (DLS), circular dichroism (CD), SEC coupled to multi angle light 
scattering (SEC-MALS), surface plasmon resonance (SPR) and enzymatic assays to 
determine the homogeneity, oligomeric state, activity and functional parameters of 
the purified enzymes. 
Dynamic Light Scattering (DLS) is a light scattering technique which can be used 
to determine any polydispersity and aggregation state/ propensity of the protein. The 
basic principle is simple: the sample in solution is illuminated by a laser beam and 
the fluctuations of the scattered light are detected by a fast photon detector at a 
known scattering angle θ. The Brownian motion of particles or molecules in 
suspension causes laser to be scattered at different intensities. Analysis of these 
intensities yields the diffusion coefficient of the particles which may be related to the 
hydrodynamic radius (Rh) using the Stokes-Einstein equation: 
   
   
      
                  
Rh= hydrodynamic diameter,  
k= Boltzmann’s constant, 
T= absolute temperature,  
η= viscosity, 
D= diffusion coefficient 
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Circular Dichroism (CD) is a biophysical method used to analyse the secondary 
structure component of a protein in solution. The CD effect relies on the differential 
absorption of linear polarised light, between the left handed (L) and right handed (R) 
components. A CD signal will be observed when chiral molecules are studied (i.e 
proteins) because L and R are absorbed to different extents (Kelly et al., 2005). CD 
signals from proteins arise from the peptide bond (absorption below 240nm), 
aromatic amino acid chains (absorption in the range 260-320nm) and disulphide 
bonds (weak absorption bands centered around 260nm). The different types of 
secondary structure (helix, sheet, turns) give rise to characteristic UV spectra in the 
far UV. These properties are used from various algorithms which analyse the data to 
provide an estimation of the secondary structure composition of the protein (Kelly et 
al., 2005). 
SEC-MALS is a method combining Size Exclusion Chromatography to separate a 
protein based on its hydrodynamic size and shape coupled to Multi Angle Light 
Scattering for absolute molar mass determination. The Light Scattering (LS), 
Refractive Index (RI), and Ultraviolet Detection (UV) combined give important 
information on the molar mass and oligomeric state in solution (Nedelkov et al., 
2006). The light-scattering detectors can provide absolute measurement of molecular 
weight and are very sensitive at detecting aggregates even at low concentrations. The 
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, (Equation 3.2) 
Where  
C: sample concentration 
θ: the measurement angle 
Rθ: the Rayleigh ratio (the ratio of scattered light intensity to incident light intensity) 
Mw: the molecular mass 
A2: the second virial coefficient 
Pθ: a term that defines angular dependence 
K: a constant which is system, solvent and sample dependent 




   
  
   
    
  
  
  , (Equation 3.3) 
Where: 
λ: laser wavelength in a vacuum 
NA: Avogadro’s number 
n0: refractive index of the solvent  
dn/dc: the change in refractive index of the solution with change in concentration 
The angular dependence of the scattered light can give information regarding the 
molecular dimensions of the polymer, i.e the radius of gyration (Rg) (Tarazona and 
Saiz, 2003). 
In SEC we are interested in the molecular mass of the sample. The distribution 
obtained from SEC is typically a molecular weight distribution describing how much 
material there is present of the various molecular weight “slices.”  The distribution is 
traditionally described by two numbers derived from it: Mw and Mn, where Mw is the 
weight-average molar mass and Mn is the number-average molar mass. The 
molecular weight is measured in each data slice from the SEC and the dn/dc and 
dA/dc and the MALS intensity.  
In SEC-MALS an important derived parameter is the dispersity (Mw/Mn). The 
Mw/Mn is a statistical analysis that relates the distribution of mass weight and mass 
number.  For a perfectly uniform sample consisting of only one molecular species the 
Mw and Mn are the same and Mw/Mn equals 1. However, this is not the case for real 
samples and this ratio is used to describe the oligomeric state of the molecule under 
study. Basically, it shows how far away the encountered distribution is from a 
perfectly monodisperse species. 
Surface Plasmon Resonance (SPR) is a biophysical technique used to characterise 
macromolecular interactions in a label-free way. In general, the interaction is studied 
between a ligand in solution, called the analyte in SPR terminology, with an 
immobilised partner on an SPR active sensor surface, the ligand in SPR terminology 
(usually the protein). Basically, SPR is an optical method which measures the 
increase of the refractive index (RI), expressed as Response Units (RU), as the 
analyte binds to the ligand leading to an accumulation of protein on the sensor 
surface. One can monitor the interaction in real time and measure the rates of 
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association (kon) and dissociation (koff) precisely and use these values to calculate the 
corresponding affinity constants (McDonnell, 2001).  
Enzymatic assays: Two different enzymatic assays were used for hexokinase 
biochemical characterisation; the commercial available from BioVision (Hexokinase 
Colorimetric Assay kit) and a coupled enzyme assay that I developed during the 
present studies.  
In the BioVision assay kit, glucose is converted to G6P by HK, G6P is oxidised from 
glucose-6-phosphate dehydrogenase (G6PDH) to form NADH which reduces a 
colourless probe that will absorb at 450 nm. The kit is generally used with sample 
from serum, tissues or cell culture but it was also successful with purified protein (5 
nM final concentration). However, the kit contains undisclosed reagents in the assay 
buffer. The concentration of the substrates (Glc, ATP) and cofactors (Mg
2+
) is not 
known and this makes it impossible to determine the Km values of HK substrates and 
to measure the IC50 of potential inhibitors. For an initial screen of inhibitors the 
substrate concentration is usually at or below the Km of the protein. If the ATP 
concentration in the assay buffer is higher than the Km, then ATP competitive 
inhibitors would not show any inhibition using these specific assay conditions. 
To this end I developed a coupled enzymatic assay, the resazurin assay (also known 
as Alamar Blue® Assay) which is mostly used to assess the cell proliferation of 
various human and animal cell lines, bacteria and fungi and cell cytotoxity (Bonnier 
et al., 2014). The assay relies on the reduction of the non-fluorescent resazurin dye 
(blue colour) to the highly fluorescent molecule resorufin (pink-red colour), 
catalysed either by reductases or dehydrogenases (Guilbault, 1975) in the presence of 
the Nicotinamide Adenine Dinucleotide (NAD) and diaphorase. During this assay 




Figure 3.1: Resazurin assay, a coupled enzymatic assay for Hexokinase activity 
measurement 
Glc is converted to G6P from hexokinase which is further metabolised from G6PDH in the 
presence of NAD. The reduction of NAD to NADH is brought about by Diaphorase which 
converts resazurin to the fluorescent molecule resorufin (excitation 530nm/ emission 
590nm). 
  
3.2 Materials and Methods 
3.2.1 DLS 
DLS was performed using a Zetasizer Auto Plate Sampler (Malvern) using 384 
polypropylene plates (Corning). Protein concentration was typically 1 mg/ ml (unless 
otherwise stated) and 60 μl added to each well. Each sample was measured three 
times with an equilibration time at 120 sec (delay time between each measurement 
10sec). The experimental temperature was set at 10
o
C. All analysis was performed 
using Malvern Zetasizer APS software, version 7.11.  
 
3.2.2 CD  
The protein was buffer exchanged, prior to analysis with CD, to remove the high 
concentration of chloride ions (0.5 M NaCl) which show high absorbance in the high 
UV region. The HiTrap 5 ml desalt column, GE Healthcare, was used for the protein 
desalting. 500 μl of protein was added in the column at 10 ml/ min with CD buffer. 
Fractions of 250 μl were collected. The desalt process was successful and the UV 
peak was fully separated from the conductivity peak. The CD buffer contains: 10 
mM Tris, pH 8.0 (sulphuric acid) and 250  mM NaF or 50mM NaF. The far UV 
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circular dichroism spectrum for 1 μΜ of hHKII was recorded at 20 nm/ min, data 
pitch 0.1 nm, response time 1 sec between 185 and 265 nm in a 0.1 cm path-length 
cuvette at 25
o
C (JASCO-810 spectrometer). Spectra were corrected by subtracting a 
buffer baseline recorded at the same temperature. Spectra were recorded in triplicate. 
Secondary structure was estimated using the Dichroweb CD secondary structure 
analysis server using the methods CONTIN, SELCON3 and CDSSTR. 
 
3.2.3 SEC-MALS  
Size-exclusion chromatography (ÅKTA-Micro, GE Healthcare) coupled to UV, 
static light scattering and refractive index detection (Viscotec SEC-MALS 20 and 
Viscotek RI Detector: VE3580, Malvern Instruments) were used to determine the 
molecular mass of protein in solution. 100 µL of 1 mg/mL (unless otherwise stated) 
was run on a Superdex-200 10/300 GL (GE Healthcare) size exclusion column pre-
equilibrated in Gel Filtration Buffer (for each protein construct, unless otherwise 
stated), at 22˚C with a flow rate of 0.5 mL/ min. 100 μl BSA at 2 mg/ml was injected 
and the monomer peak (66.8 kDa) was used as the detector off-set and calibration 
standard, run under identical conditions. Light scattering, RI and Abs280 were 




SPR measurement was performed on a BIAcore T200. His-tag hHKII was 
immobilised and covalently stabilised on an NTA sensor chip essentially as 
described before (Wear et al., 2005). Briefly, the sensor surface was primed with a 
60 sec injection of 500 µM NiCl2 at 5 µl/ min. The surface was then minimally 
activated with a 240 sec injection (at 5 μl/ min) of a mixture of N-
hydroxysuccinimide (NHS) (115 mg/ ml) and 1-ethyl-3-(-3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) (750 mg/ ml). hHKII in 10 mM Hepes (pH 7.5), 
500 mM NaCl, 1% DMSO, and 5 mM MgCl2, at concentration 500 nM, was passed 
over the sensor surface at a flow rate of 30 μl/ min. Following saturation of the 
response units (RU) signal, this was followed by a 240 sec injection (at 5 μl/ min) of 
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1 M ethanolamine (pH 8.5) to quench the remaining active succinamide esters. The 
final amount of hHKII covalently immobilised on the surface was typically around 
8,000 RU. A two-fold dilution series of glucose ranging from 2 mM to 0.0625 mM 
was run in this experiment. The binding curves were analysed for a one-to-one 





3.2.5 Enzymatic assay 
For hexokinase colorimetric assay the steps performed are as follows: 
For the NADH Standard Curve: Add 0, 2, 4, 6, 8 and 10 μl of 1.25 mM NADH 
Standard into a series of wells in duplicate in 96 well plate to generate 0, 2.5, 5.0, 
7.5, 10 and 12.5 nmol/well of NADH Standard. Adjust volume to 50 μl/ well with 
HK Assay Buffer. 
For Sample Preparation: Add 10 μl of 50 nM purified enzyme and adjust final 
volume to 50 µl with HK Assay Buffer. Prepare a parallel sample well as the 
background control to avoid interference from the NADH in the sample. For the 
reaction mix, for each well, prepare 50 µl containing: 
HK Assay Buffer 34 µl  
HK Enzyme Mix 2 µl  
HK Developer 2 µl  
HK Coenzyme 2 µl  
HK Substrate 10 µl (For background mix no substrate- 44μl of Assay Buffer). Add 
50 µl of the reaction mix to each well containing the Standard and test samples and 
50 µl of background control mix to each well containing the background control 
sample (final assay volume 100 μl). Measure OD 450 nm using the multi-detection 
microplate reader system, SpectraMax M5 (Molecular Devices) every 5 min for 30 
min. To calculate the activity, subtract the 0 standard reading from all standard 
readings. Plot the NADH standard curve. Correct sample background by subtracting 
the value derived from the background control from all sample readings. Calculate 
the hexokinase activity of the test sample: ∆OD = A2 – A1. Apply the ∆OD to the 
NADH standard curve to get B nmol of NADH generated by hexokinase during the 
reaction time (∆T = T2 - T1).  
Sample Hexokinase activity = B/ (∆T × V) × Dilution Factor = nmol/min/ml/ = 
mU/ml 
Where: B is the NADH amount from standard curve (nmol). ∆T is the reaction time 




For resazurin assay: 
For the G6P standard curve add 20 μl of 250 μM G6P in a Corning 96-solid black 
plate and take 10 μl to perform twofold dilutions in 10 μl Assay Buffer (50 mM Tris, 
pH 7.5, 150 mM NaCl, 5 mM MgCl2) to generate 125, 62.5, 31.25, 15.6, 7.8, 0 μΜ 
of G6P. Adjust volume to 100 μl/ well with Reaction mix (17 mM NAD, 100 μM 
resazurin, 0.01 U G6PDH, 0.02 U diaphorase). Incubate at RT for 10 min and take 
endpoint measurement with excitation 530 nm / emission 590 nm. Subtract the 0 
standard reading from all standard readings. Plot the G6P standard curve. 
For Km measurements 10 μl of substrate (Glc or ATP in serial dilutions) was added 
to each well and 90 μl of reaction mix was added to initiate the reaction (17 mM 
NAD, 100 μM resazurin, 0.01 U G6PDH, 0.02 U diaphorase, 10 nM HKII, 2 mM 
Glc or 7 mM ATP). The mixture was rapidly mixed and fluorescence at 530/590nm 
was monitored using a, SpectraMax M5 (Molecular Dimensions), multi-detection 
microplate reader at 21
o
C with a reading taken every 20-25 sec. The initial linear 
portion of the slopes was converted to an enzymatic rate. Km and kcat values were 
determined using a range of substrate concentrations. The initial reaction rates (Vo) 
were plotted against the concentrations of substrate and the data least squares fit to 
Equation 3.4 using Kaleidagraph v4.0 software: 
         [  ]  [   ]    [   ]                  (Equation 3.4) 
Where [HK] is the concentration of the protein added to the enzymatic assay, [Sub]0 
is the initial concentration of the substrate and Constant is an off-set correlation 
function to account for non-origin starting values for the assay out-put signal. kcat is 
the turnover number and Km the Michaelis-Menten constant (Wear et al., 2007). 
 
3.3 Results and Discussion 
3.3.1 Biophysical and Biochemical Characterisation of hHKII 
3.3.1.1 Glycerol prevents aggregation of hHKII during cryo-freezing 
DLS was performed on newly purified enzyme and enzyme after being frozen with 
liquid N2 to determine the effect of freezing process. The scattering intensity is 
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proportional to the square of molecular weight and it can be misleading in that a 
small amount of aggregation can dominate the distribution. For this reason, intensity 
distribution can be converted to volume distribution, describing the relative 
proportion of multiple components based on their mass or volume. It is a good 
practice to report the size of the peak based on the intensity analysis and report the 
relative percentages from a volume distribution analysis. 
 It is known that the formation of ice crystals can interfere with correct folding of the 
protein (Hamada et al., 2009). Fresh hHKII is homogenous with a symmetrical peak 
with a diameter of 9.9 nm (Fig. 3.2 A). Particles with a diameter of 113nm are also 
present which could represent aggregates but they are in a low concentration making 
it insignificant.  
 It was shown that the enzyme clearly aggregates after the freezing process (Fig. 3.2  
B) since the particles are estimated to have a diameter of 800 nm (~100 fold increase 





C without using an additive to prevent aggregation. Glycerol is shown 
to form an amphiphilic layer between the hydrophobic patches on the protein surface 
and the polar solvent. This helps to stabilise more compact conformations of the 
protein (Vagenende et al., 2009). DLS supports this notion; the addition of 10% 
glycerol in GF buffer (10 mM Tris, pH 8.0, 0.5 M NaCl, 5 mM MgCl2) does appear 
to prevent the formation of large aggregates (Fig. 3.2 C). The most abundant peak is 
now symmetrical with the correct diameter while the other particles (65 and 289 nm) 
form a small proportion. In the future 10% glycerol was added to every purified 




Figure 3.2: Size Distribution by Intensity and Volume of hHKII measured by DLS 
Size Distribution by intensity corresponds to left panels and Size Distribution by Volume to 
right panels.  
A. DLS was performed for fresh hHKII in GF Buffer and is estimated to be monodisperse 
with molecular weight of 144 kDa and Rh 9.9 nm. The theoretical MW is ~102 kDa but DLS 
estimates the size based on the hydrodynamic calculations for a sphere and this could explain 
the difference between estimated and real size. The freshly purified protein does not have a 
significant amount of aggregates based on the volume distribution. 
B. After cryo-freezing the protein, DLS shows the formation of large aggregates. The 
diameter of the particles is estimated to be ~820 nm which corresponds to a 100 fold increase 






C. 10% of glycerol inhibits the formation of protein aggregates as the percentage of large 
particles is insignificant on the volume distribution and the estimated diameter and size agree 
with the values from panel A (10.1 nm and 149 kDa). 
 
3.3.1.2 Enzymatic activity of hHKII is not dramatically altered after 
cryo-freezing 
The hexokinase colorimetric assay was performed to compare the activity yield 
between fresh enzyme and enzyme after being frozen with liquid N2. 5 μl of 100 nM 
stock protein in GF Buffer was added to 100 μl of final assay volume. The reaction 
was left for incubation for 25 min (measurements were taken every 5 min). 
 
Figure 3.3: hHKII is active after cryo-freezing 
The colorimetric assay was used to compare the activity rate between fresh hHKII and 
hHKII after cryo-freezing. NADH Standard was used to convert the hexokinase absorbance 
at 450 nm into hexokinase activity (nmol NADH/ min/ ml). Hexokinase stored at 4
o
C is 
more active (~33% more active) than hexokinase stored at -80
o












the formation of minor aggregates after cryo-freezing interferes with the enzyme activity but 
the rate drop is not dramatic to prevent use of the frozen protein in enzymatic assays.  
 
3.3.1.3 Biochemical characterisation of hHKII 
The resazurin assay was performed to measure the binding affinities for Glc and 
ATP. Two different ionic strength buffers were compared. For the Km determination, 
Glc concentration was titrated from 2 mM to 31.25 μΜ. For the Km ATP, ATP 
titrated from 6 mM or 3 mM. 8 mM ATP was found to inhibit the reaction probably 
because of product (G6P) inhibition (Kosow and Rose, 1970). The initial linear 
portion of the slopes (100-225 sec) was converted to rate (RFU/sec). The table shows 
the Km, kcat values between the different buffers. The physiological concentration of 
NaCl in the assay buffer (150 mM) gave similar binding affinities as the ones 
reported previously (Ardehali et al., 1996, Tsai and Wilson, 1997). The binding 
affinities were improved without NaCl in the reaction buffer. The turnover number is 
also increased in the absence of NaCl. The present studies cannot reveal the 
mechanism behind this. However, a hypothesis is that the charged groups within the 
catalytic active site are influenced by the ionic composition of the medium or that the 
movement of charged molecules into the active site of the enzyme (i.e ATP-Mg
2+) 
is 




Table 3.1: Km and kcat determination for hHKII under two different conditions of ionic 
strength 
The Km and kcat values were determined in buffers with 150 mM NaCl and 0 mM NaCl. 
Purified protein was diluted 1:1000 in each buffer and added to the assay mix. It can be seen 
that Km for both substrates decreased in 0 mM NaCl (~2 fold) while the turnover number 
increases significantly (2-4 times). The kcat/Km values for both substrates increase more than 
3 fold for Glc and around 7 fold for ATP. The ionic strength of the solution seems to be an 









































87±11 1,302±42 391±56 1,343±61 14.9 3.4 
 
 
3.3.1.4 Glucose KD is estimated with SPR 
SPR analysis of binding specificities for glucose to immobilised hHKII provided a 
useful insight into the binding mechanism. D-glucose was found to bind to 
hexokinase in a specific and dose dependent manner as shown from Figure 3.4 A. 
Steady-state binding response in SPR fits a 1:1 affinity model (3.4 B). No difference 
in KD was observed between α and β D-glucose as KD determined for both is 
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identical between each other and in the same range of KD for D-glucose (Fig.3.4 C 
and D). The mean KD calculated from 3 different experiments (different days and 
different protein immobilisation) is 217 ± 77μΜ. Glucose binds hHKII without the 
need for the presence of ATP or Mg
2+
. Both are essential for enzyme catalysis but 
not essential for binding to the enzyme. 
 
 
Figure 3.4: Glucose interacts with hHKII in a specific and dose dependent manner 
A. D-glucose is found to bind hHKII in a specific and dose dependent manner. A 
concentration series of 2 mM-0.065 mM (twofold serial dilutions) was tested. 
B. Steady-state binding was fit to a 1:1 Lagmuir binding model and KD is calculated to be 
298 μM.  
C, D. Steady state binding response for α-D-glucose and β-D-glucose was fit to a 1:1 binding 








3.3.1.5 hHKII secondary structure is different in high and low anionic 
strength buffer 
TEV hHKII secondary structure was analysed with CD in two buffers with different 
anionic strengths (low anionic strength: 50 mM NaF, and high anionic strength: 250 
mM NaF). The protein was exchanged into each buffer and analysed immediately. 
NaF is used instead of NaCl as chloride ion has a strong UV absorbance at low 
wavelengths. The output data was converted from ellipticity to mean residue 
ellipticity that is independent of protein size and protein concentration and therefore 
more suitable for comparing different concentrations of a protein. The DichroWeb 
on-line resource (Whitmore and Wallace, 2004) was used to analyse the data using 3 
different algorithms, SELCON3, CONTIN and CDSSTR. All experimental input 
data show a good fit to the calculated spectrum derived from the calculated output 
secondary structure. Protein in high ionic buffer seems to be properly folded since 
the predicted secondary structure is in agreement with the crystal structure 
(2NZT.pdb). The crystal structure of hHKII contains 43% alpha- helix and 17% beta-
strand which are very close with the predicted average of all methods (50.5% helical 
and 14.4% strand respectively). However, the secondary structure seems to change 
when protein is exchanged to buffer with 50 mM NaF. The protein is predicted to be 
less helical (32.2%) with more beta-strand sheets (25%). Previously it was shown 
that hHKII is more active in 0 mM NaCl buffer. CD shows that there is also a 
structural change at 50 mM NaF. The change in secondary structure was further 






Figure 3.5: hHKII adopts a different secondary structure in low ionic strength buffer 
CD analysis of hHKII in two buffers with low and high anionic strength (50 mM NaF and 
250 mM NaF) indicates the adoption of a different secondary structure when protein is in 50 
mM NaF. The protein in 250 mM NaF is as helical and stranded as crystal structure of the 
protein in the crystal structure (2NZT). However, when protein changes buffer the helical 
content drops ~17% and strands are increased by over 10%.  
 
3.3.1.6 hHKII changes conformation when exchanged from high ionic 
strength to low ionic strength 
SEC-MALS was used to determine the molar mass of protein in solution in four 
different buffers. Relation of the scattering intensity with accurate determination of 
concentration analysis allows an accurate measurement of the absolute molar mass of 
the molecules in solution (average mass accuracy error is ±1.97%) than SEC alone. 
Initially, protein in Gel Filtration Buffer (10 mM Tris, pH 8.0, 500 mM NaCl, 5 mM 
MgCl2) was analysed and then chloride ion concentration was decreased to 250 mM 
NaCl, 100 mM NaCl and 0 mM NaCl. Protein mass change was monitored. 100 µL 
hHKII at 1 mg/ mL was run on a Superdex-200 10/300 GL (GE Healthcare) size 
exclusion column pre-equilibrated in each buffer under study. A plot of Kav versus 
the log10 of the molecular weight of 11 standards was used to estimate the molecular 
weight of the unknown sample based on the elution position. Basically Kav is 
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calculated based on elution volumes and elution times as defined from the following 
relationship: Kav= (Ve-Vo)/(Vt-Vo). Ve is the elution volume, Vt the total volume and 
Vo the void volume of the column. Light scattering, RI and Abs280 were analysed by 
a homo-polymer model. 
Figure 3.6 shows the SEC chromatograms and a table with the SEC-MALS analysis. 
hHKII at 500 mM Nacl elutes at 12.3 ml as a single peak with a molar mass of 105 
kDa (theoretical mass is ~102 kDa). The hydrodynamic diameter, Rs, is estimated at 
4.35 nm according to the Ve of the protein. When hHKII is run in 250 mM NaCl, the 
differences are small. The Ve is the same (12.2 ml) and the molar mass is slightly 
increased to 110 kDa with estimated Rs at 4.43 nm. These numbers could indicate 
that protein has started to aggregate. In even lower NaCl (100mM) the Ve of the main 
peak dropped to 12 ml and the molar mass is estimated at 130 kDa with the Rs at 
4.57 nm. At 0 mM Nacl the Ve is 11 ml, a significant drop, with the Rs at 5.4 nm. 
The apparent mass and the average mass show a big difference (252- 165 kDa). 
These numbers do not just indicate the presence of aggregates but could represent an 
increased multimerisation and a conformational change of hHKII (as shown from 






Figure 3.6: SEC-MALS for hHKII in different ionic strength in solution 
SEC-MALS analysis of hHKII shows that protein starts to aggregate when concentration of 
NaCl is lower than 500 mM as smaller peaks start to elute sooner. However, the main peak 
that corresponds to the monomer is fully analysed in the insert table. The Ve decreases as 
ionic strength decreases and mass average increases too. When concentration of NaCl is 0 
mM the apparent mass increases almost twofold compared to apparent mass in 500 mM 
NaCl but the calculated mass from SEC-MALS does not increase within the same range. The 
average mass increase in combination with the Rs estimation could represent a 
conformational change.  
 
3.3.2 Biophysical and Biochemical characterisation of N and C domains 
of hHKII 
Chapter 2, section 2.2.3 explains the purification results for N and C domains of 
hHKII. For C domain the elution profile after GF is not a single peak that could 
correspond to a monomer, but protein elutes in two peaks which could represent a 
mixture of monomer and dimer since the resolution between the two species is poor. 
Further studies were performed on C domain to reveal that both species have the 
same activity and same functional parameters. DLS did not show any significant 
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difference in the size between the two peaks. SEC-MALS as a more powerful 
technique in molar mass estimation shows that both peaks indeed are a mixture of 
dimer: monomer.  
 
3.3.2.1 DLS performed for pool 1 and pool 2 of C domain did not show 
any significant difference in their size 
Pool 1 (0.3mg/ ml) and Pool 2 (0.25mg/ ml) were analysed with DLS. Both are 
estimated to be monodisperse with similar size. For pool 1 the Rh=7.28±1.37 nm, 
69.2 kDa and for pool 2 Rh= 7.08±1.07 nm, 64.9 kDa. According to this, protein in 
pool 1 is estimated to be slightly larger than pool 2 but no further information can be 
obtained from this technique. SEC-MALS is therefore performed to investigate the 
oligomeric state of both pools. 
 
Figure 3.7: DLS for two pools of C domain cannot give enough information regarding 






3.3.2.2 SEC-MALS shows that both pools are a mixture of monomer and 
dimer 
C domain pool 1 and 2 were further analysed with SEC-MALS for a more accurate 
estimation of the molar mass. A concentration series was tested for each pool. SEC-
MALS shows that both pools are a mixture of dimer: monomer in a ratio ranging 
from ~20:80 to 30:70. The pools eluted in 2 peaks which are analysed at Table 3.2. 
The dimerisation does not seem to be concentration dependent or disulphide bond 
dependent since when 10 mM DTT was incubated with protein no significant change 
was observed in the ratio of dimerisation. Table 3.2 contains a summary of all 
conditions tested with SEC-MALS; for all samples tested the two peaks eluted from 
Superdex 200 13/300 GL which were both analysed. 
 
Table 3.2: SEC-MALS analysis on C domain (Pool 1 and 2) 
C domain pools were analysed separately with SEC-MALS to determine their oligomeric 
state and molecular mass. Two peaks elute from SEC for all samples tested (with a good 
monodispersity Mw/Mn, around 1.001-1.005) which are estimated around 100kDa and 





3.3.2.3 C domain pools are both active and Km values for Glc and ATP 
are determined 
The resazurin assay was performed to determine the Km values for Glc and ATP for 
each pool separately. The initial rate (μΜ/ min) was plotted against the concentration 
of the substrate and Km, kcat values were calculated. Glucose concentration was kept 
stable at 2 mM when titration of ATP performed (7 mM-0.109 mM, two-fold 
dilutions) and ATP concentration was kept at 7 mM when Km of Glc (2 mM-0.031 
mM, twofold dilutions) was estimated. However, 7 mM of ATP seems to inhibit 



































Figure 3.8: Km values for Glc and ATP for two pools of C domain 
Two pools of C domain were characterised in an assay to determine Km and kcat. The Km 
values for Glc were 55 μM (pool 1) and 82 μM (pool 2). These values agree with the 
reported ones (Ardehali et al., 1996). However, the Km for ATP for both pools is lower than 
those reported. Ardehali et al., predict Km ATP to be ~4 times higher than for the intact 
enzyme. In our studies, the Km ATP for Pool 1 is in the same range as for Km ATP for full 
length hHKII and the Km ATP for Pool 2 is ~3 times lower. In our case the affinity of ATP 
for C domain seems to be as reported elsewhere (Arora et al., 1993).  
 
3.3.2.4 N domain is an active monomer of the right mass 
Two different methods (DLS, SEC-MALS) were used to analyse N domain. This 
domain behaves as a single monodisperse species with apparent molecular mass of 
51.5 kDa (theoretical mass is 53.4 kDa). The km values for Glucose and ATP were 


































Figure 3.9: Biochemical and biophysical characterisation of N domain 
According to DLS, (Intensity Distribution) N domain is a monodisperse species with Rh 
around 7.6 nm without any significant aggregation. SEC-MALS confirmed the presence of a 
monomer with the expected mass as protein elutes in a single broad peak with the molecular 
mass average across the elution profile at 51.5 kDa with good monodispersity (Mw/ 
Mn=1.003). The Km for both substrates are lower than expected (Ardehali et al., 1996). The 
regulatory site alone seems to have a higher affinity for Glucose and ATP in our studies 
under our enzymatic conditions (Km Glc 30μM, Km ATP 113μΜ).  
 
3.3.3 Untagged hHKII is not active  
Untagged hHKII activity was investigated with hexokinase colorimetric assay kit and 
was found to be ~80 times less active than hHKII (based on the initial rate between 
60 and 120 sec).  
It is not clear why untagged protein has such a low level of activity but one 
hypothesis is that the catalytic site of protein, after interaction with HiTrap Blue 
affinity column, is affected. As mentioned previously some proteins could interact 
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with this dye because of the structural similarity with nucleotide cofactors. 
Hexokinase, having a binding site for ATP, has a good potential to bind to the 
column through the active site of the protein that may lead in a conformational 
change of it or a saturation of the active site with this ligand leading to a protein that 
is not able to bind ATP at the concentration tested. 
We were unable to purify the untagged protein in satisfactory yield or in an active 
form. Appendix B shows a summary of all protocols tested for untagged hHKII 
purification with some comments for each one. None was successful, so untagged 
hHKII was considered as a difficult target for purification without a tag label. 
 
Figure 3.10: Untagged hHKII was not active after three step purification 
The activity of the purified protein was measured with the assay kit from BioVision 
and compared to the purified hHKII (tagged). The untagged hHKII Vo was estimated 
at 0.853 nmol/min/ml where the tagged protein had Vo= 46.4 nmol/min/ml. The 
activity level of untagged hHKII is too low in order to use for further studies 
(structural elucidation, functional parameters, etc.). The purification strategies for 




3.3.4 Biophysical and biochemical characterisation of TbHKI 
Chapter 2 (section 2.2.5) refers to three different purification protocols for TbHKI: 2 
refolding protocols (screening two different refolding buffers) and one purification 
protocol from soluble fraction of TbHKI. 
The enzymatic activity of similar fractions between the refolding protocols was 
tested. It was found that specific fractions had up to 10 times higher Vo when the 
Optimised Buffer (chapter 2, section 2.2.5) was used. The Optimised Buffer has 45 
mM NDBS211 (instead of 150 mM NDSB201) and 0.005% Tween 20 (instead of 
0.01%). The non-ionic detergent Tween 20 has a CMC of 0.0074%, thus one 
concentration tested was above CMC and the other below CMC. Even though Tween 
20 is considered a mild surfactant that will not affect protein activity when the 
concentration added is below CMC the protein seems more active. The refolding 
buffer 1 contained NDSB 201 which has a strong absorbance at 280 nm due to the 
ring structure in the molecule. For this reason, NDSB 201 was replaced with NDSB 
211 in the Optimised refolding buffer to make the protein concentration 
determination at 280 nm more precise. The resazurin enzymatic assay was used to 
compare the activity of refolded protein that elutes after SEC. The concentration of 
each fraction from refolding buffer 1 (with 150 mM NDSB which has a strong 
absorbance at 280 nm) was measured with Pierce™ BCA Protein Assay Kit 
(ThermoFisher Scientific). The kit is a high-precision, detergent compatible assay 
reagent set to measure total protein concentration compared to a standard at 562nm. 
The reaction was initiated by addition of 90 μl reaction mix (50 mM Hepes, pH 7.8, 
50 mM KCl, 17 mM NAD, 0.02 U diaphorase, 0.01 U G6PDH, 50 mM Tris, pH 7.5, 
5mM MgCl2, 10 mM Glc, 1 mM ATP) to 10 μl of TbHKI (elution fractions in 
triplicate). The reaction rate (Vo) was determined from the initial linear portion of the 
slopes which was converted to nmol/min/mg.  
However, the refolded protein was not studied extensively since it precipitated 
during concentration and/ or buffer exchange. It seems that protein is very unstable 
after denaturation and therefore instead of continuing to improve the refolding 




Figure 3.11: Comparison of activity in eluted fractions from two refolding protocols 
The initial rate of the refolded fractions was determined with the resazurin assay. The 
fractions in Optimized Refolding Buffer are more active with activities ranging from 
30nmol/min/mg to 198nmol/min/mg compared to an average Vo of 15nmol/min/mg for the 
refolding buffer 1.  
 
4L of cell culture where TbHKI is slightly overexpressed in the soluble fraction 
(BL21 star (DE3), TB medium, 18
o
C, 1hour cold shock) was purified successfully as 
explained in Chapter 2, 2.2.5. The Km values for both substrates were determined 
with the resazurin assay. The concentrations of Glc and ATP were variable and the 
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reaction buffer consists (50 mM TEA, pH 8.0, 5 mM MgCl2, 17 mM NAD, 100 μM 
resazurin). The initial rate in RFU/sec was plotted against substrate concentration to 
estimate the Km values. TbHKI did not behave like hHKII as the apparent Km for 
ATP is much lower, 6± 1.6 μΜ. The Km for glucose is in the same range as for 
hHKII (65 ± 5 μΜ) and agrees with reported values (Morris et al., 2006). No further 
biophysical characterisation was carried out on the protein as the final purified 
amount was not enough for both inhibition studies and biophysical studies. The 
protein eluted as a monomer after SEC and is active therefore was used for 
compound screening. 
  
3.4 Summary and Conclusions 
hHKII was extensively analysed and functional parameters were determined. Two 
different constructs (TEV and Thr hHKII) have the same sequence (apart from the 
6His tag at the N-terminus). These are expressed in the same organism (BL21 plus 
RIL (DE3) E.coli competent cells) and the elution profiles after SEC, DLS analysis 
and SEC-MALS analysis performed looked the same. We assume that both 
constructs will behave identically though the analysis performed above was 
performed in part for Thr hHKII and TEV hHKII. In general, hHKII could be 
characterised as a well behaved enzyme which could be stored for a long period at     
-80
o
C without loss of activity. The protein elutes as a monomer with a calculated Rh 
from DLS at ~10 nm which is in agreement with the crystal structure of hHKII 
(2NZT). Using PyMOL(TM) 1.8.2.3 the distance from the N-domain to the end of C-
domain of 2NZT is around ~120 Å, close to the distance estimated from DLS. The 
addition of 10% glycerol prevented the aggregation of protein and for this reason all 
future purified proteins were supplemented with 10% glycerol before cryo-freezing. 
The Km, kcat values were determined for both substrates (glucose/ ATP). Km Glc is 
145 μM and Km ATP is 695 μM. Both numbers are in good agreement with reported 
values; Km Glc= 340 μΜ, Km ATP= 1.02 mM, (Ardehali et al., 1996), Km Glc= 150 
μΜ, Km ATP= 420μΜ,(Tsai and Wilson, 1997), Km Glc=150 μM, Km ATP= 700 μM 
(Wilson, 2003). It was found that hHKII activity was improved in low ionic 
environment, i.e at zero salt concentration as shown from kcat/ Km values. More 
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specifically, the Km values for both substrates decreased up to 1.7 times. On the 
other hand the kcat, the catalytic turnover number increases (kcat ATP increases from 
343 sec
-1
 to 1,343 sec
-1
 and kcat Glc increased from 695 sec
-1
 to 1302 sec
-1
). The 
mechanism behind that was not further investigated but there are a number of 
reviews that have studied the effect of ionic strength on enzyme catalysis (Goldstein, 
1972, Nørby and Esmann, 1997). 
The KD for glucose binding to hHKII was determined for the first time using SPR 
and it was shown that the substrate binds to the protein without the presence of ATP 
or Mg
2+
. CD and SEC-MALS were implemented in different ionic strength medium 
and we could conclude that hHKII changes secondary structure (alpha-helix 
decreases- beta-strands increase) and that these conformational changes result in an 
increased hydrodynamic radius. Two hypotheses to explain these findings are, that 
the long helix which holds the N and C domain might be flexible resulting in a more 
elongated protein in low salt or alternatively, the two domains are flexible and flap-
around in solution and an environment with low salt favours a more open-domain 
conformation. 
The above studies have been implemented using the tagged constructs (TEV or Thr 
hHKII) and no comparison with the untagged hHKII could be performed. The 
untagged protein when purified was found to be almost inactive as activity rate was 
80 times lower than for the tagged protein. The C and N domains were purified 
separately and C domain was found to be a mixture of monomer:dimer in 
equilibrium. Both oligomers were active and the Km values for both substrates were 
determined. N domain is a monodisperse species of the expected mass with improved 
binding affinities for both substrates compared to the full length hHKII and C 





4. Chapter 4: A low resolution structure of hHKII 
4.1 Introduction 
The human hexokinase II constructs purified during the present studies were 
investigated with Small Angle X-ray Scattering (SAXS). Crystallisation trials have 
been unsuccessful for tagged hHKII full length and N domain (Appendix A shows 
the crystallisation trials screened for hHKII), thus an alternative method was required 
to obtain information regarding the molecular dimensions, the radius of gyration 
(Rg), the oligomerisation state, the flexibility and if possible the 3D envelope. 
To interpret scattering data directly in terms of structural parameters, the sample 
needs to be a monodisperse species or a mixture of oligomers with defined shapes 
(Jacques and Trewhella, 2010). Full length hHKII and N domain hHKII have been 
extensively characterised in solution and seem ideal candidates for SAXS. Full 
length hHKII and N domain hHKII are monomeric in solution, so it was possible to 
construct 3D envelopes using ab initio methods. However, C domain hHKII studies 
have shown that it is polydisperse in solution containing both monomer and dimer in 
equilibrium. We do not know the molecular architecture of the dimer. However, 
SAXS analysis at various concentrations of each construct, were performed and 
useful structural information was obtained for all constructs. The results will be 
discussed in this chapter. 
 
4.1.1 The Basics of Small-Angle X-ray scattering 
Small-angle scattering by X-ray arises from the secondary wavelets scattered by 
atoms within a macromolecule in solution and it is a technique performed to give 
basic low resolution shape information of a protein (Jacques and Trewhella, 2010). 
The technique, after data collection and appropriate data analysis to confirm data 
quality, will provide an ab initio shape and structure determination of the 
macromolecules (Svergun and Koch, 2003). 
An X-ray beam is used to illuminate the sample in solution (usually a protein of 
concentration > 1 mg/ml). Radiation is elastically scattered from the atoms in the 
sample. Electrons in the sample interact with the incident X-rays causing them to 
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oscillate. Oscillating electrons behave as dipoles becoming sources of spherical 
waves re-emitting the X-ray energy. The scattering curve is isotropic due to the 
random orientation of the macromolecules in solution and represents the scattering 
averaged over all their positions, conformations and orientations. For a 
macromolecule, the total scatter is a sum of all the scattering amplitudes within the 
molecule. Total scatter is a function of electron density for each atom and depends on 
the number of electrons and how the electrons are arranged, thus it depends on the 
solute concentration and the electron density contrast (Δρ) which arises from the 
difference in the electron density of the solvent and solute. The intensity of scattered 
waves is recorded on a detector. The direct beam is absorbed by a beam stop which 
size and position define the minimum angle measured in an experiment (Jacques and 
Trewhella, 2010). 
Figure 4.1 shows a schematic representation of a typical SAXS experiment. 
 
Figure 4.1: Schematic representation of SAXS experiment and the Fourier transform 
An incident X-ray beam is directed at a protein sample in buffer. X-ray scattering at angle= 
2θ is detected on the X-ray detector. I(q) represents intensity of scatter as a function of 
momentum transfer, q= (4π sinθ)/λ, where λ is the wavelength of the incident X-ray beam 
and 2θ is the angle between the direct beam and scattered radiation as shown in the figure. 
The units of q are Å
-1
. The 1D data generated as a curve of log[I(q)/q] can be analysed to 
obtain information regarding the size, oligomeric state and shape of the molecule. The 
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Fourier transform of the scattering curve reveals the dmax, i.e the linear dimension of the 
particle. For the calculation of dmax the P(r) function is constrained to be zero at r=0 and 
r=dmax. Unfolded proteins are not zero at r=0 whereas r≠0 at dmax indicates aggregated 
protein. Adapted from (Jacques and Trewhella, 2010, Svergun and Koch, 2003, Putnam et 
al., 2007, Mertens and Svergun, 2010). 
 
The scattering curve (I(q) versus q), is obtained by subtraction of the scattering 
intensity of the buffer from the scattering intensity of the protein sample plotted 
against q= (4π sinθ)/λ (Fig. 4.1) where q, the momentum transfer, is the magnitude of 
the reciprocal space scattering vector. I(q) versus q is basically the intensity as a 
function of scattering angle because λ is fixed and θ is small, typically less than 3
o 
(Jacques and Trewhella, 2010). For a specific value of q the largest contribution to 
the scattering comes from particle dimension 2π/q. Hence, the presence of large 
protein aggregates can be inferred from scattering intensity rapidly rising very close 
to the beam stop. The higher resolution data corresponding the small distances is 
present at larger values of q. From high-quality small-angle scattering data the 
experimenter can calculate two parameters with accuracy, the zero angle scattered 
intensity I(0) and the radius of gyration Rg, which relate to the shape and size of the 
particles under study. I(0) (scattered intensity from zero angle) cannot be measured 
directly as it cannot be distinguished from the unscattered radiation, i.e the direct 
beam. It can be determined though by extrapolation using Guinier’s relationship. I(0) 
relates directly to the particle’s volume (V) and Δρ scaled by concentration c. From 
I(0) it is possible to calculate the Mr of the particle in solution with the following 
relationship: 
             
        
  
, (Equation 4.1) 
Where N is the number of scattering particles per unit volume, Δρ the contrast (the 
difference in the electron density between the solvent and protein), V the particle 
volume, C the mass per unit volume, Mr the molecular mass, u the partial specific 
volume of the particle and NA is Avogadro’s number (Jacques and Trewhella, 2010). 
As I(0) is proportional to the concentration and Mr of the macromolecule monomer 
being measured, one can understand that an accurate determination of both 
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parameters is crucial for the investigation of the oligomeric state of the sample. For 
flexible systems the electron scattering contrast is not easy to be determined as the 
particle and solvent scattering are hard to distinguish (Rambo and Tainer, 2011). 
Thus, the mass estimation will not be accurate based on Guinier analysis. The Rg is 
the average squared centre of mass distances in the molecule weighted by their 
scattering densities, providing useful information on the mass distribution within a 
particle. Rg like the hydrodynamic or Stoke’s radius depends on the actual shape of 
the molecule under study and cannot be used to estimate the molecular mass of the 
studied molecule (Putnam et al., 2007). 
I(0) and Rg, for a monodisperse solution of a globular protein, are estimated using 
the Guinier equation: 
          
      
 , (Equation 4.2) 
In 1939, Guinier showed that for small values of q (in general for qRg<1.3) the 
above equation can be used and from a linear fit of ln[I(q)] versus q
2
 the slope and y 
intercept reveal the Rg and I(0) respectively. A linear Guinier plot is informative and 
can be used to show that no significant aggregation and/or no inter-particle 
interference exist in the protein under study (Jacques and Trewhella, 2010).  
Independent from the Guinier analysis, the hydrated particle volume (Vp) can be 
estimated from Porod’s equation assuming uniform electron density inside the 
particle: 
      
    
 
         ∫         
 
 
, (Equation 4.3) 
where Q is the Porod-invariant. For macromolecules with a higher Mr of 30kDa, we 
can consider a uniform electron density by subtracting an appropriate constant from 
the scattering data. By determining the Porod’s equation, errors in concentration 
measurement will not affect the estimation of the molecular mass. Typically, for a 
globular protein Vp (Å
3
) is 1.5-2 times the molecular mass (kDa) (Mertens and 
Svergun, 2010). In our studies, an average value for an average protein was used and 
molecular mass was estimated as Mr [kDa]= Vp [Å
3
]/ 1.7. 
Rg and I(0) can also be determined from an indirect Fourier transform method which 
yields the electron distance distribution function, P(r). This is a histogram of 
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distances of all possible electron pairs. From the shape of this distribution it can be 
possible to infer the domain arrangement of a protein. Because the scattering data are 
obtained within a defined limit of qmin to qmax the indirect Fourier transform depends 
upon assumptions, such as the dmax, the maximum particle diameter. This alternative 
estimate of Rg makes use of the whole scattering curve and it is much less sensitive 
to interactions or to the presence of a small fraction of oligomers. To conclude, the 
possibility to estimate the Rg and I(0) from different mathematical models allows the 
experimenter to monitor the consistency of the data (Jacques and Trewhella, 2010). 
 
4.1.2 Ab initio modelling 
The last step in SAXS analysis is to reconstruct a low-resolution molecular envelope 
of the macromolecule using nothing else than the scattering data. There are a number 
of available ab initio algorithms, but I will only refer to the ones used to generate the 
3D models during the present studies, which are the DAMMIN (Svergun, 1999) and 
DAMMIF (Franke and Svergun, 2009, Jacques and Trewhella, 2010). DAMMIN 
(Dummy Atom Model Minimisation) represents the molecule as thickly packed 
beads inside a specific search volume defined by the experimentally determined dmax. 
The algorithm performs the shape reconstruction starting from a random initial 
approximation by simulated annealing (SA) which after each step creates a new 
model by a different single bead assignment which will ultimately lead to the 
creation of a compact model with connected beads (Mertens and Svergun, 2010). 
The program compares the experimental scattering to the calculated scattering 
derived from the bead model. The newer version of DAMMIN, the DAMMIF, where 
F refers to fast, is different in several aspects. First there is no limitation on the 
search volume, second only the interconnected models are used for the calculation of 
scattering amplitudes and last each bead contributing to the total scattering at least 
once is used for the computation of scattering amplitudes (Mertens and Svergun, 
2010). However, one must keep in mind that a 3D model from the scattering data 
using the above algorithms will not necessarily stay consistent when running the 
programs multiple times. For this reason, DAMAVER (Volkov and Svergun, 2003), 
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averages all the proposed models to generate a smoothed model containing the most 
common features among all the 3D models (Mertens and Svergun, 2010). 
 
4.2 Materials and Methods 
4.2.1 SAXS sample preparation 
SAXS data was collected at the Diamond Light Source, Oxon, UK (DLS) at the B21 
BioSAXS beamline on a Pilatus 2M detector with a fixed camera length of 4.014 m 
and 12.4 keV energy (1 Å wavelength) allowing the collection of the momentum 
transfer range q between 0.0038–0.42 Å
-1
. All samples were dissolved in Gel 
Filtration buffer (10mM Tris, HCl, 0.5M NaCl, 5mM MgCl2, 10% glycerol). For N 
and C domain the buffer is supplemented with 2mM DTT. The samples were 
centrifuged at 13,000xg at 4
o
C for 20 mins. Data was collected at 25
o
C. To check for 
concentration dependent effect the following concentrations were tested: 
1) For full length hHKII: 6.20, 3.10, 1.55, 0.75 mg/ml 
2) For N domain hHKII: 5.60, 2.80, 1.40, 0.70, 0.35 mg/ml 
3) For C domain hHKII: 2.80, 1.40, 0.70, 0.35 mg/ml 
All proteins were stored at 1 mg/ ml and concentrated to the above highest 
concentration using a Vivaspin with molecular weight cut-off= 30kDa. Twofold 
serial dilutions were followed and concentrations were measured using UV 
spectroscopy, all blanked with the sample buffer. 
 
4.2.2 SAXS data analysis and modelling 
SAXS data was analysed using the Scatter 3.0H and ATSAS 2.7.2 suite. The primus 
analysis tool was also used for Guinier analysis. GNOM was used to estimate the 
dmax of each molecule in solution. Low-resolution structure models were constructed 




4.3 Results and Discussion 
4.3.1 SAXS analysis of tagged hHKII 
SAXS data were collected for tagged hHKII between 0.75 and 6.20 mg/ ml. Guinier 
analysis was performed for all concentrations. If the oligomerisation state is not 
altered by the concentration of the protein then we would anticipate the I(0)/c and Rg 
to remain constant. Otherwise, if both parameters increase with increased 
concentration of protein then it is most likely that protein aggregates or changes its 
oligomeric state. As seen from Table 4.1 the Rg does not change significantly 
between all 4 concentrations. The Rg as estimated from Guinier and P(r) distribution 
are in good agreement with each other with an average Rg at 42.26± 0.96 Å (2.2% 
error which is negligible). A linear Guinier plot confirms that sample is not 
aggregated. A slight upturn at low q starts to appear at concentrations 3.10 and 6.20 
mg/ml but only for a few data points very close to the beam stop. These points were 
not included in the analysis. I(0) determined from Guinier analysis and concentration 
estimated from absorbance at 280nm, gave an average particle mass of 76.7 kDa 
suggesting that the concentration measured by UV was an overestimation (theoretical 
mass is 102 kDa). The molecular mass calculated from the Porod volume 
(concentration independent) gave a mass ranging from 101-106 kDa, all of them 
suggesting that hHKII is a monomer in solution (theoretical mass is 102 kDa). Dmax 
was determined including scattering data from 0 to q= 0.34 (Å
-1
) as signal to noise 
ratio was not optimal for higher q. High q data is most susceptible to slight mismatch 





Table 4.1: SAXS parameters of full length hHKII along a concentration series (0.75-6.20 
mg/ ml) 
SAXS data were analysed to obtain structural information of hHKII. The Rg of the protein is 
estimated at 42.3Å from two different methods (Guinier-Real space analysis). The predicted 
assembly of the molecule is monomer based on the predicted molecular mass from Guinier 


















0.75 80 42.1 102 41.0 137 Monomer 
1.55 75 43.9 105 41.5 145 Monomer 
3.10 74 43 104 41.9 147 Monomer 
6.20 78 43.3 107 41.4 145 Monomer 
 
A 3D envelope model of hHKII was constructed from small-angle scattering data 
(1.55mg/ ml) using the ab initio programs DAMMIF and DAMMIN. DAMMIF, 
which is faster, generated 13 models, which were all very similar to each other. The 
13 models were aligned to generate an average model which was used as an input for 
DAMMIN to develop the final bead model. A molecular envelope was obtained 
using PyMOL and the known crystal structure of the monomer hHKII was docked 
into the model manually. Figure 4.2 shows that the 3D model correlates well with the 
monomer of hHKII shown in cartoon. A comparison of the X-ray solution scattering 
from SAXS hHKII (blue line) and the best fit by CRYSOL (red line) of the atomic 
resolution crystallographic data confirms this; χ
2





Figure 4.2: The 6His-tag hHKII forms monomeric assembly in solution 
A. The intensity plot; log[I(q)] against q (Å
-1
).  
B. The linear fit of Guinier analysis is indicative of non-aggregated protein at this 
concentration. Intensity plot of hHKII (1.55 mg/ ml) does not have a significant upturn or 
downturn at low q so there is no significant aggregation or inter-particle effects. 
C. Real space I(0), Rg and estimation of the maximum dimension of the particle, dmax, is 
made from an indirect Fourier-transform of the intensity data into the pair-distance 
distribution function, P(r). The P(r) distribution contains multiple shoulders after 50Å
-1
 until 





q Å-1  
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D. The experimental scattering data fit well to the calculated scattered curve predicted from 
the P(r) distribution. 
E. 3D envelope of hHKII predicted from DAMMIN modelling program (2nzt.pdb, chain A). 
There was no significant preference in N and C orientation when fitting the structure to the 
model. 
F. A comparison of the solution scattering from SAXS analysis of hHKII (blue line) and the 
best fit of the atomic resolution crystallographic data (red line); χ
2
= 0.965 from CRYSOL 
(ATSAS 2.7.2). 
 
4.3.2 SAXS analysis of N domain of hHKII 
N domain of hHKII was analysed by DLS and SEC-MALS and predicted to be a 
monodisperse species of the correct molecular mass. SAXS data were collected for N 
domain between 0.35 to 5.60 mg/ ml. The signal to noise ratio for 0.35 mg/ ml is not 
optimal for further analysis so this concentration was omitted. The remaining 
concentrations were initially analysed to establish that sample was free of 
aggregation and inter-particle interactions. Guinier analysis was performed for all 
concentrations of the N domain. The average Rg is estimated at 29.56±1.26Å. The 
average particle mass derived from Guinier analysis is in range of 37-41 kDa 
(theoretical mass 53.4 kDa) which again suggests that the concentration measured 
from UV spectrometry was overestimated. The buffer where N domain was stored 
contains 2mM DTT; oxidation might interfere with the accurate measurement of the 
concentration (Jacques and Trewhella, 2010). Interestingly the mass estimated from 
the Porod’s law is quite different (average mass estimated at 64.89±11 kDa) and with 
a significant error. The excluded volume calculated through the Porod invariant, 
  
       
    




, (Equation 4.4) 
can be converted to molecular mass from dividing the excluded volume by 1.7. 
Iexp(0) is the experimental intensity at q=0. The integral portion of the above equation 
is known as the Porod invariant. However, accuracy varies for shape and size. In 
general, this estimate is true for large globular proteins (>70 kDa) and when it 
applies to small proteins or proteins with unusual shapes it fails to make a right 
prediction (Putnam et al., 2007) In our case, due to the fact that N domain is an 
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elongated protein <70 kDa, using the Porod invariant might mean the estimation of 
mass is inaccurate. With a closer look to the data, one can see that the predicted mass 
is larger for SAXS analysis at 0.70mg/ ml (66 kDa) than it is for 5.56mg/ ml (58.29 
kDa). The mass estimated from the real-space P(r) distribution is close to the mass 
predicted from Guinier analysis. The N domain assembly is predicted to be a 
monomer according to this data. The Rg average (from both Guinier and real-space 
analysis) is 29.42±1.09 Å, around 30% smaller than the Rg of the full length protein. 
The highest quality data were used to build the 3D envelope of N domain (2.80mg/ 
ml). Figure 4.3 depicts the intensity plot and a linear Guinier plot, both of which are 
indicative that the sample is not aggregated. The dmax was estimated at 101Å. As 
previously the DAMMIF and DAMMIN programs were used to generate the final 
bead model. DAMMIF, which is faster, generated 13 models, which had similar 
shapes. The 13 models were aligned to generate an average model which was used as 
an input for DAMMIN to develop the final bead model. A molecular envelope is 
shown with PyMOL along with the docked crystal structure of N domain. Figure 4.3 
shows that the 3D model correlates well with the monomer of N domain shown in 















Table 4.2: SAXS parameters of N domain along a concentration series (0.70-5.6mg/ ml) 
SAXS data were analysed to obtain the Rg of N domain which is estimated at 29.4Å from 
two different methods (Guinier-Real space analysis). The calculated Rg is roughly 30% 
smaller than for the full length protein which was expected. The predicted assembly of the 
molecule is monomer based on the predicted molecular mass from Guinier analysis and 
Porod volume. However the calculated mass from the UV spectrometry is likely to be 
























0.70 37 28.6 66 41 28.9 101 Monomer 
1.40 39 31.6 61 40 28.8 96 Monomer 
2.80 39 28.4 60 41 28.8 101 Monomer 





Figure 4.3: The N domain of hHKII forms a compact assembly in solution 
A. Intensity plot of N domain (2.80mg/ ml) does not have an upturn or downturn at low q so 
protein does not have a significant proportion aggregated. The linear fit of Guinier analysis is 
also indicative of non-aggregated protein. 
B. Real space I(0), Rg and estimation of the maximum dimension of the particle, dmax, is 
generated from indirect Fourier-transform of the intensity data into the pair-distance 
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C. 3D envelope of N domain predicted from DAMMIN modelling program. The 3D model 
has a guitar shape and the neck seems to fit well the long helix that connects N and C 
domain. PyMOL was used to fit manually the N domain light blue cartoon) to the 3D 
envelope.  
D. A comparison of the solution scattering from SAXS analysis of the N domain (blue line) 
and the best fit of the atomic resolution crystallographic data (red line); χ
2
= 1.7 from 
CRYSOL. 
 
4.3.3 SAXS analysis of C domain of hHKII 
C domain of hHKII was analysed by SAXS in concentration series from 0.35 to 2.7 
mg/ ml. As for N domain, the lowest concentration of 0.35mg/ ml was omitted from 
the analysis as the data were not optimal in such a low concentration. Guinier and 
real-space analysis were performed to determine the I(0) and Rg. The Rg was found 
to be concentration and method independent with an average of 31.38±0.66 Å. The 
Rg for both domains is in close proximity which is expected as N domain and C 
domain have similar size and shape. The average particle mass derived from Guinier 
analysis is in range of 45-52 kDa (theoretical mass 50.8 kDa). However, the mass 
estimated from the Porod’s law is quite different (average mass estimated at 80.6±6.9 
kDa). The same phenomenon is observed for N domain. In contrary to the N domain 
however, C domain calculated mass does not improve when concentration is higher. 
At concentration 2.7mg/ ml the mass is estimated at 73.89 kDa which is exactly the 
average of monomer and dimer of C domain ((100+50)/2). This result seems to agree 
with SEC-MALS analysis (Chapter 3, section 3.3.2.2) which suggested that C 
domain is a monomer:dimer (80:20) in equilibrium. 
Volume-of-correlation analysis, Vc, overcomes the limitation of Porod analysis for 
flexible systems. Vc is defined as the ratio of I(0) to its total scattered intensity. The 
total scattered intensity is estimated by integrating the area under the curve of SAXS 
data transformed as qI(q) versus q. Vc is concentration independent as shown from 
studies on well-characterized molecules of different mass (Rambo and Tainer, 2011). 
Vc requires an accurate determination of I(0), preferably by combining both Guinier 
analysis and real-space P(r) distribution. Vc analysis was performed for C domain 
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after I(0) determination from both methods. The estimated mass according to this 
method ranges from 58 kDa to 110 kDa.  
Dmax estimations range from 96 to 109 Å. The 3D envelope was not constructed as C 
domain cannot be treated one rigid body, it is probably an equilibrium of 
monomer:dimer in solution and the 3D envelope would not be as accurate as for full 
length and N domain of hHKII. 
 
Table 4.3: SAXS parameters of C domain along a concentration series (0.70-2.80mg/ 
ml) 
SAXS data were analysed to obtain structural information for C domain of hHKII. The 
calculated Rg is 31Å in average. The predicted assembly of the molecule was hard to be 
answered based on Guinier and Porod analysis. Based on Guinier analysis the predicted 
assembly is closer to a monomer while from Porod analysis tends to be a dimer. As both 
have limitations, the volume-of-correlation analysis was performed which enables us to find 
the molecular mass of the molecule under study in a way that is independent of concentration 
and of the need for a compact, rigid system. The mass is not consistent between the different 


























0.70 45 31.1 83 67 30.2 96 
Monomer:d
imer 
1.40 47 30.9 75 110 31.3 109 
Monomer:d
imer 







Figure 4.4: The C domain of hHKII forms a multimeric assembly in solution 
A. Intensity plot of C domain (2.80 mg/ ml) does not have an upturn or downturn at low q so 








linear fit of Guinier analysis is also indicative of non-aggregated protein at this 
concentration. 
B. Integrating the area under the curve of SAS data transformed as qI(q)/q gives the total 
scattered intensity. The plot is more informative on the molecular mass of a flexible particle, 
where it is not possible to define the area under a Kratky plot. 
C. A comparison of the solution scattering from SAXS analysis of the C domain (blue line) 
and the best fit of the atomic resolution crystallographic data (red line); χ
2
= 6.1 from 
CRYSOL. 
D. Real space I(0), Rg and estimation of the maximum dimension of the particle, dmax, is 
made from indirect Fourier-transform of the intensity data into the pair-distance distribution 
function, P(r). The dmax is estimated at 95Å. The 3D envelope was not constructed as it 
would not be accurate because of the likely monomer dimer equilibrium. 
E. The experimental scattering data fit well to the calculated scattered curve predicted from 
the P(r) distribution. 
 
 
4.3.4 Comparison of flexibility and Kratky plots between full length, N 
and C domains of hHKII 
The Kratky plot is the plot of the scattering pattern as q
2
I(q) versus q and it is used to 
identify unfolded samples. Ideal globular proteins follow the Porod law and the 
scattering intensity show a decrease as q
-4
 at higher q. This results in a bell shaped 
curve with a pronounced maximum at low angles (q). Two limitations occur from 
this approach: 1) the inability to compare molecules with different molecular mass 
since the scattering intensity will be influenced from different size samples and 2) it 
is hard to make a decision whether a protein is folded or partially unfolded when the 
protein contains a high amount of large sized structured regions. To overcome this 
problem the dimensionless Kratky plot was developed were I(q) is normalized to the 
I(0) and q is normalized to the radius of gyration (plots I(q)/I(0)×(q×Rg)
2
/ qRg. This 
way the angular scale is independent of the molecular mass and size of the protein. 
The dimensionless Kratky plot on the other hand has a limitation occurring from the 
need of an accurate determination of the Guinier region (Rambo and Tainer, 2011). 
Globular proteins consistently exhibit a maximum value of 1.104 for qRg= √3 
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(indicated by grey lines on Figure 4.5). On the other hand, for completely unfolded 
polypeptide chains the plot does not have a bell-shape as the curve keeps rising and 
plateaus at a region between 1.5 and 2 qRg. In our case all dimensionless Kratky 
plots (Rg based on Guinier analysis) were overlaid and compared to each other.  
As shown in Figure 4.5 C and N domain have the characteristic parabolic shape with 
a similar maximum around 1.2 at qRg around 2. This indicates that proteins do not 
scatter very differently from a globular molecule. C domain shows a slight difference 
in shape when qRg>3 but does not clearly indicate a flexible or a completely 
unfolded particle. The C domain deviates from ideality slightly more than the N 
domain. Increases in I(q)/I(0)×(q×Rg)
2 
when qRg>6 is likely due to poor buffer 
subtraction rather than a property of the particle. The full length protein has a broad 
peak around the maximum (~1.3) which is suggestive of a multidomain protein with 
flexible linkers. 
 
Figure 4.5: Dimensionless Kratky plots between all constructs of hHKII 
The dimensionless Kratky plot is based on the Rg as estimated from the Guinier analysis. 
The grey lines indicate the maxima at which any ideal globular protein should lie. Green plot 
belongs to full length hHKII, blue to N domain and brown to C domain.  
 
Due the difficulty of definitively determining flexibility from Kratky plot analysis, 
Porod-Debye plots were examined to identify flexibility. The Porod-Debye law is an 
approximation that describes a linear relationship between q and I(q) for a small 
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range of q just larger than the Guinier limit of q. In a Porod-Debye plot q
4
I(q) is 
plotted against q or q
4
. Application of the Porod-Debye law should result in a Porod 
plateau at a value of q just outside the Guinier region for “rigid” particles that have a 
well-defined electron density contrast between the protein and the solvent. Flexible 
proteins do not have a well-defined contrast due to the many conformations of the 
ensemble (Rambo and Tainer, 2011). The Porod plateau is most easily observed in 














 (SIBYLS plot). 
 
Figure 4.6: Porod-Debye plots for all constructs of hHKII 
Porod-Debye plots show characteristic plateau; the intensity decay follows q
-4
. Green plot 
corresponds to full length hHKII, blue plot to N domain and brown plot to C domain. This 
suggests that each construct can be characterized as well-folded proteins in solution. 
 
4.4 Summary and conclusions 
The major aim of the present work was to gain structural insights of the full length 
hHKII and each domain separately (N and C domains). Although full length hHKII 
is folded, active and homogenous I could not crystallise it and SAXS was sought as 
an alternative method to obtain structural information on hHKII. SAXS data were 
collected for a concentration series of all three constructs.  
The Rg of the full length hHKII is 42.3 Å, of N domain is 29.4 Å and for C domain 
is 31 Å. The average Rg from the crystallographic data is estimated at 40.6 Å, 25.9 Å 
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and 27 Å respectively for monomers. Both methods are essentially in agreement. The 
Rg for N and C domains is smaller than for the full length protein as anticipated and 
similar to each other. The average dmax of full length hHKII, based on SAXS, is 145 
Å, 96 Å for N domain and 109 Å for C domain, compared to 137 Å, 88 Å and 75 Å 
based on the X-ray structure. Once again, the SAXS results are not far away from 
those calculated from crystallographic data for the full-length and N-domain 
constructs. The N domain is estimated to be 96 Å instead of 88 Å but the construct is 
not identical. The SAXS analysis was performed on a construct that has the 6His tag 
attached with a TEV cleavable site (15 residues). These residues could account for 
the longer dmax. C domain is the one that shows a significant larger dmax possibly 
because of the complexity of the system. 
The molecular mass estimation for full length hHKII was very close to the theoretical 
mass (102 kDa) of the protein by using the Porod analysis which is concentration 
independent. Based on Guinier analysis the predicted mass is smaller (75-80 kDa) 
probably because the measured concentration with UV spectrometry was an 
overestimation. The mass prediction of N domain using the Guinier analysis and Pr 
distribution is in agreement, thus smaller than the size of a monomer. The UV 
concentration measurement was not as accurate. Using the Porod analysis the 
concentration is closer to a monomer which suggests that the assembly of the N 
domain in solution is monomeric. The results agree with other biophysical analysis 
of the N domain.  
SAXS data for C domain were analysed as the Guinier plots were indicative of a 
non-aggregated and soluble sample, well suitable for SAXS analysis. The Rg is in 
good agreement between Guinier analysis and distance distribution function. On the 
contrary the mass estimation was not consistent. Based on Guinier analysis it is 
predicted to be a monomer, based on Porod analysis the mass is an average of 
monomer and dimer. As C domain was predicted to be an equilibrium of 
monomer:dimer in solution based on SEC-MALS, the system flexibility might 
interfere with an accurate mass estimation using the above SAXS methods. For this 
reason the volume-of-correlation (Vc) was added to the analysis. Vc is expected to 
estimate a more accurate mass for a flexible/ intrinsically unstructured system and it 
is also concentration independent. The predicted mass this way was not consistent 
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across the different concentrations of the C domain. The C domain data could not be 
exploited to create a 3D envelope as the analysis of the SAXS data were not clear 
and not as expected thus the generated model would not be correct. 
To further compare the three constructs the dimensionless Kratky plots were 
analysed. As shown in Figure 4.5 C and N domain have the characteristic bell-shaped 
curve with a similar maximum close to a maximum observed for globular molecules. 
C domain shows an increase at far qRg which is not likely to indicate a flexible 
domain. It is more likely to represent a poor subtraction of buffer since the resolution 
is low at the region qRg>6. The rather flat topped Kratky plot for full-length hHKII 
is interesting as it is suggestive of a multi-domain protein with some flexibility. 
However, the Porod-Debye plot for hHKII has a clear Porod plateau which is 
evidence of a well-defined protein-solvent boundary and a rigid particle. It would be 
tempting to hypothesize that the hHKII has overall well folded domains with some 
pivot points that may facilitate enzymatic action. 
The 3D envelope was constructed for full length hHKII and N domain hHKII as they 
are well characterised and are monodisperse species in solution. The crystal 
structures were manually docked to the envelopes using PyMOL. The manual fits of 
model-crystal structure were close to crystallographic shape of the proteins. The best 
fit of experimental data to crystallographic data was seen for full length protein. The 
3D-envelope of N domain has a guitar shape and the neck correlates well with the 
long helix that connects the two domains to each other in the atomic resolution 
structure.  
Taken together, these data would indicate that full length and the N-terminal domain 
construct of hHKII are monomeric in solution and do not differ much in overall 
architecture from the crystallographic atomic resolution structures. The C-terminal 







5. Chapter 5: Screening for hits against human hexokinase II 
5.1 Introduction 
The discovery of a new drug is a long and expensive process. It takes an average of 
10-15 years for a drug to reach the market and the cost is estimated between US$800 
million up to US$1.8 billion (Macalino et al., 2015). The main technique for the 
discovery of new lead compounds is the physical screening of large libraries of 
chemical compounds against a target molecule (High Throughput Screening- HTS) 
(Shoichet, 2004). In the early 1990s the development of combinatorial chemistry and 
HTS technologies, which enabled the screening of huge libraries in less time, spread 
the hope for an accelerated drug discovery process (Lavecchia and Giovanni, 2013). 
Table 5.1 shows some examples of recently approved drugs, derived from HTS 
process. 
 











Tipranavir Protease HIV 2005 
Boehringer 
Ingelheim 







































Thrombocytopaenia 2008 GlaxoSmithKline 
 
Overall hit rates are often low as many hits fail in the lead optimisation process due 
to absorption, distribution, metabolism, excretion and toxicity deficiencies 
(ADMET/Tox). These issues became the reason for an alternative method to be 
found, which would be cost-efficient and would limit the hits identified with 
unsuitable properties (Lavecchia and Giovanni, 2013). 
Computer-aided drug discovery (CADD) techniques have been used as an alternative 
and complementary approach to drug discovery. These in silico approaches have 
been developed by a number of research groups and pharmaceutical companies in 
order to speed up the discovery of potent lead compounds and also minimise the 
chance of failure in a later stage. It is important to highlight that rational drug design 
using CADD, studies the interaction of the complex between a protein and a ligand 
and makes use of that structural knowledge to design more potent lead compounds. 
HTS on the other hand, requires no a priori knowledge of the binding mechanism of 
the drug on the protein (Macalino et al., 2015).  





Ligand and Structure based approaches 
Ligand based drug design: In cases where the three-dimensional (3D) structure of a 
protein is not available, ligand-based approaches utilise structure−activity data from 
already known actives to discover new candidate compounds with similar properties 
for experimental evaluation (Scior et al., 2012). It is thought that compounds with 
similar structure will interact in a similar manner with the target protein (Macalino et 
al., 2015). Common ligand-based design techniques are quantitative structure-
activity relationship (QSARs) and pharmacophore based methods. QSAR modelling 
aims to predict a correlation between the physicochemical and structural properties 
of a ligand and its potency. Ligand-based pharmacophores make use of the known 
biological activities of different (structurally and functionally) ligands, to create a 
model with the essential atom groups which need to be present for the binding to the 
target protein (Drwal and Griffith, 2013). 
Structure based drug design (SBDD), the use of 3D structural information gathered 
from biological targets, is a scientific area that has received a lot of attention with 
many successful applications in recent years. At the beginning of the 1990s the first 
reviews were published, where the X-ray structure of HIV-1 protease was taken into 
consideration for the design of inhibitors (Erickson et al., 1990). However, with the 
completion of the human genome project and the fast development of technology, 
especially with the development of faster computers, this field has now more 
opportunities for a successful discovery of drug leads. The development in X-Ray 
detectors and the exceptionally powerful synchrotron X-ray sources also make 
possible the determination of many more protein structures (Anderson, 2003). The 
structure-based drug design process results in the discovery of a lead, i.e a compound 
that binds specifically to the target protein with at least micromolar affinity. It can 
often be toxic or unstable, thus it serves as  a first step followed by other 
optimization steps until a low nanomolar drug is discovered (Verlinde and Hol, 
1994). A diagram containing the main steps of the SBDD, from the computational 





Figure 5.1: Steps performed during a typical SBDD project 
Starting from a known target structure virtual screening takes place to identify ligands. Best 
hits are purchased and tested for affinity and potency. Ideally a structure of the complex 
receptor-ligand (at least micromolar inhibition shown) should be determined. Analysis of the 
structure provides helpful insight on the key intermolecular interactions. These are taken into 
consideration for the computational design of improved lead compounds which are then 
tested again. In vivo assays are implemented for the highly potent inhibitors and if they are 
in the nanomolar range clinical trials can be followed.   
 
Structure-based virtual screening (SBVS) utilises the 3D structure of the 
biological target to dock millions of compounds from a virtual library to the desired 
site of the macromolecule. Scoring algorithms predict the binding affinity with this 
site and rank the compounds (Scior et al., 2012). In general SBVS consists of four 
steps: 
i. Molecular target selection/preparation. Accurate structural information is 
very important. Crystal structures are widely used for structure-based drug 
discovery but they have to be evaluated for the resolution, reliability, or R 
factors, coordinate error, temperature factors and chemical “correctness”. The 
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big advantage of crystal structures is that the water molecules are visible 
which is useful for the process (Anderson, 2003). 
ii. Compound database selection. The selection of a virtual library, among many 
freely accessible databases of commercial compounds, for the high-
throughput virtual screening (Jorge Moura Barbosa and Del Rio, 2012). 
iii. Molecular docking. Molecular docking programs aim to identify the most 
likely binding conformation of a small ligand within a specified binding site 
in the protein. These programs use specific scoring functions to estimate the 
binding energetics of the formed complex between the ligand and the 
receptor. (Ferreira et al., 2015). 
iv. Post-docking analysis. The VS process results in a long list of compounds 
(hundreds of thousands or millions) and a visual analysis is conducted to 
prioritise hits based on the desired criteria, for example if the ligand makes 
the predetermined interactions with the target protein (Ferreira et al., 2015). 
 
5.2 Materials and methods for SBVS of hHKII  
The structure-based virtual screening was performed by Dr. Douglas Houston. The 
following diagram summarises the steps used for the identification of virtual hits for 
hHKII. The structure templates, the compound database, the docking programs and 
the scoring functions used for this purpose are described here. Moreover, the docking 





Figure 5.2: Diagram of virtual screening. 
EDULISS, the database containing ~3 million compounds, was filtered according to the 
Oprea’s “reduced complexity” rules. 0.5 m compounds were docked with AutoDock Vina 
and the top 5,000 based on Vina score were docked with AutoDock. The compounds with 
the agreed or without an agreed binding mode from both programs were then scored 
applying multiple scoring algorithms. The top hundred compounds were visually analysed to 
decide which are going to be tested. The number of compounds in a step can be different for 
different sites docked. 
 
5.3 EDULISS Database 
EDULISS (Edinburgh University Ligand Selection System) is a relational database 
for data mining small molecules. The database comprises of 3 million commercially 
available compounds from 28 suppliers (Hsin et al., 2011). For each compound a 
single 3D and 2D coordinates are stored along with over 1600 topological, 
geometrical, physicochemical and toxicological descriptors per compound. Also, the 
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vast majority of the compounds fit the Lipinski’s rule of five and many compounds 
fulfill the Oprea lead-like criteria (Hsin et al., 2011). Lipinski’s rule of 5 is a rule that 
is used from the pharmaceutical companies to evaluate a drug. According to 
Lipinski’s rule of 5, (Lipinski et al., 1997) a drug is more likely to have poor 
absorption or permeation when: 
 There are more than 5 hydrogen bond donors (expressed as the sum of OHs 
and NHs) 
 The molecular weight is over 500 
 The Log P is over 5 
 There are more than 10 hydrogen bond acceptors (expressed as the sum of Ns 
and Os) 
The more stringent Oprea-criteria for a promising lead-like compound (Hann and 
Oprea, 2004) are the following: 
 The molecular weight should not be over 460 
 The number of rotatable bonds should be less than 10 
 The calculated Log P should be between −4 and 4.2 
 The number of hydrogen bond acceptors should be ≤9 
 The number of hydrogen bond donors should be ≤5 
 The number of rings should be ≤4. 
However, one should never forget that a compound with the above characteristics 
might not necessarily make it to the final stage of drug discovery as it may be toxic, 
teratogenic, be metabolised quickly, unable to reach the target macromolecule in the 
right concentration, too difficult to synthesise and/or too expensive. There is no way 
to estimate what changes it will provoke regarding the metabolic, transport and 
signaling pathways once administered to the human body (Verlinde and Hol, 1994). 
The EDULISS library was initially filtered using the software ''Filter-it'' 
(http://silicos-it.be.s3-website-eu-west-1.amazonaws.com/software/software.html). 
The number of compounds that proceeded to the docking routine was reduced to 0.5 
million. This command-line program filters molecules with unwanted properties and 




5.4 AutoDock 4.0 and Vina 
Virtual screening, being one of the common strategies for the identification of new 
lead compounds, relies on a receptor-based computational docking of libraries 
containing compounds (Shoichet, 2004). The importance of an accurate docking tool 
for this purpose is clear. In general protein-ligand docking programs consist of two 
essential components, sampling and scoring. Sampling refers to the generation of 
putative ligand binding orientations/conformations near a binding site of a protein. 
The scoring function is used to predict the binding tightness for individual ligand 
orientations/conformations with a physical or empirical energy function. The lowest 
energy score indicates the likely best orientation/conformation of a ligand, referred to 
as the binding mode (Huang and Zou, 2010). Two methods are known for the 
automated docking: The matching and the docking simulation methods (Rosenfeld et 
al., 1995). Matching methods try to dock the ligand, as a rigid-body, by matching its 
geometry to the active site. Docking simulation methods allow flexibility within the 
ligand combined with more advanced molecular mechanics to calculate the binding 
energies. (Morris et al., 1998). AutoDock 4 and AutoDock Vina belong in this group 
(Morris et al., 2009, Trott and Olson, 2010). 
AutoDock 4 calculates the interaction energy between a ligand and a macromolecule 
in a grid-based method, where the target protein is embedded in a grid and different 
atom types of a ligand are placed at each grid point while computing the interaction 
energy. This grid of energies is stored and used during the docking simulation. 
Autogrid is the program that creates the grid points in the interaction map by 
assigning different atom types around the binding site of the macromolecule.  
AutoDock 4 uses the Lamarckian genetic algorithm (LGA) and the semi empirical 
free energy force field scoring to predict binding free energies of the ligands to the 
protein (Morris et al., 2009). LGA is a hybrid of the genetic algorithm (GA) method 
and the local search (LS) method, described in detail from Morris et al, 1998 (Morris 
et al., 1998). This algorithm overcomes the docking obstacles when more degrees of 
freedom are involved in the process.  
The semi empirical free energy force field uses an improved thermodynamic model 
for the binding process as it includes the intramolecular energies of the unbound 
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structure, resulting in a more accurate prediction of the free energy. A full 
desolvation model that includes both favorable and unfavorable energetics and a 
model to predict the proper alignment of groups with multiple hydrogen bonds are 
also included (Huey et al., 2007). AutoDock Vina has an optimised algorithm that 
takes advantage of the local optimisation method that calculates derivatives to 
generate a gradient speeding up the optimization significantly. AutoDock Vina also 
calculates the grid maps internally to further quicken the procedure. Finally, the runs 
can be performed at the same time by using multithreading. As a result, AutoDock 
Vina had improved the speed by two orders of magnitude compared to AutoDock 4 
while improving the accuracy of the predictive binding modes (Trott and Olson, 
2010). 
Both programs were compared during a virtual screening for the identification of 
actives for HIV protease using two different chemical libraries. The library which 
contained molecules with low molecular weight and few rotatable bonds was 
screened against both programs and gave similar results with significant level of 
accuracy. However, Vina was capable of preferentially ranking active compounds in 
the virtual screen of another library which consisted of larger molecules, with more 
rotatable bonds, while AutoDock 4 failed to do so (Chang et al., 2010). 
 
5.5 Consensus Docking 
For our studies virtual screening was improved using a relatively easy method named 
consensus docking (Houston and Walkinshaw, 2013). Houston with their work 
showed that, when combining more than one docking program and using only the 
docked compounds that are in the same location with the same orientation and 
conformation (referred to as binding pose), then the accuracy is improved. For this 
conclusion, a subset of 228 protein-ligand crystal complexes from the PDBbind-CN 
database, which is supplemented with experimental data, was used. More 
specifically, combining AutoDock and Vina poses and excluding the ones that were 
not close to each other, the correctly docked poses (i.e. the RMSD between the 
docked pose and crystallographic pose was less than 2 Å) were 82%, instead of 64% 
for the best docking program (55% for the other) (Houston and Walkinshaw, 2013). 
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In our case Vina was used first, as it is faster than Autodock, and the top 5,000 
compounds from this were docked with AutoDock and the binding poses examined.  
 
5.6 Scoring functions and consensus scoring 
The scoring function of a protein-ligand docking program predicts the binding 
energy for individual ligand orientations/conformations aiming to differentiate the 
preferential binding mode, i.e the one with the lowest energy score. Many scoring 
functions have been developed which can be divided into three main categories 
according to their method of derivation: force-field (FF), empirical and knowledge-
based scoring functions (Huang and Zou, 2010). For our studies 5 different scoring 
functions were selected to rank the virtual hits: DrugScore, X-score, NNScore 1.0, 
NNScore 2.0 and RFscore 4. 
DrugScore is a knowledge-based scoring function that consists of distance dependent 
pair potentials with novel torsion angle potentials and a newly developed potentials 
for the estimation of solvent accessible surface (Neudert and Klebe, 2011). 
X-Score is an empirical consensus scoring function which consists of three different 
scoring algorithms, each of which has five adjustable terms: atom classification, van 
der waals interaction, hydrogen bonding, deformation penalty and hydrophobic 
effect. These 5 adjustable parameters affect the overall free energy change when a 
protein-ligand complex is formed according to Wang et al. A larger training set (200 
protein-ligand complexes) has been used to calibrate these, thus an error of 2 kcal/ 
mol in the estimated binding free energy was shown (Wang et al., 2002). 
RF-Score function performs under a machine learning approach. Compared to 
scoring functions that generate under a rigid set of parameters which ultimately will 
fail to conform for all protein complexes, RF-Score does not account for any a priori 
relationship between the complex components and the binding data. Thus it is more 
flexible to estimate a more accurate prediction within the big diversity of protein-
ligand complexes. RF-Score has been shown a valuable tool especially as a re-
scoring function (Ballester and Mitchell, 2010). 
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NNScore is a neural network based scoring function that can be used to re-score the 
docked poses of potential hits. A neural network, that is designed to mimic the 
microscopic organization of the brain, does not need specific formulas describing the 
relationship that governs the components studied by the network. Knowing that, 
Durrant & McCammon (2010), while designing NNScore, had only to define the 
properties of a ligand protein complex that affect the binding affinity and allow for 
the system itself to find the relationship, analyse and finally characterise the 
complex. Although the network succeeded to discriminate between well-docked and 
poorly-docked ligands as well as true ligands from decoy compounds, the designers 
suggest its use in combination with more traditional scoring functions (Durrant and 
McCammon, 2010). NNScore 2.0 is an updated version of NNScore neural network, 
supplemented with a much greater number of binding characterizations (Durrant and 
McCammon, 2011). 
As consensus docking increases the accuracy of the predictive binding mode, 
consensus scoring, which combines more than one scoring function for the prediction 
of the binding mode, leads to an improved prediction of hits (Charifson et al., 1999). 
 
5.7 Final choice of the compounds for the bioassays 
Consensus docking and consensus scoring were combined to rank the virtual hits. 
Consensus docking has been shown to be slightly biased towards molecules that have 
a higher score (Houston and Walkinshaw, 2013). In the present study ~50% of the 
top hundreds hits are molecules showing a different binding mode but having a lower 
score for binding affinity. The other ~50% arises from molecules that are predicted 
to have the same binding mode (RMSD with a cutoff of 2 Å) and the best score. 
For the final ranking of all the candidates the “rank-by-rank” strategy was followed 
(Wang and Wang, 2001), where we determined the rank position of a candidate from 





 with X-Score then the average rank will be (10+20)/2=15. The 
consensus scoring was more sophisticated in our studies as more scoring functions 
were added to our schemes. As will be explained in detail later we performed several 
docking studies and different scoring functions were used (or updated versions at the 
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time of the run). The specific scoring functions for each one will be discussed at the 
relevant section. The following diagram summarises the steps undertaken, starting 
from Vina docking until the final ranking of all hits. 
 
Figure 5.3: Scoring and ranking the virtual hits 
The diagram summarises the steps taken from the initiation of the docking studies. Solid 
lines show the same steps, dashed line shows the difference between the two ranking 
schemes. 0.5 m of compounds were docked with Vina and the top 5,000 (scored by Vina) 
proceeded to AutoDock, which added a new score for the predictive binding mode (AD). 
The 5,000 candidates were further analysed with the scoring functions (X-score 1.2 and 1.3, 
DrugScore, NNScore1.0, NNScore2.0 and RF-score) to estimate the binding affinity on the 
target receptor. At the same time only the candidates docked in the same way with both 
docking software (Vina, AD) were scored using the same scoring algorithms and ranked 
accordingly. The consensus docking is performed before the scoring stages in order to gain a 
more accurate prediction of binding affinity due to the fact that the binding mode has more 
chances to be correct (Houston and Walkinshaw, 2013). The consensus scoring is then 





All the virtual hits from in silico screening were filtered using multiple techniques, 
including prioritisation of compounds that met Lipinski rules and Oprea criteria. In 
addition, the hit list was analysed by an experienced medicinal chemist (Dr Phill 
Cowley, Head of Chemistry, IOmet Pharma Ltd.) to remove compounds which were 
potentially reactive, non-specific in terms of their biological action or not drug-like. 
This allowed the focus to be on compounds that were more likely to be of use as lead 
compounds in the initiation of a drug discovery program. 
 
5.8 Structure model templates 
5.8.1 Structure choice for human hexokinase docking studies hHKII 
structure  
As mentioned in Chapter 1, the crystal structure of hHKII has been determined from 
SGC in 2006, with Glc (substrate) and G6P (natural inhibitor) present (PDB code: 
2NZT). As it was the only available structure at the PDB, the holo form was 
considered for the SBVS strategy. hHKII contains two domains, the N (1-475) and C 
(476-917) terminal domain, showing a significant level (~60%) of identity. In 
contrast to HKI and HKIII, both domains for HKII are functional with comparable 
catalytic activities (Tsai and Wilson, 1996), (Ardehali et al., 1996). As both catalytic 
sites are identical choice of domain should not make a difference in the docking 
process. However, since many studies have been performed on the catalytic C 
domain and the inactive N domain of isoforms I and III (Arora et al., 1993), (Tsai 
and Wilson, 1997), (White and Wilson, 1989), the docking was performed at the C 
domain. Figure 5.4 shows the monomer of hexokinase II consisting of two domains 
along with a closer-up representation of residues of C domain which interact with 




Figure 5.4: Monomer of hHKII and active site occupied by Glc and G6P (Glc-G6P site) 
Cartoon representation of monomer hHKII (2NZT) consisting of two domains, the N 
(purpleblue) and C (cyan) domain. Both domains bind the ligands, Glc and G6P, which are 
shown as pale green and salmon sticks respectively. The residues interacting with hydrogen 
bonds with each ligand at the C domain are shown in the box. Residues interacting with Glc: 
T620, K621, N656, D657, N683, E708, E742. Residues interacting with G6P: D532, T536, 
D657, T680, D861, T863, S89. 
 
A closer analysis of the C domain from the above structure shows that the active site 
is not in an optimal conformation for drug discovery. It forms a relatively closed 
conformation, allowing a restricted docking space which would not allow the 
accommodation of compounds of lead-like size. An analysis of the available crystal 
structures for human hexokinase was carried out, searching for another isoform that 




hHKI structure  
A structure from HKI (PDB code: 1DGK) was found to hold a more open 
conformation of the active site. The crystal structure of the quadruple mutant 
(Glu280→Ala, Arg283→Ala, Gly284→Tyr, and Thr536→Ala) is a monomer with 
one molecule of ADP and Glc bound to the C-terminal half and one molecule of Pi, 
Glc and ADP to the N terminal half (Aleshin et al., 2000). The monomer of hHKI is 





Figure 5.5: Monomer of mutant hHKI with Glc and ADP bound. 
Cartoon representation of monomer hHKI (1DGK) consisting of two domains, the N (light 
orange) and C (orange) domain. Both domains bind the ligands, Glc and ADP, which are 
shown as pale green and deep olive sticks respectively. Glc interacts with S603, F604, T620, 
Lys621, N656, D657, S682, N683, E708, E742. Selected interactions from the ADP/Glc 
monomer complex of the C domain are shown in the box. ADP interacts with S788, Lys785, 
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G747, T863, T680, A536, N537. Blue dots indicate hydrogen bonds, black dots represent 
interactions with phosphate groups.  
 
A grid surface representation (Fig. 5.6) of 1DGK and 2NZT reveals a surface cleft 
where ADP is binding only for 1DGK. 2NZT does not contain the open cavity 
formed by ADP binding. 
 
Figure 5.6: Surface grid representation of C domain of 1DGK and 2NZT 
Overlay and grid representation of the C domain of 2NZT (cyan) and 1DGK (orange).  ADP 
is bound on the outer surface of the 1DGK while 2NZT has Glc and G6P bound. The 
difference between the two surfaces can be seen as 2NZT adopts a closed conformation close 
to the ADP binding site.  
 
An overlay of 1DGK and 2NZT shows that ADP binding on hexokinase I (1DGK) 
moves a loop and a helix in order to accommodate ADP. Side chains of T784, T536 




Figure 5.7: Overlay of 1DGK and 2NZT on ADP binding site. 
ADP binding on 1DGK moves a helix so that T784 does not clash on ADP. Also a loop is 
moved so that A536 can interact with the phosphate group from ADP. In comparison with 
2NZT, both helix and loop are clashing on ADP, as this structure is only a complex of 
Glc/G6P, and it adopts a different secondary structure. (2NZT has Thr instead of Ala at 536 
as 1DGK is a mutant). 
 
For this reason the use of 1DGK for the docking studies is preferable, since the 
docking space from this wider pocket would allow the identification of more ligands 
which will either bind to Glc/G6P binding site or ADP binding site. To make a 
decision whether the use of 1DGK is feasible we had to evaluate if the residues 
interacting with the Glc and G6P from 2NZT (0-4.0 Å distance) were the same with 
the same side chain orientation. By comparing the sequence of both isoforms the 
binding sites for Glc and G6P are completely conserved as well as the side chain 




Figure 5.8: Sequence alignment between 2NZT and 1DGK (C domain). 
The residues interacting with Glc and G6P are coloured grey and yellow respectively. 
Common residues for both ligands are shown as cyan. The active sites are completely 
conserved apart from one mismatch because 1DGK is a mutant (T536→A536).   
 
An overlay of the structures 1DGK and 2NZT was performed to identify any 
possible side chain movement between the residues of the active sites. Figure 5.9 
shows that all residues from both sites have the same orientation in isoforms I and II. 
1DGK crystal structure forms a wider pocket and this template was used for the 
docking. A536 was mutated to T536 using PyMOL, in order to create an identical 
binding site for substrate and product as it is for 2NZT, hexokinase isoform II. 
 
1DGK:C_domain      AHFHLTKDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGDFLALDLG 
2NZT:C_domain      EHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLG 
                     
1DGK:C_domain      GANFRVLLVKIRSGKKRTVEMHNKIYAIPIEIMQGTGEELFDHIVSCISDFLDYMGIKGP 
2NZT:C_domain      GTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGV 
                  
1DGK:C_domain      RMPLGFTFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRREEFDLDVVAV 
2NZT:C_domain      SLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAV 
                    
1DGK:C_domain      VNDTVGTMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMVEGDQGQMCINMEWGAFGD 
2NZT:C_domain      VNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGD 
                    
1DGK:C_domain      NGCLDDIRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKGFLFRGQISE 
2NZT:C_domain      NGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISE 
                    
1DGK:C_domain      TLKTRGIFETKFLSQIESDRLALLQVRAILQQLGLNSTCDDSILVKTVCGVVSRRAAQLC 
2NZT:C_domain      RLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLC 
                     
1DGK:C_domain      GAGMAAVVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTVKELSPKCNVSFLLSE 
2NZT:C_domain      GAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSE 
                    
1DGK:C_domain      DGSGKGAALITAVGVRLRTEASS 




Figure 5.9: Superposition and grid representation of the Glc/G6P site between 2NZT 
and 1DGK. 
The C domains of 2NZT and 1DGK are coloured cyan and orange respectively. Structures 
are overlaid and shown in a grid mode. The residues of the binding sites of Glc (pale green) 
and G6P (salmon) are conserved between the two isoforms. Only one different residue 
differs at position 536, as 1DGK is a mutant of isoform I. ADP, present only in 1DGK, is 
shown as deep olive stick.  
 
In summary, the computer-simulated docking studies were performed using the 
widely distributed molecular docking software AutoDock and AutoDock Vina. The 
protein structure used for this was extracted from the PDB with the code 1DGK. The 
structure belongs to the hHKI which has an extensive sequence similarity to hHKII. 
The latter will be used for screening the selected virtual hits. The active site, where 
the substrate and product are bound in the crystal structure of isoform II, was the 
selected docking space. Figure 5.10 shows the surface of 1DGK highlighting the 




Figure 5.10: Surface of 1DGK highlighting the docking area of the Glc/G6P site. 
C domain of 1DGK (orange), Glc (pale green stick) and G6P (salmon stick) are present in 
the 2NZT structure whereas ADP (deep olive stick) is present in the 1DGK structure. All 
ligands are added to the overlay of 1DGK-2NZT. The black box represents the limits of the 
docking area. As can be seen the docking area includes the binding sites of all natural 
substrates/products.  
  
5.9 Docking studies on the ADP binding site of hHKI 
The ADP binding site (1DGK) was also subjected to docking studies. The 
interactions between the protein and ADP in a distance from 0-4Å were analysed 
with CCP4 and the following residues were found to form contacts (hydrogen bonds 
and van der waals): 
G535, A536, N537, G679, T680, G747, M748, T784, K785, S788, G862, T863, 
L864, L867. 
 
An alignment with HKII shows that this site is highly conserved so it is worth 




Figure 5.11: Alignment of the ADP binding site between 1DGK and 2NZT. 
The residues interacting with ADP, as found from 1DGK crystal structure were compared to 
2NZT. The results show that the sites are identical since all residues are conserved (one 
mismatch shown as red, occurs from 1DGK because is a mutant).  
The new docking area is restricted to the ADP binding site. Figure 5.12 shows the 
new docking space. This new docking performance aims to identify compounds that 
would mimic the ADP binding to the target molecule.  
 
 
1DGK:C_domain      AHFHLTKDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGDFLALDLG 
2NZT:C_domain      EHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLG 
                     
1DGK:C_domain      GANFRVLLVKIRSGKKRTVEMHNKIYAIPIEIMQGTGEELFDHIVSCISDFLDYMGIKGP 
2NZT:C_domain      GTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGV 
                  
1DGK:C_domain      RMPLGFTFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRREEFDLDVVAV 
2NZT:C_domain      SLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAV 
                    
1DGK:C_domain      VNDTVGTMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMVEGDQGQMCINMEWGAFGD 
2NZT:C_domain      VNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGD 
                    
1DGK:C_domain      NGCLDDIRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKGFLFRGQISE 
2NZT:C_domain      NGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISE 
                    
1DGK:C_domain      TLKTRGIFETKFLSQIESDRLALLQVRAILQQLGLNSTCDDSILVKTVCGVVSRRAAQLC 
2NZT:C_domain      RLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLC 
                     
1DGK:C_domain      GAGMAAVVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTVKELSPKCNVSFLLSE 
2NZT:C_domain      GAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSE 
                    
1DGK:C_domain      DGSGKGAALITAVGVRLRTEASS 
2NZT:C_domain      DGSGKGAALITAVACRIREAGQ- 




Figure 5.12: Surface of 1DGK highlighting the docking area of the ADP site. 
C domain of 1DGK (orange), Glc (pale green stick) and G6P (salmon stick) are present in 
the 2NZT structure whereas ADP (deep olive stick) is present in the 1DGK structure. All 
ligands are added to the overlay of 1DGK-2NZT. The new docking study was restricted to 
the ADP binding site, as the blue box highlighting the docking space excludes the binding of 
Glc and G6P molecules. 
 
5.10 Docking results for the Glc/G6P site of hHKI 
As discussed in section 5.8 the Glc/G6P site of hHKI (Fig. 5.10) was docked using 
AutoDock Vina and AutoDock. From the initial list of ~3 million compounds, 5,000 
were proceeded to the docking process. The consensus docking was performed and 
2,467 compounds were found to have the same binding mode predicted from both 
programs. Two different scoring schemes were performed after the docking which 




5.10.1 1st scoring scheme for ranking the docked compounds from the 
active site 
The scoring algorithms from each program were used, i.e DrugScore and X-score 
1.2. A complete ranked list of 103 compounds was generated which was visually 
analysed. The calculated average AutoDock and AutoDock Vina scoring energies of 
these hits are between -6.12 to -12.1 kcal/mol and -6.7 to -10.4 kcal/mol respectively. 
Nine compounds were purchased from the first ranking method, named AS1RS1, 
AS1RS2 etc. The MW for all compounds is <500, with an average of 360 and the 
average of cLogP is 1.77. 
Table 5.2 shows the ligands including their binding modes and their chemical 
structure. 
 
Table 5.2: Ligands with their docking poses as predicted by AutoDock and Vina in the 
active site of C domain of hHKI. 
The surface of C domain of 1DGK is shown as orange. Ligands coloured in green (Vina) and 
magenta (Autodock) represent the predicted binding modes by each software. The ranking 
order is according to the consensus scoring from AD, Vina, DrugScore and X-Score as well 
as consensus docking. The chemical structure, Vina, AD, DSX and X-score for each 
compound are shown. The last column shows the percentage of inhibition/ activation at 
100μΜ (final inhibitor concentration) based on the enzymatic assays performed in the 
present study (see Chapter 7).  























































-8.8 -7.43 5.92 -135.320 +1% 
 
 
5.10.1.1 Predicted interactions between virtual hits and target 
molecule 
The hydrogen bonds of each complex (protein-ligand) were identified using 
WinCoot. WinCoot cut-off distance measurements for hydrogen bonds were set up to 
a maximum of 3.3 Å. Table 5.3 summarises all the interactions identified from 
WinCoot. The two different docking programs show differences even though 
consensus docking has been performed. However, the number of the different 
residues is small for all compounds, with zero difference for compound AS1RS2 to a 
maximum of 4 differences observed for compound AS1RS6. The rest show 1-2 
differences so overall agreement between the two programs is observed. The 
compounds AS1RS7-8 form contacts with different residues than from the other 
compounds. For these 2 compounds G747, E783, T784 and K785 participate in the 
interactions, which are not seen for any other compound. Also these 2 compounds 
are predicted to make fewer contacts with the target. Compound AS1RS5 also shows 









Table 5.3: List of residues that form hydrogen bonds with virtual hits from Glc-G6P site 
(1st ranking scheme). 
The table shows all the residues that form hydrogen bonds (0- 3.3Å) with the template 





















D657, G681, T863 
Yes. 
AS1RS2 
K621, D657, T661, 
T680, G681, D861, 
S897 
K621, D657, T661, 





N537, R539, D895 
A536, R539, D895 Yes. 
AS1RS4 
D532, A536, 
N537, R539, T680, 
T863, K866 
D532, A536, R539, 










D532, N537, R539, 
T680, T863, D895, 
G898 
A536, R539, N557, 
T680, D895 
Yes. 
AS1RS7 T680, G747, T784 
M567, T680, 
G747, T784, K785 
Yes. 
AS1RS8 T680, E783, T784 E783 Yes. 
AS1RS9 
D532, A536, 
N537, R539, N557, 
D895 







On analysing the 1DGK/virtual hits interactions it can be seen that all compounds 
bind with similar orientation to the docking area apart from compounds 7 and 8. 
These compounds interact with the polar pocket T784/ E783, whereas the other 
ligands orient their side chains away from this polar pocket.  
 
Figure 5.13: The purchased compounds docked in the active site of 1DGK with 
interacting residues. 
WinCoot was used to identify all the hydrogen bonds with the surrounding residues in a 
maximum distance of 3.3 Å. The common residues (between AD and Vina orientations) are 
shown. The different contacts are not shown.  
 
The ligands can be further categorised into three groups based on their predictive 
binding site: 
1) Compounds AS1RS1 and AS1RS2 expand in both Glc and G6P binding sites 
2) Compounds AS1RS3-6 and AS1RS9 fill the G6P and ADP binding site 




Figure 5.14 shows the predicted binding site of all the compounds compared to the 






Figure 5.14: Ligands binding site relative to the natural ligands of hHKI and hHKII. 
Ligands present in 2NZT, Glc and G6P, are shown as pale green and salmon sticks. ADP 
present in 1DGK is shown as deep olive stick. The ligand binding poses as predicted from 
docking programs are shown as green sticks (Vina) and magenta (AutoDock). Panel A 









compounds AS1RS3-6 and 9 that bind to both G6P and ADP site and panel C shows 
compounds AS1RS7-8 predicted to bind closer to the ADP binding site. 
 
5.10.2 2nd scoring scheme for ranking the top docked compounds from 
the Glc/G6P site: 
The top 2,467 were re-ranked using the updated version of X-Score 1.3. Moreover, 
multiple scoring functions were added to the consensus scoring scheme (NNScore 
1.0, NNScore 2.0 and RFScore 4). The latter method completely altered the ranked 
order of the compounds. The calculated average AutoDock and AutoDock Vina 
scoring energies of 109 top hits are between -5.43 to -12.37 kcal/mol and -6.6 to -
10.4 kcal/mol respectively. Nine compounds were chosen for screening from this 
docking. The MW is less than 380 for all compounds. Table 5.4 shows the ligand 
predicted binding modes, the chemical structures and the scoring functions. 
 
Table 5.4: Ligands docking poses predicted by AutoDock (AD) and Vina in the active 
site of C domain of human hexokinase I. 
Ligands coloured in green (Vina) and magenta (Autodock) represent the predicted binding 
modes from each software. The table order is according to the consensus scoring from the 
total of scoring functions (AD, Vina, DrugScore and X-Score 1.3, NNScore 1.0 and 2.0 and 
RFScore 4.0). The chemical structure, Vina, AD and NNScore 1.0 for each compound are 
shown. The last column shows the percentage of inhibition/ activation at 100μΜ (final 





Docked Poses from 




























-8.4 -8.0 -0.7185 -22% 
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Docked Poses from 


























-8.6 -8.0 -0.7636 +1% 
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Docked Poses from 























-7.3 -5.9 0.9029 -8% 
 
Interactions between virtual hits and target molecule 
Table 5.5 shows all the residues that form hydrogen bonds (0- 3.3 Å) with the 
template structure, as identified from WinCoot. Between the two different docking 
programs, different interactions are found because of small differences in compound 
orientation between them. The number of the different residues is small for all 
compounds. Another interesting observation is that 2RS1 in AutoDock binding mode 
forms no hydrogen bond while only one interaction is formed with Vina binding 
mode. 2RS23615 forms no hydrogen bonds according to Vina orientation but 3 
bonds according to AutoDock. The latter also forms interactions with the residues 





Table 5.5: List of residues that form hydrogen bonds with virtual hits for Glc/G6P site 












2RS1 No hydrogen bond T680 Yes. 
2RS2 
G747, T784, S788, 
T863 
T784, S788 Yes. 
2RS08628 
K621, D657, T680, 
G681, T863 
D532, G535, 
K621, D657, T680, 
G681 
Yes 
2RS23615 G747, T784, 7K85 No hydrogen bond Yes 
2RS11168 
D532, N537, R539, 
T680, G681, D895, 
T863 





D657, G679, T680, 
G681, E708 




D532, N537, R539, 
T680, G681, T863 




A536, N537, R539, 
G862, T863, D895 




A536, N537, R539, 
D861, G862, 
T863, K866, E894 
A536, N537, R539, 





Figure 5.15 depicts the hydrogens formed as predicted from the docking programs. 
As shown in Table 5.5 there are differences between the two programs but the 
common interactions are shown here. Compound 2RS1, 2RS2 and 2RS23615 bind to 
the ADP binding site. Compound 2RS1 and 2RS23615 are not in close proximity to 
form hydrogen bonds according to AutoDock and Vina respectively thus they are 
predicted to interact with the other program. For these compounds both binding 




Figure 5.15: Docked compounds in the Glc/G6P of 1DGK (from re-ranking the top hits) 
with interacting residues. 
WinCoot was used to find the hydrogen bonds within a distance of 0-3.3 Å from the ligand. 
5.11 Docking results for ADP binding site 
The filtering process of the library for the ADP site resulted in 5,000 compounds 
which entered the docking process. Then scoring algorithms DSX and X-Score 1.2 
were applied to rank the compounds based on their binding affinity. The top 93 
compounds were analysed and six compounds were purchased to test their inhibitory 
potency against hHKII. All the compounds had MW<380 and cLogP from 2.3-4.3. 
The surface of the 1DGK is shown. Table 5.6 shows the ligands predicted binding 






Table 5.6: Ligands docking poses predicted by AutoDock (AD) and Vina in the ADP 
pocket of C domain of human hexokinase I 
Ligands coloured in green (Vina) and magenta (Autodock) represent the predicted binding 
mode from each software. The table order is according to the consensus scoring (AD, Vina, 
DrugScore and X-Score). The chemical structure, Vina, AD, DSX and X-score for each 
compound are shown. The last column shows the percentage of inhibition/ activation at 
100μΜ (final inhibitor concentration) based on the enzymatic assays performed (see Chapter 
7).  
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-9.1 -9.2 7.28 -140.17 +32  
NP2 
  
-8.9 -9.3 7.14 -143.23 +12 
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Docked Poses from 


































Interactions between virtual hits and target molecule 
Table 5.7 shows all the residues that form hydrogen bonds (0- 3.3 Å) with the 
template structure, as identified from WinCoot. Only NP4 forms more than two 
hydrogen bonds (with both AutoDock and Vina). The remaining compounds are 
limited to 2-3 bonds. The compounds from the ADP pocket could be characterised as 
less likely to inhibit the protein in low micromolar concentration. NP5 according to 
Vina is not in a hydrogen bond distance from any residue.  
 










NP1 M748, T784 T680 Yes. 
NP2 T680, M748 T680T, M748 No. 
NP3 G747, T784 G747, T784, K785 Yes. 
NP4 
G747, M748, 
Y749, L750, G751, 
E752, T784, L785 
G747, M748, 
G751, E752, L785 
Yes. 
NP5 No hydrogen bond T784 Yes. 
NP6 T680, T784 T680, G747, T784 Yes. 
 
Figure 5.16 depicts the hydrogens formed as predicted from the docking programs. 
As shown in Table 5.7 there are differences between the two docking programs but 
the common ones are shown in this figure. NP1 is the only compound that does not 
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show a posematch. For this reason both binding modes from AD (magenta) and Vina 
(green) are shown. In addition, both binding modes are shown for compound 5. 
These are in agreement (posematch) but the predicted interactions are poor, resulting 






Figure 5.16: Docked compounds in the ADP site of 1DGK with interacting residues. 
Six compounds were purchased after analysis of the top hits from docking the ADP binding 
site. WinCoot was used to find the hydrogen bonds within a distance of 0-3.3 Å from the 
ligand. 
 
5.12 Discussion and summary 
In this chapter the docking studies, which were performed with the aim to discover 
novel inhibitors for human HKII, are explained in detail. The SBVS has been a very 
common method for the generation of potential lead-compounds. The Glc/G6P site 
and the ADP site of hHKI were docked using two different, widely known docking 
softwares, AutoDock and Vina. Hexokinase isoform I has identical sites with isoform 
II and the structure of the former (1DGK) was used as it was found to be in a better 
conformation. For both sites the following scoring functions were used to predict the 
binding affinity of the predicted binding modes: DrugScore and X-score 1.2. The 
consensus scoring method (“rank-by-rank”) was used as it has been shown to 
improve the accuracy of the scoring algorithms. For the Glc/G6P site only, in order 
to be “time and money” efficient, the docked compounds were re-ranked using an 
additional list of scoring algorithms such as: NNScore 1.0 and NNScore 2.0, 
RFScore 4.0 and an updated version of X-Score (1.3 instead of 1.2). This completely 
altered the ranking order of the compounds and it was anticipated that the 
compounds purchased from these results would show improved inhibition efficiency. 
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Surprisingly one compound from the ADP site is an activator. NP1 was found to 
activate significantly the enzyme (by 32%) by binding to the ADP binding site. It is 
difficult to make a hypothesis on the activation of the enzyme. There are not any 
known synthetic activators of hHKII to date.  
The most potent inhibitors are the AS1RS8 and 2RS5 which bind to the ADP and the 
Glc/G6P site respectively. The former compound was predicted to make fewer 
contacts based on the binding mode of the docking software (Fig. 5.13). However, 
the hydrophobic rings of AS1RS8 at each end of the molecule participate in 
hydrophobic interactions whereas the other inhibitors lack any of those interactions, 
as they bind to the polar Glc/G6P site. Figure 5.17 shows the inhibitor binding mode 
and the residues that could interact with it. The hydrophobic double ring at one end 
could participate in hydrophobic interactions (yellow dash) with T863, L864, L867 
which are 4.4, 3.4 and 3.7 Å away respectively. While the phenyl ring at the other 
end is in close distance with M567 and F623 (3.6 and 3.8Å respectively). These 
hydrophobic interactions could stabilise the ligand as they are stronger than hydrogen 
bonds (blue dash) and this could explain the higher inhibition observed despite the 
fact that the other inhibitors form more hydrogen bonds. 
 
 
Figure 5.17: Hydrophobic interactions of AS1RS8 with 1DGK 
The predicted binding mode of AS1RS8 is shown in magenta sticks. This inhibitor is 




2RS5, shows 36% inhibition while it is predicted to bind to the Glc/G6P site. It is the 
most potent inhibitor compared to the others that are predicted to bind in the same 
pocket (AS1RS4, AS1RS6). However, according to the predictive binding mode the 
compound makes similar interactions with the latter two. Figure 5.18 shows the 
residues that are predicted to interact with 2RS5 via hydrogen bonds proposing a 
modification that could improve the compound potency. 
 
Figure 5.18: SAR of 2RS5 in the active site of 1DGK 
The grey sticks show the modelling of the compound 2RS5 in the active site of hHKI. 2RS5 
was purchased after the second ranking method of the docked compounds in the Glc/G6P 
site. It forms hydrogen bonds with the highlighted residues (orange sticks). An extra 
hydrogen bond could be formed with N557 by changing the part shown with the black 
arrow. 
From the first ranking scheme, of the Glc/G6P site AS1RS8, AS1RS4 and AS1RS6 
show 35%, 15% and 13% inhibition at ~100 μΜ. To improve the latter two 
inhibitors, we have identified a number of substitutions that could be made to the 
rings of the molecules in order to increase the number of hydrogen bonds and/or 
hydrophobic interactions with the target. It is extremely difficult to make a 
sophisticated SAR analysis in the absence of a crystal structure showing the actual 
binding site of the compound and the key interactions with its target. However, based 
on the modelling of the compounds to the Glc/G6P site of the enzyme we could 
propose a number of key changes to the molecules aiming to optimize the activity.  
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AS1RS4 is predicted to bind to the polar Glc/G6P site of the enzyme participating in 
six hydrogen bonds. In Figure 5.19 the black arrow shows the benzene ring on the 
one end of the molecule that could be modified with the addition of a methyl which 
could interact with the hydrophobic side chains of M555 and L541. The –CH3 could 
improve the lipophilicity as well. Otherwise a MeOH group could be added that 
would act as a hydrogen bond donor (HBD) and could potentially make an extra 
hydrogen bond with N557. The ring on the other end of the molecule (shown by the 
blue arrow) could be modified with a methyl (-CH3) substituent to shorten the 
distance between the hydrophobic side chain of I677 and the hydrophobic ring in 
order to interact. The yellow dashes show the distance between the lead candidate 
and the residues (shown as grey) that are not predicted to interact with the molecule 
based on the modelling. 
 
Figure 5.19: SAR of AS1RS4 in the active site of 1DGK 
The green sticks show the modelling of the compound AS1RS4. Magenta sticks show the 
inhibitor AS1RS8. AS1RS4 is predicted to participate in six hydrogen bonds shown as blue 
dashes. The benzene ring on the one end of the molecule could be modified to make stronger 
hydrophobic interactions. Otherwise a HBD could be added to make an extra hydrogen bond. 
The ring on the other end of the molecule could be modified with a methyl (-CH3) 




AS1RS6 contains a polar ring on the end that could be modified with the addition of 
an extra HBD linker that could interact with an extra residue (Fig. 5.20). The black 
arrow shows the polar ring on the end of the molecule that could interact with A536. 
The grey dashes show the distance between the polar ring and A536 (4 Å). 
  
 
Figure 5.20: SAR of AS1RS6 in the active site of 1DGK 
The cyan sticks show the modelling of the compound AS1RS6. AS1RS6 participates in 
hydrogen bonds with the residues shown as orange sticks.  
 
However, these modifications were not applied to the compounds for further studies. 
The lack of a crystal structure in complex with at least one of the inhibitors from 
each site makes it very hard to be confident about the key elements of the compounds 
for the binding and the inhibition of the target protein. 
From the compounds purchased, after re-ranking as mentioned above, only two 
compounds show considerable inhibition compared to three compounds from the 
first scoring scheme. The new strategy did not improve the number of inhibitors as 
anticipated. Compounds 2RS23615 and 2RS5 show considerable inhibition of the 
enzyme (22% and 36% inhibition respectively). Compound 2RS23615 is predicted to 





6. Chapter 6: Screening hits for Trypanosoma brucei 
hexokinase I (TbHKI) 
6.1 Introduction 
This chapter will discuss the methods performed to discover novel compounds that 
could potentially inhibit the TbHKI in vitro. The approach followed here involves the 
Structure Based Virtual Screening (SBVS), as for hHKII, with the difference that for 
the specific target (TbHKI), an experimental X-ray structure is unavailable.  
Protein modelling can however provide a reasonably reliable template to allow 
structure-based drug design studies. Among the three major approaches to three-
dimensional structure prediction, homology modelling is the easiest one (Krieger et 
al., 2003) and is based on the observation that homologous proteins with high percent 
of sequence identity adopt practically identical structures. When the sequence 
homology rises up to 50%, a good protein model is expected to be predicted, whereas 
in cases that sequence identity drops to 20% the structural differences are impossible 
to predict (Chothia and Lesk, 1986). More recently, Rost, analysed more than a 
million sequence alignments showing that it is possible to differentiate true from 
false positives for sequences which share a low level of similarity (Rost, 1999). 
In our case, a homology model of TbHKI was generated to discover ligands of the 
active site. In general, the following steps are performed during a homology model 
generation: 1) fold assignment and template selection, 2) target-template alignment, 
3) model building and 4) model evaluation (Martí-Renom et al., 2000). The 
generated model is then used as a docking template to identify virtual hits which can 
then be tested against TbHKI. Since the docking will only take place in the active 
site of the protein, which is expected to be conserved among proteins of the same 




6.2 Materials and methods 
6.2.1 Template selection for TbHKI homology modeling 
We compared the TbHKI sequence to all the sequences of known structures stored in 
the PDB, using BLAST, and the highest sequence identity was found to be 38% for 
Arabidopsis hexokinase 1 (athxk1), followed by human hexokinase isoform I (37% 
identity).  
We decided to model the amino acid sequence using the X-ray structure of human 
hexokinase isoform I (PDB code: 1DGK). TbHK1 shares 37% sequence identity 
with the full length of hexokinase isoform I. However, the active site is conserved, 
and it may provide a good model regardless that the overall sequence homology is 
not so high. The active sites of related proteins will have similar geometries because 
of the necessity to maintain a functional binding site (Lesk and Chothia, 1980). 
Figure 6.1 shows the pairwise comparison of TbHK1 with human hexokinase 
isoform I, using Clustal Omega (Larkin et al., 2007). The generated model should be 
in a “ligand bound conformation”, so the sidechain of the residues interacting with 




Figure 6.1: Amino acid alignment of human hexokinase isoform 1 (1DGK) and TbHK1. 
Protein sequence for TbHK1 was found from http://tritrypdb.org/tritrypdb/ (Aslett et 
al., 2009). Clustal Omega was used to align the two sequences. Grey residues interact with 
Glc, yellow residues interact with G6P and cyan residues interact with both ligands. Glc 
binding site is 100% conserved, while G6P site is not completely identical between the two 
different species. Apart from the mismatch at residue 536 there is another true mismatch. 
Residue 863 is different and not because 1DGK is a mutant. Residue at 863 is threonine for 
human hexokinase I while it is serine for TbHK1 (S421).  
 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      MIAAQLLAYYFTELKDDQVKKIDKYLYAMRLSDETLIDIMTRFRKEMKNGLSRDFNPTAT 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
1DGK:N|PDBID|CHAIN|SEQUENCE      VKMLPTFVRSIPDGSEKGDFIALDLGGSSFRILRVQVNHEKNQNVHMESEVYDTPENIVH 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      GSGSQLFDHVAECLGDFMEKRKIKDKKLPVGFTFSFPCQQSKIDEAILITWTKRFKASGV 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      EGADVVKLLNKAIKKRGDYDANIVAVVNDTVGTMMTCGYDDQHCEVGLIIGTGTNACYME 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      ELRHIDLVEGDEGRMCINTEWGAFGDDGSLEDIRTEFDRAIDAYSLNPGKQLFEKMVSGM 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      YLGELVRLILVKMAKEGLLFEGRITPELLTRGKFNTSDVSAIEKNKEGLHNAKEILTRLG 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      VEPSDDDCVSVQHVCTIVSFRSANLVAATLGAILNRLRDNKGTPRLRTTVGVDGSLYKTH 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      PQYSRRFHKTLRRLVPDSDVRFLLSESGSGKGAAMVTAVAYRLAEQHRQIEETLAHFHLT 
TbHKI                            --MSRRLNNILEHISI------------QGNDGETVRAVKRDV-----AMAALTNQFTMS 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      KDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGDFLALDLGGANFRV 
TbHKI                            VESMRQIMTYLLYEMVEGL---EGRESTVRMLPSYVYKADPKRATGVFYALDLGGTNFRV 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      LLVKIRSGKKRTVEMHNKIYAIPIEIMQGTGEELFDHIVSCISDFLDYMG--IKGPRMPL 
TbHKI                            LRVACKEGA--VVDSSTSAFKIPKYALEGNATDLFDFIASNVKKTMETRAPEDLNRTVPL 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      GFTFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRREEFDLDVVAVVNDT 
TbHKI                            GFTFSFPVEQTKVNRGVLIRWTKGFSTKGVQGNDVIALLQAAFG-RVSLKVNVVALCNDT 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      VGTMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMV----EGDQGQMCINMEWGAFGD 
TbHKI                            VGTLISHYFKDPEVQVGVIIGTGSNACYFETASAVTKDPAVAARGSALTPINMESGNFDS 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      NGCLDDIRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKGFLFRGQISE 
TbHKI                            KYRFVLPTTKFDLDIDDASLNKGQQALEKMISGMYLGEIARRVIVHLSSINCL-PAALQT 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      TLKTRGIFETKFLSQIESDRLALLQVRAILQ--QLGLN-STCDDSILVKTVCGVVSRRAA 
TbHKI                            ALGNRGSFESRFAGMISADRMPGLQFTRSTIQKVCGVDVQSIEDLRIIRDVCRLVRGRAA 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      QLCGAGMAAVVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTV-KELSPKCNVSF 
TbHKI                            QLSASFCCAPLVKT-----QTQGRATIAIDGSVFEKIPSFRRVLQDNINRILGPECDVRA 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      LLSEDGSGKGAALITAVGVRLRTEASS 
TbHKI                            VLAKDGSGIGAAFISAMVVNDK----- 










1DGK:N|PDBID|CHAIN|SEQUENCE      MIAAQLLAYYFTELKDDQVKKIDKYLYAMRLSDETLIDIMTRFRKEMKNGLSRDFNPTAT 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
1DGK:N|PDBID|CHAIN|SEQUENCE      VKMLPTFVRSIPDGSEKGDFIALDLGGSSFRILRVQVNHEKNQNVHMESEVYDTPENIVH 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      GSGSQLFDHVAECLGDFMEKRKIKDKKLPVGFTFSFPCQQSKIDEAILITWTKRFKASGV 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      EGADVVKLLNKAIKKRGDYDANIVAVVNDTVGTMMTCGYDDQHCEVGLIIGTGTNACYME 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      ELRHIDLVEGDEGRMCINTEWGAFGDDGSLEDIRTEFDRAIDAYSLNPGKQLFEKMVSGM 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      YLGELVRLILVKMAKEGLLFEGRITPELLTRGKFNTSDVSAIEKNKEGLHNAKEILTRLG 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      VEPSDDDCVSVQHVCTIVSFRSANLVAATLGAILNRLRDNKGTPRLRTTVGVDGSLYKTH 
TbHKI                            ------------------------------------------------------------ 
                                                                                              
 
1DGK:N|PDBID|CHAIN|SEQUENCE      PQYSRRFHKTLRRLVPDSDVRFLLSESGSGKGAAMVTAVAYRLAEQHRQIEETLAHFHLT 
TbHKI                            --MSRRLNNILEHISI------------QGNDGETVRAVKRDV-----AMAALTNQFTMS 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      KDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGDFLALDLGGANFRV 
TbHKI                            VESMRQIMTYLLYEMVEGL---EGRESTVRMLPSYVYKADPKRATGVFYALDLGGTNFRV 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      LLVKIRSGKKRTVEMHNKIYAIPIEIMQGTGEELFDHIVSCISDFLDYMG--IKGPRMPL 
TbHKI                            LRVACKEGA--VVDSSTSAFKIPKYALEGNATDLFDFIASNVKKTMETRAPEDLNRTVPL 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      GFTFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRREEFDLDVVAVVNDT 
TbHKI                            GFTFSFPVEQTKVNRGVLIRWTKGFSTKGVQGNDVIALLQAAFG-RVSLKVNVVALCNDT 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      VGTMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMV----EGDQGQMCINMEWGAFGD 
TbHKI                            VGTLISHYFKDPEVQVGVIIGTGSNACYFETASAVTKDPAVAARGSALTPINMESGNFDS 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      NGCLDDIRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKGFLFRGQISE 
TbHKI                            KYRFVLPTTKFDLDIDDASLNKGQQALEKMISGMYLGEIARRVIVHLSSINCL-PAALQT 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      TLKTRGIFETKFLSQIESDRLALLQVRAILQ--QLGLN-STCDDSILVKTVCGVVSRRAA 
TbHKI                            ALGNRGSFESRFAGMISADRMPGLQFTRSTIQKVCGVDVQSIEDLRIIRDVCRLVRGRAA 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      QLCGAGMAAVVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTV-KELSPKCNVSF 
TbHKI                            QLSASFCCAPLVKT-----QTQGRATIAIDGSVFEKIPSFRRVLQDNINRILGPECDVRA 
 
1DGK:N|PDBID|CHAIN|SEQUENCE      LLSEDGSGKGAALITAVGVRLRTEASS 
TbHKI                            VLAKDGSGIGAAFISAMVVNDK----- 













6.2.2 Model building 
Two different softwares were employed for the protein structure prediction, Phyre2 
(Kelley et al., 2015) and I-TASSER (Zhang, 2008). Phyre2 has two primary modes 
for model building, the normal and intensive. For 'normal' mode, Phyre2 builds a 
hidden Markov model (HMM) of the user sequence and compares this to a library of 
HMMs built for a representative set of known protein structures. Regions of the user 
sequence with no significant match to known structures are left unmodelled. The 
'intensive mode' will create a complete model even in the absence of known 
homologs structures, using a simplified protein-folding simulator (Kelley et al., 
2015). In our case the 'normal' mode was chosen with one-to-one threading using 
1DGK as the template.  
I-TASSER builds 3D models based on multiple-threading alignments by LOMETS 
and iterative TASSER assembly simulations. Yang, 2015, discusses the operation of 
the I-TASSER suite in detail (Yang et al., 2015). One-to-one threading was 
performed, with 1DGK as the template. 3 models were generated from I-TASSER 
that differ in the C-score. C-score is a confidence score for estimating the quality of 
predicted models by I-TASSER. It is calculated based on the significance of 
threading template alignments and the convergence parameters of the structure 
assembly simulations. C-score is typically in the range of [-5, 2], where a C-score of 
higher value signifies a model with a high confidence and vice-versa. The model 
with the higher C-score (1.45 in our case) was chosen as our model template.  
A superposition of the models from Phyre2 and I-TASSER with 1DGK was 
performed and analysed. 
 
6.3 Results  
6.3.1 Homology model choice 
Phyre model was chosen as the template for our docking studies as the modeling 
seems to have worked exceptionally well, maintaining the orientation of all the 




I-TASSER, did not work very well in our case, as almost all the residues have a 
different orientation in the pocket with N213 for TbHK1 to have a rotated side chain 
up to 3.2Å away from the template. N656 in 1DGK makes a hydrogen bond with Glc 
(N from Asn with O from Glc), so it is essential to keep the same orientation for the 




Figure 6.2: Superposition of models generated from Phyre-2 and I-TASSER against 
template 1DGK. 
Panel A shows the overlay of Phyre-2 model (light blue) with 1DGK (orange). The residues 
of Glc and G6P binding site (stick representation) have the same ligand bound orientation as 
desired. Only two residues are different (T94 and S421 for T. brucei) in the protein 
sequence, as highlighted on the right. The modeling maintained the same atom orientation of 
template. 
Panel B shows the alignment between 1DGK (orange) and I-TASSER model (limon). The 
residues do not seem to have maintained the same orientation as template and especially 
N213 side chain, as shown on the right, has a big rotation of 3.2Å away from the ligand. This 








6.3.2 Docking space of TbHKI 
The Glc/G6P and ADP sites of TbHKI were used for the docking studies. The 
docking space is shown by the black box. A closer look into the box identifies two 
pockets that could accommodate lead-size compounds. The residues present in the 
pocket are identified and shown in a stick representation.  
 
Figure 6.3: Docking space of TbHKI. Two pockets are present in the docking space. 
The surface of TbHKI is shown as light blue. The black box shows the limits of the docking 
area. Inside the box, two pockets very close to each other, are present. The black arrow 
shows a closer view of Glc/G6P_1 with the residues shown as sticks. 
The residues which form this pocket are: D90, G92, G93, T94, N95, R97, S161, K179, 
D214, I234, T237, G238, N240, D419, G420, S421, G455.  
Purple arrow shows ADP pocket which consists of the following residues: G92, G93, T94, 
K120, L123, K179, G180, F181, G236, T237, G308, M309, R339, G340, E343, S344, R345. 
 
Vina and AutoDock were the docking softwares used for the docking studies. From 
the initial list of ~3 million compounds, 5,000 were proceeded to the docking 
process. The consensus docking was performed and 1,595 compounds were found to 
have the same binding mode predicted from both programs. The compounds were 
169 
 
ranked following the “rank-by-rank” strategy as mentioned in Chapter 5, section 5.7. 
The scoring algorithms used for the final ranking are the following: X-score 1.3, 
Drugscore, NNScore 1.0 and 2.0 and RF-score. The final choice of compounds was 
made using multiple techniques, including prioritisation of compounds that met 
Lipinski rules and Oprea criteria. In addition, the hit list was analysed by an 
experienced medicinal chemist (Dr Phill Cowley, Head of Chemistry, IOmet Pharma 
Ltd.) to remove compounds which were potentially reactive, non-specific in terms of 
their biological action or not drug-like. Following the prioritisation of the 
compounds, 4 compounds were purchased. 
 
6.3.3 Virtual hits obtained from SBVS 
Table 6.1 shows the structure, the binding mode and the scores of the purchased 
compounds from the in silico studies against TbHKI. It also shows the % of 
inhibition at 100μΜ based on the enzymatic assays performed. The assay and 
conditions used for the inhibition studies are described in detail at Chapter 7. 
It is interesting that 2 out of 4 compounds activate the enzyme by a significant 
amount (over 20%). One compound shows a small, non-significant inhibition and 




Table 6.1: Ligand docking poses predicted by AD and Vina in the active site of 
Trypanosoma brucei hexokinase I. 
Ligands coloured in green (Vina) and magenta (AD) represent the predicted binding modes 
from each software. The ranking order is according to the consensus scoring from AD, Vina, 
DrugScore and NNScore1.0 as well as consensus docking. The chemical structure, Vina, 
AD, and NNScore and the % of inhibition or activation are shown for each compound. The 
cLogP values are in the range of 1.4-4.3 and the molecular weight is <380 for all. All the 
compounds show consensus docking. The surface of the TbHKI model active site is shown 
as light blue. 


































According to the binding mode only TbHK1.1 is predicted to bind to Glc/G6P site 
while the rest to the ADP site (Figure 6.3). The predicted hydrogen bonds based on 
the binding mode of each program (AD, Vina) are calculated using WinCoot (3.3 Å 
cut-off distance). Table 6.2 shows the residues that participate in these interactions. 
TbHK1.4 is predicted to have the least interactions thus it is the compound that 
shows the best inhibition (65%) of the enzymatic activity. TbHK1.1 and TbHK1.2 
activate the enzyme while they bind on a different pocket.  
 
Table 6.2: Predicted interactions with TbHKI based on binding mode of the docking 
Fsoftware. 
WinCoot was used to calculate the hydrogen bonds formed between each compound and 
each predicted mode with the target molecule. Residues in bold are the residues which are 







Between AD and 
Vina 
TbHK1.1 
T94, N95, R97, 
K179, D214, T237, 
G238, S421 
N95, R97, S161, 




T94, T237, G308, 
S344, R345 




T237, G308, S344, 
R345, K425 
T94, T237, S344, 
R345, K425 
Yes 
TbHK1.4 S344, M349 S344 Yes 
 
The compounds obtained from the hHKII in silico studies (Chapter 5) were screened 
against the TbHKI since the proteins share such a high percentage of sequence 
identity in the active site. The enzymatic biochemical assays showed that most of 
compounds activate the enzyme rather than inhibit it. More specifically, 17 
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compounds out of 24 were found to activate the enzymatic activity (from 6.25% up 
to 77.5%, Table 6.3). 
Table 6.3: Inhibitions studies of purchased compounds on TbHKI 
The compounds purchased from docking studies on hHKII were screened against TbHKI. 17 
compounds were found to activate the enzyme. Only 4 compounds inhibited the enzyme in a 
significant percentage (>20%) while the remaining 3 compounds had no significant effect on 
the enzymatic activity.  
Compound ID 




% Inhibition (-)/ 
Activation (+) 
at 100μM 
AS1RS1 +28.75 2RS5 +77.5 
AS1RS2 +27.5 2RS6 +30 
AS1RS3 +30% 2RS08628 -66.25 
AS1RS4 +10 2RS23615 +32.5 
AS1RS5 +17.5 2RS11309 -5 
AS1RS6 +32.5 2RS11168 +6.25 
AS1RS7 -28.5 NP1 +58.75 
AS1RS8 -7.5 NP2 +27.5 
AS1RS9 +12.5 NP3 -56.25 
2RS1 +7.5 NP4 -31.25 
2RS2 +21.25 NP5 0 





6.4 Discussion and summary 
The compound screening, yielded inhibitors and activators, suggesting that there 
might be an activator-binding site. There are no known activators for TbHKI in the 
literature. The finding of novel activators for TbHKI is very interesting. To further 
investigate this we searched the PDB and identified a number of synthetic activators 
for human glucokinase. These activators serve as a potential therapeutic approach for 
type 2 diabetes mellitus therapy. All activator compounds are found to bind to an 
allosteric site, close to the glucose-binding site with the following residues to interact 
with the activator: V452, V455, r63, Y215, V62, M210, I211, Y214 and M235 
(Kamata et al., 2004). A sequence alignment was performed to investigate whether 
this is a conserved pocket, also present in TbHKI. However, the alignment showed 
that the only three residues are conserved while the remaining 6 are different. So we 
cannot argue that the present activators bind to the same pocket.  
 
Figure 6.4: Sequence alignment of human glucokinase with TbHKI 
The sequence alignment between human glucokinase and TbHKI was performed with 
Clustal Omega (Larkin et al., 2007). The highlighted residues are the residues that form the 
allosteric pocket found in glucokinase. Binding of ligands in that pocket has been found to 
activate the enzyme. The identical residues are highlighted with green colour. 
 
human_glucokinase      -------ML-------DDRARMEAAK-KEKVEQILAEFQLQEEDLKKVMRRMQKEMDRGL 
TbHKI                  MSRRLNNILEHISIQGNDGETVRAVKRDVAMAALTNQFTMSVESMRQIMTYLLYEMVEGL 
 
human_glucokinase      RLETHEEASVKMLPTYVRSTPEGSEVGDFLSLDLGGTNFRVMLVKVGEGEEGQWSVKTKH 
TbHKI                  E---GRESTVRMLPSYVYKADPKRATGVFYALDLGGTNFRVLRVACKEGAV----VDSST 
 
human_glucokinase      QMYSIPEDAMTGTAEMLFDYISECISDFLDKHQ--MKHKKLPLGFTFSFPVRHEDIDKGI 
TbHKI                  SAFKIPKYALEGNATDLFDFIASNVKKTMETRAPEDLNRTVPLGFTFSFPVEQTKVNRGV 
 
human_glucokinase      LLNWTKGFKASGAEGNNVVGLLRDAIKRRGDFEMDVVAMVNDTVATMISCYYEDHQCEVG 
TbHKI                  LIRWTKGFSTKGVQGNDVIALLQAAFGR-VSLKVNVVALCNDTVGTLISHYFKDPEVQVG 
 
human_glucokinase      MIVGTGCNACYMEEMQNVELVEGDE----GRMCVNTEWGAFGDSGELDEFLLEYDRLVDE 
TbHKI                  VIIGTGSNACYFETASAVTKDPAVAARGSALTPINMESGNFDSKYRFVLPTTKFDLDIDD 
 
human_glucokinase      SSANPGQQLYEKLIGGKYMGELVRLVLLRLVDENLLFHGEASEQLRTRGAFETRFVSQVE 
TbHKI                  ASLNKGQQALEKMISGMYLGEIARRVIVHLSSINCLP-AALQTALGNRGSFESRFAGMIS 
 
human_glucokinase      SDTGDRKQIYN--ILSTLGLR-PSTTDCDIVRRACESVSTRAAHM----CSAGLAGVINR 
TbHKI                  ADRMPGLQFTRSTIQKVCGVDVQSIEDLRIIRDVCRLVRGRAAQLSASFCCAPLV----- 
 
human_glucokinase      MRESRSEDVMRITVGVDGSVYKLHPSFKERFHASVR-RLTPSCEITFIESEEGSGRGAAL 
TbHKI                  ----KTQTQGRATIAIDGSVFEKIPSFRRVLQDNINRILGPECDVRAVLAKDGSGIGAAF 
 
human_glucokinase      VSAVACKKACMLGQ 





TbPFK (Trypanosoma brucei phosphofructokinase) is an allosteric protein with 
respect to its substrate, fructose-6-phosphate (Nwagwu and Opperdoes, 1982). Also 
trypanosomatid pyruvate kinase is allosteric regulated by fructose 2,6-bisphosphate, 
which promotes an active conformation of the enzyme (R-state) (Verlinde et al., 
2001). TbHKI is not proven to be an allosteric enzyme. There are no studies that 
prove any cooperativity on substrate binding by TbHKI and no allosteric activators/ 
inhibitors are known.  
Interesting kinetics have been observed for the enzyme of T. cruzi HK. T. cruzi HK 
has a hysteretic behaviour and shows transition from a less active to a more active 
enzyme and the opposite way while conformational changes are taking place (Acosta 
et al., 2014). This could also be the case for TbHKI, but no studies have been 
performed to prove that. However, if this is the case then the activators upon binding 
to TbHKI could affect the enzyme’s activity by bringing the enzyme into a more 
active conformation.  
Based on the present studies, we cannot propose an activation mechanism. The novel 
finding of the docking and screening studies against the TbHKI should be further 
examined in future work to establish the mechanism behind this. It would be 
interesting to test whether the activators increase the affinity for glucose or ATP. Or 
do they only increase Vmax? Also kinetic measurements with different 
concentrations of enzyme varying the Glc or ATP concentration could show if there 
is a cooperative behaviour depending on the concentration of TbHKI. Nevertheless, 
we could suggest that TbHKI could behave like T. cruzi hexokinase showing a 
hysteretic behaviour.  
Regarding the inhibitors, TbHK1.4 inhibits the enzyme around 65% and is predicted 
to bind to the ADP site. When the compounds from the hHKII docking were tested 
against TbHKI, four were identified as inhibitors AS1RS7, NP4, NP3 and 
2RS08628. The latter is a more potent inhibitor for TbHKI since the percentage of 
enzymatic inhibition is higher for TbHKI (66% versus 11% for hHKII). The 
remaining three had almost no effect on hHKII so they could be characterised as 





7. Chapter 7: Inhibition studies on hHKII and TbHKI 
7.1 Introduction 
The characterisation of the interactions of a compound with its target, and how the 
natural substrates and physiological conditions will influence this activity, is an 
important piece of information when performing inhibition assays. There are three 
main types of inhibition to describe the binding of a compound to its target molecule: 
a) Competitive inhibition: a competitive inhibitor will bind to the free enzyme. The 
binding of the substrate to the active site will exclude binding of the inhibitor in the 
same site and vice-versa. As a result, the binding of a competitive inhibitor will 
result in an increase of the apparent Km for its substrate without changing the Vmax. 
b) Noncompetitive inhibition: in this case the inhibitor binds to a different site than 
the substrate, thus the inhibitor can bind equally well to both free enzyme and the 
enzyme bound to its substrate. The binding of a noncompetitive inhibitor will lower 
the Vmax without changing the apparent Km for the substrate. 
c) Uncompetitive inhibition: This type of inhibitor binds exclusively to the enzyme-
substrate complex resulting in a lower Vmax and Km respectively.  
An allosteric inhibitor binds to a different site than the active site (known as the 
allosteric site) followed by a conformational change which is necessary for the 
inhibition to take place. This conformational change can lead to a different 
conformation of the active site, or reduce the ability to lower the activation energy of 
catalysis. An allosteric inhibitor can be all the three above categories, competitive, 
noncompetitive or uncompetitive (Strelow et al., 2012). 
The classical steady-state experimental conditions involve the measurement of the 
initial velocity where the substrate conversion is less than 10% or the product 
formation is also less than 10%. In this case the initial velocity depends on the 
enzyme and substrate concentrations and it fits to the linear portion where slope does 
not change with time (Vo stays constant). Vo for each reaction progress curve is 
equivalent to product formation divided by difference in time which essentially is the 
slope of the initial region of the curve, Vo.= ΔY/ΔX= slope (Brooks et al., 2012). 
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Concentration-response plots are studied for the effect of a ligand on the enzymatic 
activity. The enzyme concentration and the substrate concentration respectively, are 
kept constant and the inhibitor is titrated. The inhibition at each concentration is 
measured. It is important to use an adequate concentration of inhibitor to saturate the 
reaction and provide well-defined top and bottom plateau values. The concentration 
of the compound that depletes the enzymatic activity by 50% is termed the IC50. For 
an enzymatic assay to detect competitive inhibitors the reaction conditions should 
meet the following criteria: the reaction should run under initial velocity conditions 
and the substrate concentration should be equal or below the Km value (Brooks et al., 
2012). 
Cell based assays are used after the initial discovery of a promising molecule. If the 
molecule has a significant effect in the cell based assay then it goes to the next phase 
of the process.  
In this work we describe the inhibitions studies performed to identify the inhibitors 
potency against hHKII and TbHKI. More specifically, the biophysical methods, the 
biochemical enzymatic assay and the cell based assay for TbHKI which produced 
interesting results that will be discussed below.  
 
7.2 Materials and methods 
7.2.1 SPR analysis of ligand binding to hHKII 
SPR experiments were performed on a BIAcore T200 (GE Healthcare). His-tagged 
hHKII was immobilised and covalently stabilised on an NTA sensor chip essentially 
as described previously with minor modifications (Chapter 3, section 3.2.4). Briefly, 
the sensor surface was primed with a 60 sec injection of 500 µM NiSO4 at 10 µl/min. 
The surface was then minimally activated with a 240 sec injection at 5 μl/min, of a 
mixture of 0.2 M EDC and 50 mM NHS. 500 nM hHKII in 10 mM Hepes (pH 7.5), 
500 mM NaCl, 1% DMSO, 5 mM MgCl2, 62.5 μΜ EDTA and 0.05% P20, was 
passed over the sensor surface at a flow rate of 30 μl/min. After attainment of the 
required level of immobilisation, this was followed by a 240 sec injection (at 5 
μl/min) of 1 M ethanolamine (pH 8.5) to quench any remaining active succinamide 
177 
 
esters. The final amount of hHKII covalently immobilised on the surface was around 
8,000 RU. A two-fold dilution series of glucose ranging from 2 mM to 0.0625 mM 
was passed over the sensor surface. The binding curves were analysed with a one-to-
one binding model using the analysis software provided with the instrument (v2.02, 
GE Healthcare). 15 compounds from active site and ADP binding site of hHKII 
(Chapter 5) were screened at 100 μM at final DMSO concentration of 1%. 
Compounds were initially screened at 100 μΜ on a surface of 40-200 RU of hHKII 
(flowcell-2) in 1% DMSO at 30 µl/min with a contact time of 30 sec and dissociation 
time of 30 sec. Solvent correction, carry-over assessment and a 25 % DMSO wash 
between samples were performed as standard. hHKII specific hits were further 
analysed with a two-fold concentration series from 100 μM to 3.12 μM in 1 % 
DMSO, at 30 µl/min with a 30 sec contact and dissociation time.  
 
7.2.3 hHKII inhibitions studies using resazurin coupled assay 
Glucose-6-phosphate-dehydrogenase from Leuconostoc mesenteroides (G6PDH) was 
purchased from Merck Millipore (code: 346774). NAD
+
, ATP, D-glucose, 
diaphorase from Clostridium kluyveri (code: D5540) and resazurin (code: R7017) 
were all purchased from Sigma-Aldrich. hHKII assays were also an adaptation of the 
coupled enzymatic assay containing G6PDH and resazurin (Chapter 3, section 3.2.5). 
Briefly, test compounds (10 mM in 1 μL volume) were added to a 96 well black, 
opaque plate for a final compound test concentration of 100 μM in an 89 μL mixture 
containing 10 nM of hHKII, 18.8 mM NAD
+
, 0.01 U G6PDH, 0.02 U diaphorase, 
150 mM NaCl, 5 mM MgCl2 and Tris (50 mM, pH 7.5). The plate was incubated for 
15 min at 4
o
C and a further 15 min at RT (21
o
C). To initiate the reaction, 10 μL of 1 
mM Glc, 5 mM ATP and 1 mM resazurin was added to the wells and fluorescence 
monitored at 530 nm excitation and 590 nm emission wavelength every 25 sec. A 
control reaction was supplemented with 1% DMSO and blank controls were made in 
the absence of hHKII. To account for possible inhibition of the coupled enzyme 
(G6PDH), all the compounds were screened to assess their activity against G6PDH 
in the absence of hHKII. Once more, test compounds (10 mM in 1 μL volume) were 
added to a 96 well black, opaque plate for a final compound test concentration of 100 
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μM in a 99 μL mixture containing 17 mM NAD
+
, 0.01 U G6PDH, 100 μΜ resazurin, 
and 0.02 U diaphorase. The plate was incubated for 15 min at 4
o
C and 15 min at RT 
(21
o
C). To initiate the reaction 12.5 μΜ of G6P was added to each well. The change 
in fluorescence was monitored as above.  
 
7.2.4 TbHKI inhibition studies using resazurin coupled assay 
TbHKI assays were also an adaptation of the coupled enzymatic assay containing 
G6PDH and resazurin. Briefly, test compounds (10 mM in 1 μL volume) were added 
to a 96 well black, opaque plate for a final compound test concentration of 100 μM in 
an 89 μL mixture containing 0.6 μg of TbHKI, 18.8 mM NAD
+
, 11.1 μΜ ATP, 0.01 
U G6PDH, 0.02 U diaphorase, 5 mM MgCl2 and TEA (50 mM, pH 8.0). The plate 
was incubated for 15 min at 4
o
C and a further 15 min at RT (21
o
C). To initiate the 
reaction, 10 μL of 1 mM glucose was added to the wells and fluorescence monitored 
at 530 nm excitation and 590 nm emission wavelength every 25 sec. The control 
reaction was supplemented with 1% DMSO and blank controls were made in the 
absence of TbHKI.  
 
7.2.5 IC50 equation 
The titration curve was fitted with log [inhibitor] vs response –variable slope (four 
parameters) using GraphPad 5 (GraphPad software, San Diego California USA).  
The equation used is shown below: 
                                                      ) (Equation 7.1) 
Where Y= the response 
X= compound concentration 
Bottom= initial velocity with compounds 
Top= Initial velocity of free enzyme 




7.2.6 T. brucei viability assay 
Dr. Li-Hsuan Yen performed the growth inhibition tests of bloodstream-form 
Trypanosoma brucei brucei (strain 427) using the LILT (long incubation low 
inoculation test) method (Brun and Lun, 1994, Räz et al., 1997, Hoet et al., 2004). 
The parasites were cultured in complete HMI-9 medium (Invitrogen) containing 10% 
FBS (Invitrogen) at trypanosome density in each well of 2500/well. Three-fold 
dilution series (from 45 µM – 0.020 µM) of the indicated compounds were prepared 
in the plate; the maximal concentration of DMSO was 0.45%. After 72 hours of 
incubation at 37°C and 5% CO2, 50 µl Alamar blue (0.2% diluted with DPBS 1x) 
was added to each well and plates were incubated at 37°C and 5% CO2 for an 
additional 4 hours. Fluorescence was measured on the multiplate reader. The cells 
were counted using the Beckman Coulter cell counter. Two known anti-trypanosome 
drugs, Suramin and Fexinidazole, were used as controls in the assay. The EC50 
values obtained for these controls (excel data analysis) were reproducible and 
consistent with the published values (Chauviere et al., 2003, Sokolova et al., 2010).  
 
7.3 Results  
7.3.1 Ligand identification from SPR 
SPR is a biophysical label-free detection method of small-molecule binding affinity 
and kinetics. To identify the binding of small ligands to the target protein it is crucial 
to maintain the correct conformation, structure and binding-site accessibility. It is 
necessary to achieve the correct immobilisation conditions that will not affect the 
ligand biding characteristics. After protein immobilisation in a sensor chip (CM5 and 
NTA most commonly used) it is essential to study a positive control to prove that the 
protein of interest is in ligand binding conformation and shows the expected binding 
affinity (KD). Subsequently, the ligand of interest is injected over the sensor surface 
with a continuous flow and its association on the target protein is monitored in real 
time, followed by running buffer which causes the ligand to dissociate and the 
dissociation rate is also monitored in real time (Cusack et al., 2015). 
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In our studies, glucose (Glc) was chosen as the positive control. Glc was used in a 
two-fold dilution series from 2 mM to 0.0165 mM and was successfully bound to 
hHKII as shown in Figure 7.1. 
ATP was also tested on the same surface (CM5), having hHKII covalently attached. 
When the solution containing ATP in running buffer passed over the surface a 
negative binding response occurred. A negative signal could imply that the analyte 
binds more strongly to the reference channel. However by analysing the raw data we 
could see that this was not the case for our results. Another reason for a negative 
signal could be due to a buffer mismatch. The ATP solution was made from a 100 
mM stock in weak buffer system (10 mM Hepes). Such a high concentration of ATP 
results in an acidic solution (pH around 3.0) thus the addition of concentrated NaOH 
was necessary. This could result in a buffer mismatch and different refractive index 
can be seen as a negative binding curve. Apart from the above scenarios, the high 
concentration of ATP and the running time (0.9 mM, 30 sec) in combination to the 
millimolar affinity for the target might result in a fast dissociation of the analyte 
which remains associated on the matrix longer than anticipated. This phenomenon is 
not matched by the reference cell where there is no specific binding and thus a 
negative binding response occurs. Finally, some negative binding responses originate 
from the different behaviour of reference and ligand channels to the injected analyte 
solution because of the difference in ligand density between the two channels. When 
the running buffer is replaced by the analyte buffer (in this case ATP containing 
buffer) the analyte interacts disproportionally on both surfaces. Because the volume 
of the ligand (protein) is larger on the ligand channel the reference channel will 
produce a larger bulk solvent response than the ligand surface resulting in an 
inaccurate reference subtraction. For these reasons the study of the ATP binding 
needs further optimization. However, since the KD for Glc was as predicted (298 
μΜ) and is close to the Km value, we can safely assume that the Glc active site 




Figure 7.1: Glucose serves as a positive control for the SPR inhibition studies 
Glucose, the natural substrate of hHKII, was run as a positive control with SPR (2mM to 
0.0625 mM in two-fold serial dilutions). The molecule shows a non-linear concentration 
dependent binding to hHKII. (A). The lines are in accordance with the increasing 
concentration of Glc, the higher the concentration the higher the reported RU. 0.5 mM of Glc 
was repeated to monitor the consistency of the binding. The binding curves were analysed 
and fit to a 1:1 Lagmuir binding model. KD was determined from this experiment at 298 μΜ.  
 
15 compounds were analysed with SPR for binding to hHKII. The compounds tested 
are the virtual hits from the 1
st
 ranking scheme of the Glc/G6P site of hHKII 
(AS1RS1-9, Chapter 5) and the purchased compounds from the docking of the ADP 
site respectively (NP1-6, Chapter 5). Following single concentration screen 
assessment of binding, three were found to specifically inhibit the ligand on the 
































































Figure 7.2: Assessment of 15 ligands tested on single concentration 
The ligands were tested at single concentration of 100 μΜ. Each compound was measured 
once and is represented above by a single number. The Response Unit (RU) is corrected for 
the MW of each ligand. The two glucose controls are marked. The ranks (Rank-1, 2) are the 
theoretical boundaries for KD between 500 μM and 100 μM. Three ligands that show a 
maximum KD of 500 μΜ were selected for the dilution series. Compound 5 which 
corresponds to NP6, compound 6 to NP4 and finally compound 14 to AS1RS6. 
 
The three compounds with a predicted KD lower than 500 μΜ were screened with 
serial dilutions (from 100 μΜ to 3.1μΜ) to determine a more accurate KD value(Fig. 
7.3). NP4 shows a concentration dependent response which does not saturate under 
the present concentrations tested. There is a big jump of the RU from 50 μΜ to 100 
μΜ (from ~2RU to ~5RU) which possibly indicates that the inhibitor is weak and 
higher concentrations should be tested in order to saturate the binding of the protein. 
However, the data follow a 1:1 Lagmuir model and KD is calculated at 600 μΜ. NP6 
binding to the surface is complicated showing non-specific binding along with 
possible solubility issues and the KD was not determined. AS1RS6, is the only 
compound from the Glc/G6P site of hHKII. NP4 and NP6 are predicted to bind to the 
ADP binding site. Once more, for this compound a KD could not be determined. The 
reason for this is that the ligand is very weak and no saturation was reached, or the 







Figure 7.3: Binding sensor grams of six concentrations tested for ligands NP4, NP6 and 
AS1RS6 
(A) NP4 predicted KD is calculated at 600 μΜ. (B) NP6 binding to the surface is complicated 
showing non-specific binding along with possible solubility issues. (C) AS1RS6, is 































































































7.3.2 Assay development and optimisation for HK inhibition studies 
The most common assay for the study of hexokinase activity is the enzymatic assay 
which couples the G6P formed via the hexokinase reaction to its catalysis by G6PDH 
and consequent reduction of NAD
+
. The reaction is monitored via absorbance at 340 
nm while using the extinction coefficient of NADH. The lower detection limit of this 
assay is estimated between 1-5 μΜ NADH (Batchelor and Zhou, 2002). It is also 
known that most of compounds absorb at the same wavelength. A different approach 
was sought to decrease the potential background signal of compounds and to 
improve the limit of detection of the assay to be more appropriate for HTS. An 
alternative enzymatic assay has been described previously where the highly 
fluorescent molecule resorufin is produced from the oxidation of the Amplex Rex 
reagent and submicromolar concentrations of NADH are detected by measuring 
excitation at 530 and emission detection at 590 nm (Batchelor and Zhou, 2002). 
More recently the same group (Batchelor and Zhou, 2004) developed a coupled 
enzymatic assay to quantify cell death based upon the measurement of G6PDH 
which is known to exit the cytosol when plasma membrane integrity is compromised. 
In this assay G6PDH is coupled to the reduction of resazurin to the highly 
fluorescent molecule resorufin. 
For our studies we propose the use of a coupled-enzymatic assay where hexokinase 
is coupled to both G6PDH and diaphorase (the enzyme that reduces the resazurin to 
resorufin) in order to monitor the kinetics of hexokinase measuring increase in 
fluorescent intensity. As mentioned previously in Chapter 3 (Fig. 3.1), the assay 
relies on the reduction of the non-fluorescent resazurin dye (blue colour) to the 
highly fluorescent molecule resorufin (pink-red colour) from diaphorase which 
simultaneously oxidises NADH to NAD
+
.  
Regarding the choice of G6PDH, it is reported that the signal-to-noise ratio for 
Leuconostoc mesenteroides G6PDH is 1.6 times better than for baker’s yeast (Zhu et 
al., 2009) thus the former was purchased for our studies. It is also reported that 0.1 U 
G6PDH/ml of reaction is both economical and sensitive so we kept the same 










 is used so the latter was chosen for our studies. Finally, Zhu and 
his colleagues adopt the addition of 0.2 U diaphorase/ ml of reaction mix since the 
detection capability is not improved by the addition of a higher amount (Zhu et al., 
2009).We also adopted the same concentration. 
To validate the specificity of the reaction we performed a series of dropout 
experiments in which only one of the reagents was omitted from the reaction mixture 
each time. This would enable us to monitor if the increase in fluorescence is 
significant only when the complete reaction is performed. Figure 7.4 shows that 
there is a significant increase of the fluoresence for the complete reaction which is 
not affected by the concentration of the G6PDH. However, the reaction without the 
addition of NAD
+ 
(or NADH) shows considerable enzymatic activity. The 
fluorescence units are higher compared to the remaining four dropout experiments. 
In addition, the activity is significantly higher when 0.1 U of G6PDH is used. This 





 is also present in the protein powder that allow the coupled reaction to take 
place. The signal-to-noise ratio is better when 0.01 U G6PDH is added in the 
reaction (2.77:1) rather than after the addition of 0.1 U G6PDH (1.86:1). The 







Figure 7.4: Dropout experiment for the coupled enzymatic assay 
A dropout experiment was performed at two different amounts of G6PDH, 0.01 U and 0.1 U 
(final concentration in 0.1 ml of reaction mixture). Results are listed as follows: 1) complete 
reaction (0.01 or 0.1 U G6PDH, 100 μΜ G6P, 100 μΜ NAD+, 10 μΜ resazurin, 0.02 U 
diaphorase), 2) No G6PDH, 3) No G6P, 4) No NAD+, 5) No resazurin, 6) No diaphorase.  
The generation of a standard curve is essential in order to be able to convert the 
fluorescence units into moles of product (G6P). For this reason we monitored the 
increase of fluorescence units as a function of G6P concentration. The concentration 
of G6P ranges from 25 μΜ to 1.56 μΜ. Data from three experiments are plotted in 






Figure 7.5: Standard curve for the coupled enzymatic assay 
Background (no G6P) has been subtracted for these points. The standard curve covers a 
range of G6P from 25 to 0 μΜ G6P. The R
2 
is 0.996.  
 
To continue with the assay development we had to determine the Km of the substrates 
of the coupled enzyme system (i.e G6P, NAD
+
 and resazurin) under the specific 
conditions (buffer, pH, temperature). The assay buffer is made up with 50 mM Tris-
HCl, pH 7.5, 5 mM MgCl2 and 150 mM or 0mM NaCl and the assays are performed 
at RT (21
o
C). For measuring the kinetics of hexokinase the reaction catalysed by this 
enzyme needs to be the rate-limiting step, i.e the slowest step. The remaining 
components of the system need to be in saturating conditions so that their 
concentrations do not change while measurable concentrations of the G6P (product 
of hexokinase reaction) are formed.  
For this reason sequential reactions were performed to identify the Km of each 
substrate. The initial rate of the reaction was taken from the linear slope and plotted 
against the substrate concentration and the data least squares fit to equation 3.4 using 
Kaleidagraph v4.0 software. Table 7.1 contains the calculated Km values for each 
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Table 7.1: Km values for the components of the enzymatic assay 
The Km values were calculated for each intermediate of the coupled enzymatic assay. The 
table shows the corresponding values under two different anionic strength environments. For 
G6P and NAD
+
 the Km values increase when the ionic strength increases.  
Substrate Km (M) in 0 mM NaCl Km (M) in 150 mM NaCl 
G6P 289 ± 17×10
-6





 348 ±10 ×10
-6
 1,771 ± 81×10
-6
 
NADH 1.3 ± 0.4×10
-6 
 4 ± 1.4×10
-6
 
Resazurin 83 ± 9.9×10
-6




To have an excess of the NAD
+
 in the reaction mix, a concentration 10-fold higher 
than the Km in 150 mM NaCl was used (17 mM). The Km of resazurin was calculated 
using 10-fold lower concentration of diaphorase (0.002 U) since a higher amount 
saturated the reaction very rapidly and it was impossible to measure the initial rate. 
However, in the final assay to maintain the saturating conditions 10 times more 
enzyme is added (0.02 U). The signal to noise ratio is decreasing with increasing 
concentration of resazurin thus a similar value to the Km was initially added to the 
reaction mix (100 μM) followed by measuring the Km values of HK (Glc and ATP) 
in order to monitor the accuracy of the assay. 
The predicted Km values for hHKII are in agreement with the literature (Chapter 3). 
This suggests that the assay is ready to use for screening of inhibitors. As with the 
majority of enzymatic screens, the resazurin coupled assay is designed to identify 
inhibitors regardless of their mode of action. For this reason the assays are performed 
at the estimated Km values for both substrates. For ATP only, a 10-fold highest 
concentration was tested to identify any competitive inhibitors. After the initial 
screen of the compounds, the actives (the ones with the best inhibition potency) were 
followed-up by retesting them for an IC50 determination in a concentration response 




7.3.3 3-bromopyruvate as a control compound for the enzymatic assay 
3-bromopyruvate (3BrPa) is a known inhibitor of the glycolytic pathway. 3BrPa is a 
halogenated analogue of pyruvic acid with alkylating properties. Among the other 
glycolytic enzymes, 3-BrPa is believed to inhibit HKII through a covalent 
modification of cysteine residues or by dissociating the HKII from the mitochondrial 
apoptosis-inducing factor (AIF) leading to cell death of the rapid proliferating cancer 
cells (Cardaci et al., 2012). Among a great number of studies implemented in cancer 
cells regarding the ability of 3BrPa to inhibit their growth (See chapter 1 for 
references), two reviews were found to estimate an IC50 and a Ki value for 3-
bromopyruvate with biochemical methods. Ko and his colleagues performed studies 
on hexokinase activity from VX2 tumour tissues and they determined a Ki value for 
3BrPa at 2.4mM (Ko et al., 2001). Wang and his colleagues developed a capillary 
electrophoresis-based method for screening inhibitors of hexokinase by monitoring 
the ADP formation. The IC50 against hexokinase from Saccharomyces cerevisiae was 





During our studies, two different IC50 values were obtained since a 10 min pre-
incubation of the enzyme with 3BrPa leads to a lower IC50 than when the reaction is 
started immediately after the addition of 3BrPa. In more detail, when the assay was 
performed without incubation of 3BrPa-HK, the compound was titrated from 1000 
μΜ to 0.97 μΜ (2-fold serial dilution). The final Glc concentration was 200 μΜ and 
for ATP was 700 μΜ. The IC50 was determined at 128 μΜ. The reaction is not 
saturated since the enzyme retains almost 40% of the activity at the highest 
concentration of the inhibitor. The IC50 was also calculated after pre-incubation of 
the enzyme with 3BrPa (10 min). 50 μΜ of 3BrPa were incubated with 50 nM HK 
and the reaction was initiated after addition of the reaction mix while diluting the 
complex 3BrPa-HK by 5-fold. The initial velocity versus log [3BrPa] was plotted 
and the IC50 was calculated at ~2 μΜ. It is obvious that the IC50 is much lower when 
the pre-incubation period of 10 min was performed. Apart from the dramatic drop of 
the IC50 (65 times) the enzymatic activity was completely depleted now leading to a 
more accurate IC50 determination. We could argue that the incubation period is 
presumably allowing time for the covalent modification to take place.  
 
 
Figure 7.6: IC50 determination for 3BrPa under different incubation periods 
3BrPa was purchased from Sigma Aldrich (code:16940). 3BrPa in powder was solubilised in 
Assay buffer (50 mM Tris, pH7.5, 150 mM NaCl, 5 mM MgCl2). Each inhibitor 
concentration was measured in triplicate and the average value was used to construct the 
inhibition plots.  
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7.3.4 Enzymatic screen of 28 virtual screens against hHKII 
28 compounds were tested against hHKII at a single concentration (100 μΜ) for an 
initial screen. The compounds tested are all weak inhibitors since none of them 
completely inhibited the enzymatic activity. The highest percentage of inhibition 
observed is approximately 36%. 
 
Figure 7.7: Enzymatic screen of 28 hits at 100 μΜ against purified hHKII 
The total number of compounds in house was tested against pure purified hHKII. The protein 
was incubated with the compounds for 30min before addition of the substrates which 
initiated the reaction. Four compounds show a significant inhibition >20%, compounds 
2RS23615 (22% inhibition), AS1RS8 (35% inhibition), AS1RS6 (13% inhibition) and 2RS5 
(36% inhibition). These 4 compounds were further titrated to obtain a concentration response 
curve. 
 
Four compounds which showed inhibition above 13% and which were dissolved in a 
high DMSO stock concentration were further studied in a dilution series to determine 
the IC50 of each one. As all four are predicted to be weak inhibitors the higher 
concentration tested was increased. More specifically for compound 2RS23615 the 
higher concentration tested was 200 μM, for compound AS1RS8 130 μM, for 
compound AS1RS6 500 μM and finally for compound 2RS5 200 μM. The IC50 of 
















produce a sigmoidal curve. The IC50 for the remaining inhibitors were calculated at 
447 μΜ for AS1RS6, 62.3 μΜ for AS1RS8 and finally 127 μΜ for 2RS5.  
 
Figure 7.8: Concentration response curves for 3 inhibitors of hHKII 
Concentration-response plots were constructed to determine the effect of the inhibitors on 
the enzymatic activity. Initial rate of reaction (Vo in micromoles/min/mg) is plotted against 
log [inhibitor concentration] at constant enzyme and substrate concentration. The reaction 
did not reach complete inhibition. The maximum inhibition observed is around ~60% thus 
the IC50 is an estimate. The IC50 was calculated by setting manually the bottom restraint at a 
value between 0 and 0.2 (in the same range as the non-origin starting values for the assay 
out-put signal). The data are a mean average of 3 measurements. The titration curve was 
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7.3.5 Enzymatic screen of 28 virtual screens against TbHKI 
28 compounds were tested against TbHKI at a single concentration (100 μΜ) for an 
initial screen. The virtual hits obtained after docking the active site of the TbHKI 
homology model are 4 (TbHK1-4). However all of the purchased compounds were 
tested against TbHKI since both enzymes are highly conserved thus it is likely that 
they are also active against the parasites isoform. When the assay was performed 
with the addition of 1×Km of ATP the initial velocity was calculated and the activity 
of the control reaction (no inhibitor) was compared versus the activity after the 
addition of the inhibitors. The results are shown in Figure 7.9. 
 
Figure 7.9: Enzymatic screen of 28 hits at 100μΜ against purified TbHKI 
The total number of purchased compounds was tested against purified TbHKI. The protein 
was incubated with the compounds for 30 min before addition of the substrates (at Km 
values) which initiated the reaction. The initial rates were calculated from the slope of the 
line which is defined as the change in the product formation divided by the change in time. 
Two compounds showed a significant inhibition (65%) of the initial rate at 100 μΜ 
(2RS08628 and TbHK1.4). These were further titrated to obtain an IC50. The majority of the 















































Among the virtual hits for TbHKI only one inhibits the enzyme, TbHK1.4. This 
compound and the compound 2RS08628 (docking of the Glc/G6P site of hHKII) 
were titrated from 200 μΜ to 6.25 μΜ and an inhibition curve was obtained. The 
inhibitors did not inhibit completely the reaction. They both inhibit the reaction by 
65% thus the IC50 is an estimate. In order to predict an accurate value of IC50, higher 
concentrations of the compounds should be tested. However, the IC50 here is 
predicted at 80 μΜ and 65 μΜ for TbHK 1.4 and 2RS08628 respectively. 
  
Figure 7.10: Concentration response curves for 2 inhibitors of TbHKI 
Concentration-response plots were constructed to determine the concentration of the 
inhibitor that is required for a 50% inhibition in vitro. Initial rate of reaction (Vo in 
nanomoles/mg/sec) is plotted against log [inhibitor concentration] at constant enzyme and 
substrate concentration. The IC50 was calculated by setting manually the bottom restraint at a 
value between 0 and 0.01 (in the same range as the non-origin starting values for the assay 
out-put signal). The data are a mean average of 3 measurements. The titration curve was 
fitted with log [Inhibitor] vs response – variable slope (four parameters) using GraphPad 
Prism 5. 
 
7.3.6 T. brucei viability assay results 
All of the purchased compounds were tested with the viability assay under the 
conditions described previously. A list showing the % of inhibition at 45 μΜ with the 
calculated EC50 is shown at Table 7.2. Not all compounds have an EC50 value as they 
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did not saturate the inhibition of the parasite and the EC50 could not be determined. 
The compounds are ranked based on their potency on killing the parasites at 45 μΜ. 
The first compound on the list, 2RS2 has an EC50 in low μΜ but the same compound 
was found to activate the enzyme on the enzymatic assay so the results here may 
arrive from inhibition of another enzyme of the glycolytic pathway. In fact only 1 
compound seems to be in agreement between the two assays. TbHK1.4 has an IC50 
potency of 80 μΜ and the % of killing is >55% at 45 μΜ. The other compound that 
inhibited the enzymatic assay (2RS08628 with IC50 calculated at 65 μΜ), shows a 
small percent of killing the parasites (29%) which is too low to estimate an accurate 
EC50. Both compounds however could be considered as specific for hexokinase of T. 
brucei. 
Figure 7.11 shows the inhibition of growth curves at different concentrations of 
compounds the two most potent inhibitors (2RS2 and AS1RS8). The highest 
concentration of compound 2RS2 tested kills all cells and the EC50 is calculated at 
5.40μΜ. For compound AS1RS8 the same concentration does not lead to a complete 
saturation since 97% of cells died. To be more accurate the experiment should be 
repeated starting with a higher concentration, although the EC50 is estimated around 
~20μΜ. However these results are not in agreement with the enzymatic assay as 





Table 7.2: Cell viability assay results. The % killing of parasite cells and the EC50 values 
are shown  
The compounds were assayed with the cell viability assay to monitor their potency against 
the parasites in BSF. The virtual hits obtained from hHKII and TbHKI docking were tested. 
9 of them kill more than 55% of parasite cells and an EC50 was calculated. Among these 9 
compounds only one of them has been found to inhibit the enzyme in the enzymatic assay 
(TbHK1.4). This compound was discovered after docking the active site of TbHKI. It can be 
considered as a true hit specifically inhibiting the target enzyme. The remaining 3 
compounds purchased after the same docking (TbHK1.2, 1.3 and 1.4) seem to kill a 
significant percentage (>48%) of the parasites. However, the enzymatic assay results do not 
correlate; therefore their target could be another enzyme. (For chemical structures of the 
above compounds please refer to Chapter 5). 
Compound ID 
% Killing 
at 45 μM 
EC50 (μM) Compound ID 
% Killing 
at 45 μM 
EC50 (μM) 
2RS2 100% 5.39 AS1RS7 41% n.a 
AS1RS8 97% 17.47 2RS4 38% n.a 
NP1 87% n.a AS1RS9 37% n.a 
NP6 85% n.a AS1RS2 36% n.a 
NP3 82% n.a 2RS6 33% n.a 
TbHK1.1 66% n.a AS1RS5 33% n.a 
2RS23615 64% n.a AS1RS3 31% n.a 
TbHK1.3 58% n.a 2RS08628 29% n.a 
TbHK1.4 55% n.a AS1RS1 29% n.a 
NP5 55% n.a 2RS11309 25% n.a 
NP4 51% n.a NP2 23% n.a 
AS1RS6 50% n.a 2RS5 21% n.a 
TbHK1.2 48% n.a 2RS11168 20% n.a 






Figure 7.11: Inhibition of growth curves at different concentrations of compounds 
2RS2 and AS1RS8 
The highest concentration of compound 2RS2 tested kills all cells and the EC50 is calculated 




















7.4 Discussion and Summary 
The aim of this study is the development of a novel coupled assay which will be used 
for inhibitor screening. The most common assay for the study of hexokinase activity 
is the enzymatic assay which couples the hexokinase reaction with G6PDH while 
measuring the absorbance at 340 nm. However, in order to decrease the potential 
background signal of compounds and to improve the limit of detection a different 
assay was developed. The novel assay couples the hexokinase reaction to G6PDH 
along with diaphorase, an enzyme that converts resazurin to resorufin which is a 
fluorescent molecule. The concentrations of the intermediates were 10-fold higher 
than the Km values determined here under the specific enzymatic conditions. This 
way the rate limiting step belongs to the hexokinase reaction while the remaining 
rates are saturated. The Km values for Glc and ATP of hexokinase were determined 
with the new assay and are in excellent agreement to the literature (Chapter 3).  
After the Km determination a control inhibitory assay was performed. 3BrPa was 
used as the control inhibitor. The IC50 calculated using the assay developed here is 
much lower than the reported values. One can bear in mind that the IC50 depends on 
the enzyme concentration. The reported values elsewhere (Refer to 7.3.3) have been 
determined following a completely different strategy making it hard to compare the 
results. 
In addition, the pre-incubation time of the enzyme with the ligand decreased the IC50 
by more than 65 times. This dramatic drop was anticipated as the incubation time 
gives extra time for the ligand to saturate the binding sites before addition of 
substrate. For 3BrPa, which is believed to covalently modify the hHKII, a pre-
incubation time could lead to a lower IC50 value since the ligand has modified the 
enzyme prior to the substrate addition which initiates the reaction. However, no 
comparison between the two methods could be made because different 
concentrations are used for the two experiments. The final hHKII concentration is the 
same for both assays but the incubation period was carried out with a 5-fold higher 
concentration. The concentrations of 3BrPa tested are also different since the activity 
was completely inhibited when the same concentration of compound was used for 
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incubation. Thus 10-fold lower compound concentration was used for incubation 
with the enzyme.  
Screening of inhibitors was performed. Firstly, the majority of purchased compounds 
was screened at constant concentration and the primary hits were further studied with 
a concentration-response curve. Comparing the results to the previously performed 
SPR studies, two ligands were found to inhibit hHKII based on the enzymatic assay, 
AS1RS6 and NP6. The remaining compound, NP4, was not detected as a hit based 
on the enzymatic assay so the two methods do not agree. It is likely that the binding 
of the ligand on the surface was not specific or that SPR is a more powerful method 
and is able to identify the interaction with the protein and those compounds. 
The most potent inhibitor based on the IC50 is the ligand AS1RS8 which was 
discovered from docking of the hHKII active site with an estimated IC50 at 62.3 μΜ. 
The predicted binding site and interactions are discussed in Chapter 5. The other 
compounds range from 127 μΜ (2RS5) to 448 μΜ (AS1RS6). The compounds tested 
did not inhibit completely the reaction. They were found to inhibit the reaction with a 
maximum of ~60% thus the IC50 is an estimate. In order to have an accurate IC50 the 
experiments should be repeated with a higher concentration of ligand. However it is 
not known if the compounds will be soluble at higher concentrations. 
The same strategy was followed for screening against TbHKI. The compounds were 
initially screened at a constant concentration of Glc equal to the Km (100μΜ) and 
different concentrations of ATP, one that was equal to the Km (10μΜ) and one 10 
times higher than the Km (100 μΜ) to distinguish a competitive inhibitor from a 
noncompetitive. When the assay was performed with the addition of 10×Km of ATP 
the reactions were completely depleted, which suggests that all of the inhibitors are 
competitive against ATP. Among the 28 compounds, two were further studied with a 
response concentration curve and two IC50 values at micromolar ranges were 
estimated. TbHK1.4 (80 μΜ) was specifically purchased after docking of the model 
for TbHKI. The other inhibitor, 2RS08628 (65 μΜ), was obtained from the docking 
of hHKII. Dr. Li-Hsuan Yen performed the cell viability results to show whether 
these compounds were effective in killing T.brucei parasites in vitro. The compounds 
were tested at 45 μΜ. TbHK1.4 shows 55% of killing and 2RS08628 only 29%. 
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These do not show strong inhibition potency and an EC50 was not determined. In 
contrast, the top two compounds that show almost 100% killing with an estimated 
EC50 at low micromolar were not found to inhibit the enzymatic reaction. This could 








8. Chapter 8: Conclusion and future outlook 
8.1 Overall conclusions of the work 
As explained in detail in the Introduction the aim of the present study is the 
discovery of novel potent and specific inhibitors against hexokinase from human and 
Trypanosoma brucei. Hexokinase, the first enzyme of the glycolytic pathway, is a 
validated target for therapeutic development of cancer and Human African 
Trypanosomiasis respectively. A structure-based strategy was used to identify and 
test novel inhibitor molecules. Despite testing a variety of constructs and testing a 
large number of crystallisation conditions it was not possible to obtain suitable 
crystals for X-ray studies. However published X-ray structures were used and 
provided suitable templates for modelling and virtual screening studies. Large virtual 
chemical libraries were used in docking studies and top hits (best binders) were 
selected and tested for enzyme inhibition against the target protein. The steps 
performed here in this Structure-Based study are summarised below: 
Protein purification and characterisation: Regarding the hHKII, different 
constructs were produced and purified (Chapter 2 Fig. 2.1); with the 6His-tag protein 
used for the inhibition studies. The protein elutes as a monomer of the correct 
molecular mass (based on GF) and is extremely pure (>95%). SEC-MALS further 
supported this notion as the predicted molecular mass is 105kDa (theoretical MW is 
102kDa) with an excellent monodispersity. The protein was extensively 
characterised by DLS, CD and SPR and it was proven to be folded, non-aggregated 
and active with the Kd for Glc to be determined for the very first time using the SPR 
method (217μM). It was very interesting to discover by performing the SEC-MALS 
method that the protein aggregates immediately when is exchanged to buffer with 
low anionic strength. A series of NaCl concentrations were tested (500, 250, 100, 
0mM) and it was found that protein aggregates in lower concentrations of NaCl 
without losing its activity. The activity is actually improved when the assay is 
performed with 0mM NaCl. In addition, the protein seems to increase its 
hydrodynamic radius in a significant way when exchanged to 0mM NaCl which 
could indicate a mass conformation. One hypothesis behind this is that the long helix 
holding the N and C domains together might be flexible resulting in an elongated 
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form of the protein. The electrostatic surface potential of this long helix was studied 
with PyMOL and we did not find any possible interactions as the helix itself and the 
surrounding environment are mostly negatively charged. On the contrary, the 
domains are known to be flexible since they adopt a closed conformation upon the 
substrate biding (Kuser et al., 2008) thus they could adopt different conformations 
when the anionic strength lowers/ increases and this might result in a different 
hydrodynamic radius of the protein which can be seen with SEC-MALS. The protein 
did not crystallise even though many different conditions were tested (Appendix A). 
For this reason the N and C terminal domains were purified separately and a low 
resolution SAXS structure was determined for the N- terminal domain. The C-
terminal domain is likely to exist in equilibrium of monomeric and dimeric forms 
making the SAXS analysis unreliable for the development of a 3D envelope. On the 
contrary, the 6His-tag hHKII and the N-terminal domain constructs of hHKII are 
monomeric in solution and a 3D envelope was successfully constructed from SAXS 
data. The two macromolecules do not differ much in overall architecture from the 
crystallographic atomic resolution structures (PDB code: 2NZT). 
The untagged protein was found to be inactive while not very pure after a 3 step-
purification explained in detail in Chapter 2, section 2.2.4. Appendix B shows a 
number of different protocols investigated with unfavourable results. The 
purification of the protein needs further optimisation in order to obtain a pure and 
active form.  
Regarding TbHKI, the expression trials were unsuccessful to yield enough soluble 
protein. Most of TbHKI is expressed in IBs. For this reason, two different refolding 
protocols were tested; the second trial using the Optimised Buffer (Chapter 2, section 
2.2.10) resulted in an improved activity. The latter purified protein was unstable in 
solution and it precipitated during concentration and/or buffer exchange so we could 
not continue the studies in order to investigate the oligomerisation state of the 
protein; instead this protein was used to screen the potential inhibitors. The protein 
was active with Km values of 65μΜ for Glc and 6μΜ for ATP. The affinity for ATP 
is increased compared to the reported values (Morris et al., 2006). It is shown that 
TbHKI can form heterohexameric assemblies (Chambers et al., 2008b) albeit the 
monomeric assembly (based on the GF) was studied here.  
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Virtual Screening: The Glc/G6P site and the ADP site of hHKI were used as 
templates for docking studies using two different softwares, AutoDock and Vina. 
hHKI has very similar sites with isoform II and the structure of the former (PDB 
code: 1DGK) was used as it was found to be in a better conformation which is 
expected to accommodate lead-size compounds. For TbHKI, since the crystal 
structure is not resolved to date, two homology models using the on-line tools Phyre2 
and i-TASSER were generated. The structure of hHKI was used as a template (PDB 
code: 1DGK, 37% identity based on BlastP) for the 1:1 threading. Between the two 
homology models obtained the model from Phyre2 was used for our docking studies 
since the amino acid residues of the active site are in a ligand bound conformation 
(as shown from structure superposition with 1DGK). 28 compounds in total were 
purchased from the docking studies which were further tested to determine their 
inhibitory potency against hHKII and TbHKI. 
The computational docking studies in the present work, led to the discovery of a 
number of inhibitors for both targets. More specifically for hHKII the successful 
ligands reach a percentage of 30% (8 out of 28) and 25% respectively (1 out of 4) for 
TbHKI. We could argue that these results are a very good starting point that could be 
followed by ligand modifications in order to build more efficient actives. It is widely 
known that many drugs in the market have been discovered through the process of 
SBDD (i.e Tamiflu, Gleevec, Exanta, Nesina). Based on our results we are confident 
that the in silico methods are of great importance in drug discovery and can result in 
the discovery of actives in a cost-effective and time-saving manner.  However, even 
though the molecular docking was successful in identifying a number of inhibitors 
the predicted binding modes could not be confirmed; this unfortunately makes it 
impossible to fully evaluate the docking programs outcome. 
 
Inhibition studies on hHKII and TbHKI: The purchased compounds after the 
virtual screening were assayed in order to determine their inhibitory potency and 
determine an IC50 value if possible. Regarding the hHKII, 8 compounds were found 
to inhibit (>12%) the enzymatic reaction at 100 μΜ. The SAR analysis is explained 
at Chapter 5, section 5.12. The most potent inhibitor, AS1RS8, is predicted to bind to 
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the ADP site and not to the Glc/G6P site. It is predicted to form fewer hydrogen 
bonds, compared to the total of virtual hits obtained. However, the higher potency 
could be attributed to the hydrophobic interactions seen by studying the predicted 
binding mode. The IC50 is estimated at ~62 μΜ. 2RS5 which is predicted to bind to 
the Glc/G6P site has an IC50 of 127 μΜ while AS1RS6 (same site) ranks in the final 
position with IC50 at ~448 μΜ. Unfortunately, no crystal structure was obtained with 
a ligand bound to the protein, thus future work should include crystallisation trials of 




Table 8.1: Summary of 8 compounds that show >12% inhibition of the enzymatic assay 
at 100 μΜ 
The IC50 was successfully determined for three inhibitors. The remaining five inhibitors are 
predicted to be quite weak and the higher stock concentration available to test would not be 
high enough for an IC50 determination. 
Compound ID % Inhibition at 100 μΜ IC50 
AS1RS8 -35% 62 μΜ 
2RS5 -36% 127 μΜ 
AS1RS6 -13% 448 μΜ 
TbHK1.4 -16 Could not be determined 
NP6 -14 Could not be determined 
2RS11168 -12% Could not be determined 
2RS23615 -22% Could not be determined 
AS1RS4 -15% Could not be determined 
 
In respect to TbHKI, four compounds were purchased after the performance of the 
docking studies (Chapter 6, section 6.3.3 for chemical structure) which are predicted 
to bind to different pockets in close proximity (Fig. 6.3). Because the enzyme from 
T. brucei is expected to have maintained a conserved binding site all compounds 
(hits against hHKII as well) were screened against the parasite isoform. The 
screening of the compounds with an enzymatic assay was followed by testing them 
directly against the parasites (Chapter 7, section 7.2.5). Among the 28 compounds an 
IC50 value at micromolar range was estimated for TbHK1.4 (80 μΜ) and 2RS08628 
(65 μΜ). The cell viability assay was performed to show whether these compounds 
were effective in killing T. brucei parasites in vitro. The compounds were tested at 
45 μΜ and TbHK1.4 shows 55% of killing and 2RS08628 only 29%. The potency is 
not high enough for an accurate EC50 to be determined. On the contrary, a low EC50 
was estimated for 2RS2 and AS1RS8 (5 μM and 17 μM respectively) which show 
almost 100% killing of parasites. However, these compounds did not inhibit the 
enzymatic reaction suggesting that the real target of the ligands is a different enzyme.  
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Table 8.2: Summary of 4 compounds that inhibit either the enzymatic activity in vitro 
or kill the parasites in vitro 
Among the 28 compounds tested against purified TbHKI two were found to inhibit the 
enzyme in low micromolar. Two more were found to completely kill the parasites and an 
EC50 was determined. However the target is not the hexokinase enzyme.  
Compound ID 
% Inhibition (-)/ 
Activation (+) 
IC50 % killing EC50 
2RS08628 -66.25  65 μΜ 29 - 
TbHK1.4 -65 80 μΜ 55 - 
2RS2 +21.25 - 100% 5 μΜ 
AS1RS8 -7.5 - 100% 17 μΜ 
 
Future work: Further work is required in order to characterise the TbHKI regarding 
its oligomeric state, secondary structure as a function of the storage conditions of the 
recombinant enzyme. All results presented here were obtained using protein directly 
from the purification process. Moreover, since the enzymatic assay revealed that 
most of the ligands are activators it would worth studying the mechanism behind the 
activation of the protein. It would be interesting to test whether the activators 
increase the affinity for Glc or ATP, or whether they only increase the Vmax. Kinetic 
measurements with different concentrations of enzyme varying the Glc or ATP 
concentration could show if there is a cooperative behaviour depending on the 
concentration of TbHKI in order to suggest that TbHKI behaves like T. cruzi 
hexokinase showing a hysteretic behaviour (Acosta et al., 2014). 
For hHKII it is essential to obtain a crystal structure of the protein with the present 
inhibitors to study the interactions formed in order to perform a more sophisticated 
SAR analysis. It would be also very interesting to obtain the structure of the protein 
under different anionic environment to monitor the transition mode of the protein to 
an elongated form as SEC-MALS predicts. Finally, to propose whether the inhibitors 
are Glc or ATP competitive, more enzymatic assays need to be performed with 
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Precipitates after 2M 
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Precipitates after 15% 
PEG3350 
immediately/ 























immediately at PEG 
3350 16% and PEG 
8000 16%. No 
precipitation at 
PEG1450/ No crystal 
growth either. 


































drop, 1:1 in 
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PEG 3350 (6, 
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No bad precipitants, 
14-22% PEG 3350, 
pH 7.0-8.0 gave the 
best conditions close 
to crystallization/ 







Screen 1 & 2 
from Molecular 
Dimensions 































Precipitates after 1M 
ammonium sulphate 








Purification trials of Untagged hHKII 
Cell pellet treatment Purification steps  Comments 
Ammonium sulphate 
precipitation (40%) 
HIC Column screening 
Butyl FF gave the best 
separation of target 
protein, followed by Octyl 




Butyl FF, Gel Filtration 
Superdex 26/60 200pg 
2.5ml/ min 





HiTrap QFF 1ml Buffer 
A: 0mM NaCl, Buffer B: 
1M NaCl 
 
A: Linear gradient 100% 
20CV 
Broad peak-not clean HK 
B: Step gradient: Step 1: 
30%B for 20CV 
Step 2: 50% B for 20CV 
Step 3: 100% B for 20CV 
Not clean HK 
 
 
